Located in the heart of downtown Minneapolis, the hotel is directly connected by covered skyways to the Minneapolis Convention Center and the Minnesota Orchestra.
Registration is located in the Minneapolis Foyer located on the 3rd floor of the hotel.

REGISTRATION HOURS:
- Saturday, June 11: 1:00 PM - 5:30 PM
- Sunday, June 12: 7:30 AM - 5:00 PM
- Monday, June 13: 7:30 AM - 5:00 PM
- Tuesday, June 14: 7:30 AM - 5:00 PM
- Wednesday, June 15: 7:30 AM - 3:00 PM

CPDD PHOTOGRAPHY POLICY
Please respect our presenters. CPDD does not permit photographs, videotaping, or audio taping of any session.

POSTER SESSIONS
The poster room is located on the 2nd floor in the Marquette Ballroom. Posters must be removed from boards immediately following the poster session.
- Sunday, June 12: 11:30 AM - 1:30 PM
- Monday, June 13: 8:00 AM - 10:00 AM
- Tuesday, June 14: 8:00 AM - 10:00 AM
- Wednesday, June 15: 8:00 AM - 10:00 AM
QUESTIONS
If you have questions during the conference, we encourage you to:
1) Stop by the registration desk located in the Minneapolis Foyer.
2) Email info@cpdd.org with additional questions or concerns or call
   (615) 432-0099.
3) Visit the Speaker Ready Room located in Red Wing for assistance with a
   presentation or presenter questions.

JOIN THE CONVERSATION
CPDD has gone social and we invite you to join the online conversation. Please be
sure to follow/like the following CPDD social media accounts:

@CPDDorg  @CPDDmembers  @CPDD

And do not forget to use the hashtag #CPDD2022 if you post pictures or comments
about the Meeting.

CPDD’S DISCLAIMER STATEMENT
Information obtained via CPDD channels, including webinars, conferences,
websites, etc., is intended for only information and research purposes. CPDD
cannot be held liable for the information consumed and may not reflect the
opinions of CPDD or its members. The content and information shared should be
used at the discretion of the consumer.

Funding for this conference was made possible (in part)
by 5 R13 DA 013192 - 15
from the National Institute on Drug Abuse
The views expressed in written conference materials or publications and by speakers
and moderators do not necessarily reflect the official policies of the Department of
Health and Human Services; nor does mention of trade names, commercial practices,
or organizations imply endorsement by the U.S. Government.
WEAR A MASK
Masks are strongly recommended at all CPDD events. Make sure and pack yours!

WEAR YOUR BADGE
A CPDD badge is required at all times for entry. Your badge indicates proof of vaccination.

GRAB A LANYARD
Magenta = Keep Your Distance
Yellow = Limited Contact
Green = Handshakes & High Fives

ATTENDEES THAT EXPERIENCE SYMPTOMS OR FEEL ILL ONsite SHOULD QUARANTINE IN THEIR GUESTROOM AND CALL JESSE HOWARD AT 606-233-3049 TO RECEIVE NEXT STEPS.
CPDD 2021 - 2022
BOARD OF DIRECTORS

EXECUTIVE COMMITTEE
William Stoops, PhD
President

Amy Janes, PhD
President-Elect

Jack Bergman, PhD
Treasurer

Stacey Sigmon, PhD
Past-President

Sandra Comer, PhD
Public Policy Officer

BOARD MEMBERS
Sudie Back, PhD
Qiana Brown, PhD, MPH, MSW, LCSW
F. Ivy Carroll, PhD
Ziva Cooper, PhD
Kelly Dunn, PhD, MBA
Albert Garcia-Romeu, PhD, MA
Deborah Hasin, PhD
Angela Heads, PhD
Jermaine Jones, PhD
Frances R. Levin, MD
Wendy Lynch, PhD
Marco Pravetoni, PhD
James Rowlett, PhD
Dace Svikis, PhD
Michael Taffe, PhD
Erin Winstanley, PhD
2022 PROGRAM COMMITTEE

Chair: Kelly Dunn, PhD, MBA

MEMBERS
Matthew Banks, PhD, Pharm D
Eduardo Butelman, PhD
Mance Buttram, PhD
Kevin Freeman, PhD
Diann Gaalema, PhD
Scott Hadland, MD, MPH, MS
Jermaine Jones, PhD
Mikhail Koffarnus, PhD
Dustin Stairs, PhD
Justin Strickland, PhD
Jennifer Tidey, PhD
Denise Vidot, PhD
Heather Ward, MD
Reagan Wetherill, PhD
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM</td>
<td>Plenary, Eddy Lectures &amp; Awards Ceremony*</td>
<td>Minneapolis D</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>Speaker Ready Room</td>
<td>Red Wing</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>Poster Session 1, Exhibits &amp; Lunch</td>
<td>Marquette Ballroom</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>Drug and Alcohol Dependence and Drug and Alcohol Dependence Reports Journals Editorial Meeting</td>
<td></td>
</tr>
<tr>
<td>1:30 PM</td>
<td>Presidential Symposium*</td>
<td>Minneapolis D</td>
</tr>
<tr>
<td>2:30 PM</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>3:00 PM</td>
<td>Late-Breaking Oral Session 1**</td>
<td>Minneapolis D</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>Oral Communication: Advances in Contingency Management</td>
<td>Symphony Ballroom III</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>Oral Communication: Advancements in Monoclonal Antibodies</td>
<td>Conrad BC</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>Oral Communication: Role of Sex/Gender on SUDs</td>
<td>Orchestra AB</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>Workshop: Test of Two Implementation Science Strategies to Increase Medications for Opioid Use Disorders (MOUD) in Jail Settings**</td>
<td>Minneapolis ABC</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>Oral Communication: Prenatal Science I</td>
<td>Orchestra CD</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>Pre &amp; Postdoctoral Networking</td>
<td></td>
</tr>
<tr>
<td>4:30 PM</td>
<td>Symposium: Beyond Delta-9-THC: The Blossoming of Minor Cannabinoids**</td>
<td>Minneapolis ABC</td>
</tr>
<tr>
<td>4:30 PM</td>
<td>Symposium: Using Behavioral and Brain Biotypes to Enhance Treatment Outcomes in Addiction Medicine**</td>
<td>Minneapolis D</td>
</tr>
<tr>
<td>4:45 PM</td>
<td>Oral Communication: Sexual Minority Health and SUDs</td>
<td>Conrad BC</td>
</tr>
<tr>
<td>4:45 PM</td>
<td>Oral Communication: Alcohol and Psychiatric Comorbidities</td>
<td>Symphony Ballroom III</td>
</tr>
<tr>
<td>4:45 PM</td>
<td>Oral Communication: How Do Flavorings Influence Nicotine Use Behaviors</td>
<td>Orchestra AB</td>
</tr>
<tr>
<td>4:45 PM</td>
<td>Oral Communication: Choice Behaviors</td>
<td>Orchestra CD</td>
</tr>
<tr>
<td>6:00 PM</td>
<td>Fischman Lecture Presented by Frances Levin, 2020 Fischman Awardee**</td>
<td>Minneapolis D</td>
</tr>
<tr>
<td>7:00 PM</td>
<td>CPDD Presidential Reception</td>
<td>The Gallery</td>
</tr>
<tr>
<td>7:15 PM</td>
<td>Workshop: Advantages and Challenges of Big Data Approaches to Detect Novel Biology Underlying Substance Use Disorders**</td>
<td>Minneapolis ABC</td>
</tr>
<tr>
<td>7:15 PM</td>
<td>Workshop: Conducting Pragmatic Trials of Interventions to Improve Care for Substance Use in Medical Settings: Lessons From 4 Trials</td>
<td>Symphony Ballroom III</td>
</tr>
<tr>
<td>7:15 PM</td>
<td>Workshop: Epidemiology and Public Health Research Methods</td>
<td>Orchestra AB</td>
</tr>
<tr>
<td>7:15 PM</td>
<td>Workshop: News You Can Use: Media Relations 101</td>
<td>Orchestra CD</td>
</tr>
<tr>
<td>7:15 PM</td>
<td>Workshop: Academic/Community Partnerships as a Strategy for Reducing Health Disparities in Substance Use**</td>
<td>Minneapolis D</td>
</tr>
<tr>
<td>7:15 PM</td>
<td>Oral Communication: Trends in Polysubstance Use</td>
<td>Conrad BC</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>--------------------------------------------------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>8:00 AM</td>
<td>Poster Session 2, Exhibits &amp; Continental Breakfast</td>
<td>Marquette Ballroom</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Symposium: The Best Offense is Defense! Blocking and Tackling Stimulants in the Periphery to Prevent CNS Action**</td>
<td>Minneapolis D</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Symposium: The Importance of Gender, Culture and Intersectional Issues in Substance Use Interventions: Lessons in Health Disparity Research in South Africa and the U.S.**</td>
<td>Minneapolis ABC</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Symposium: From Bench to Bedside to Policy: Updating Our Understanding of Kratom</td>
<td>Orchestra AB</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Symposium: Dose-Dependent Subjective Effects of THC and Cannabis Concentrates: From Naturalistic Investigation to Population Analysis</td>
<td>Orchestra CD</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Oral Communication: Social Environment and SUD Behaviors</td>
<td>Conrad BC</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Oral Communication: Machine Learning Applications for SUDs</td>
<td>Symphony Ballroom III</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>Lunch On Own</td>
<td>N/A</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>Human Forum: Resuming Research on Substance Use Disorders After Lifting COVID-19 Distancing Measures: Challenges and Opportunities</td>
<td>Orchestra AB</td>
</tr>
<tr>
<td>12:30 PM</td>
<td>CPDD Early Career Investigator Travel Awards Luncheon (By Invitation Only)</td>
<td>Minneapolis E</td>
</tr>
<tr>
<td>1:00 PM</td>
<td>Mini-Symposium: Gabapentin, Friend or Foe? Emerging Trends, Use Behaviors, and Adverse Events**</td>
<td>Minneapolis D</td>
</tr>
<tr>
<td>1:00 PM</td>
<td>Mini-Symposium: Catching up on Sleep: Insights Into the Bidirectional Relationship Between Drug Use and Sleep Impairments, and Relapse Potential**</td>
<td>Minneapolis ABC</td>
</tr>
<tr>
<td>1:00 PM</td>
<td>Oral Communication: Methamphetamine Basic Science</td>
<td>Conrad BC</td>
</tr>
<tr>
<td>1:00 PM</td>
<td>Oral Communication: Ecological Momentary Assessment Innovations</td>
<td>Orchestra CD</td>
</tr>
<tr>
<td>1:00 PM</td>
<td>Oral Communication: Genetics of SUDs I</td>
<td>Symphony Ballroom III</td>
</tr>
<tr>
<td>2:15 PM</td>
<td>Fischman Lecture Presented by Laura Bierut, 2022 Fischman Awardee**</td>
<td>Minneapolis D</td>
</tr>
<tr>
<td>3:45 PM</td>
<td>Oral Communication: Neuroscience of SUDs I</td>
<td>Orchestra AB</td>
</tr>
<tr>
<td>3:45 PM</td>
<td>Oral Communication: Cannabinoid Science</td>
<td>Orchestra CD</td>
</tr>
<tr>
<td>3:45 PM</td>
<td>Oral Communication: The Role of Neighborhood on SUDs</td>
<td>Symphony Ballroom III</td>
</tr>
<tr>
<td>3:45 PM</td>
<td>Symposium: &quot;Extending&quot; the Benefits of Extended (virtual and augmented) Reality to SUD Patients**</td>
<td>Minneapolis D</td>
</tr>
<tr>
<td>3:45 PM</td>
<td>Symposium: NDEWS Methods to Detect New and Emerging Psychoactive Substances Presented by New and Emerging Scientists**</td>
<td>Minneapolis ABC</td>
</tr>
<tr>
<td>5:30 PM</td>
<td>SBIR Poster Session (Small Business Innovation Research - SBIR)</td>
<td>Marquette Ballroom</td>
</tr>
<tr>
<td>6:00 PM</td>
<td>Primm Singleton Reception</td>
<td></td>
</tr>
<tr>
<td>7:00 PM</td>
<td>Workshop: Early Career Member Committee: Navigating a Career in Addiction Science**</td>
<td>Minneapolis D</td>
</tr>
<tr>
<td>7:00 PM</td>
<td>Workshop: 28th Annual Contingency Management Working Group</td>
<td>Orchestra AB</td>
</tr>
<tr>
<td>7:00 PM</td>
<td>Workshop: Learnings From the Rural Opioid Initiative About Methods to Conduct Research With Rural PWUD</td>
<td>Orchestra CD</td>
</tr>
<tr>
<td>7:00 PM</td>
<td>Workshop: A Path Less traveled: Becoming a Medical Device Developer for the Substance Use Disorders**</td>
<td>Minneapolis ABC</td>
</tr>
<tr>
<td>7:00 PM</td>
<td>Workshop: Implementing Peer Recovery Coaches for Improving Recovery in People With Substance Use Disorders: Insights Form Researchers, Stakeholders, and Clinicians</td>
<td>Conrad BC</td>
</tr>
<tr>
<td>7:00 PM</td>
<td>Oral Communication: The Neuroscience of Alcohol</td>
<td>Symphony Ballroom III</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Location</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>8:00 AM</td>
<td>Poster Session 3, Exhibits &amp; Continental Breakfast</td>
<td>Marquette Ballroom</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Symposium: Circadian and Sleep Factors in Substance Use Disorders: Role of the Extracellular Matrix</td>
<td>Orchestra CD</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Symposium: Innovative Approaches for Expanding Access to Pharmacotherapy for Opioid Use Disorder**</td>
<td>Minneapolis D</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Symposium: Links Between Early Life Adversity and Addiction**</td>
<td>Minneapolis ABC</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Symposium: Cross-Cultural Cannabis Science: Lessons Learnt and How to Move Forward</td>
<td>Conrad BC</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Oral Communication: Behavioral Pharmacological Research</td>
<td>Symphony AB</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Oral Communication: Harm Reduction Efforts for SUDs</td>
<td>Symphony Ballroom III</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>Lunch (On Own)</td>
<td>N/A</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>Animal Forum: Getting the Word Out: Strategies for Effective Communication About Animals in Research</td>
<td>Orchestra AB</td>
</tr>
<tr>
<td>1:00 PM</td>
<td>Policy Forum: Impact of COVID-19 Opioid Treatment Program Policy Relaxations on Patient Outcomes</td>
<td>Orchestra CD</td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Late-Breaking Oral Session 2**</td>
<td>Minneapolis D</td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Oral Communication: Cocaine Preclinical Science</td>
<td>Orchestra AB</td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Journals: Drug and Alcohol Dependence &amp; Drug and Alcohol Dependence Reports</td>
<td>Minneapolis ABC</td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Oral Communication: Opioid Use in Justice-Involved Persons</td>
<td>Conrad BC</td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Oral Communication: Prenatal Science II</td>
<td>Symphony Ballroom III</td>
</tr>
<tr>
<td>3:30 PM</td>
<td>Workshop: Event-Related Potentials and Substance Use Disorders: Identifying Clinically Relevant Metrics to Inform Therapeutics</td>
<td>Orchestra AB</td>
</tr>
<tr>
<td>3:30 PM</td>
<td>Workshop: Did You Hear About the Looming Global Fentanyl Crisis?: A Quick Start for Addiction Scientists Across the World**</td>
<td>Minneapolis D</td>
</tr>
<tr>
<td>3:30 PM</td>
<td>Workshop: Meeting the Demand: Expanding the Addiction Workforce From Programs to Peers</td>
<td>Orchestra CD</td>
</tr>
<tr>
<td>3:30 PM</td>
<td>Workshop: Engaging Communities to Deliver Effective Opioid Use Programs for Native Americans**</td>
<td>Minneapolis ABC</td>
</tr>
<tr>
<td>3:30 PM</td>
<td>Workshop: Advances in Adolescent Recovery Research and the Society for Adolescent Substance Abuse Treatment Effectiveness (SASATE)</td>
<td>Conrad BC</td>
</tr>
<tr>
<td>3:30 PM</td>
<td>Oral Communication: Nicotine Co-Use</td>
<td>Symphony Ballroom III</td>
</tr>
<tr>
<td>4:45 PM</td>
<td>Oral Communication: What is the Role of Diet in SUDs?</td>
<td>Symphony Ballroom III</td>
</tr>
<tr>
<td>5:45 PM</td>
<td>CPDD Business Meeting</td>
<td>Minneapolis D</td>
</tr>
<tr>
<td>7:30 PM</td>
<td>Dessert and Dancing</td>
<td>Minneapolis E</td>
</tr>
<tr>
<td>Time</td>
<td>Event Description</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>8:00 AM</td>
<td>Poster Session 4, Exhibits &amp; Continental Breakfast</td>
<td>Marquette Foyer</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Symposium: The Orexin System in Addiction**</td>
<td>Minneapolis D</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Symposium: Through the Looking Glass: Metacognition, Interception, Hallucinogens,</td>
<td>Minneapolis ABC</td>
</tr>
<tr>
<td></td>
<td>and Non-Ordinary States as Potential Avenues for Novel Addiction Treatments**</td>
<td></td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Symposium: Biopsychosocial Risk Processes Underlying Hazardous Cannabis Use and</td>
<td>Orchestra CD</td>
</tr>
<tr>
<td></td>
<td>Cannabis Use Disorder</td>
<td></td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Symposium: Accounting for Older Adults in Substance Use Research, Treatment, and</td>
<td>Orchestra AB</td>
</tr>
<tr>
<td></td>
<td>Policy: Current Findings and Future Considerations</td>
<td></td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Oral Communication: Genetics of SUDs II</td>
<td>Symphony Ballroom III</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Oral Communication: Intersectionality Between SUDs and Suicidality</td>
<td>Conrad BC</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>Media Forum: Harnessing Your Expertise: CPDD Media Training With Reporting on</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Addiction</td>
<td></td>
</tr>
<tr>
<td>12:00 PM</td>
<td>Brunch With Champions</td>
<td>Minneapolis E</td>
</tr>
<tr>
<td>1:30 PM</td>
<td>Oral Communication: Infectious Diseases and SUDs</td>
<td>Symphony Ballroom III</td>
</tr>
<tr>
<td>1:30 PM</td>
<td>Oral Communication: Cocaine Clinical Research</td>
<td>Conrad BC</td>
</tr>
<tr>
<td>1:30 PM</td>
<td>Oral Communication: Neuroscience of SUDs II</td>
<td>Orchestra AB</td>
</tr>
<tr>
<td>1:30 PM</td>
<td>Oral Communication: Fentanyl: Focus on Toxicology</td>
<td>Orchestra CD</td>
</tr>
<tr>
<td>1:30 PM</td>
<td>Mini-Symposium: Facilitating Compassionate and Consistent Care for Women and</td>
<td>Minneapolis D</td>
</tr>
<tr>
<td></td>
<td>Neonates Affected by Opioids**</td>
<td></td>
</tr>
<tr>
<td>1:30 PM</td>
<td>Mini-Symposium: Using Big Data to Optimize Benzodiazepine Prescribing and Deprescribing Across the Lifespan**</td>
<td>Minneapolis ABC</td>
</tr>
<tr>
<td>2:45 PM</td>
<td>Oral Communication: Cravings and Cues in SUDs</td>
<td>Orchestra AB</td>
</tr>
<tr>
<td>2:45 PM</td>
<td>Oral Communication: Fentanyl: Focus on Subjective/Affective Properties</td>
<td>Orchestra CD</td>
</tr>
<tr>
<td>2:45 PM</td>
<td>Oral Communication: Towards Standardization of Clinical Trial Outcomes</td>
<td>Symphony Ballroom III</td>
</tr>
<tr>
<td>2:45 PM</td>
<td>Oral Communication: Racial Disparities and SUDs</td>
<td>Minneapolis ABC</td>
</tr>
<tr>
<td>2:45 PM</td>
<td>Oral Communication: The Role of Anxiety in SUDs</td>
<td>Conrad BC</td>
</tr>
<tr>
<td>2:45 PM</td>
<td>Mini-Symposium: Use of Technology to Facilitate Translational Substance Use</td>
<td>Minneapolis D</td>
</tr>
<tr>
<td></td>
<td>Disorder Research**</td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td>Oral Communication: Imaging Research With Nicotine</td>
<td>Orchestra AB</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>Oral Communication: Methamphetamine Clinical Research</td>
<td>Orchestra CD</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>Oral Communication: Alcohol and Coping Behaviors</td>
<td>Symphony Ballroom III</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>Oral Communication: Meaningful Interactions With Cannabinoids</td>
<td>Minneapolis D</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>Oral Communication: Behavioral Economics</td>
<td>Conrad BC</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>Oral Communication: Unique Challenges for SUDs in Rural Environments</td>
<td>Minneapolis ABC</td>
</tr>
<tr>
<td>5:00 PM</td>
<td>Closing General Session - Sweepstakes Drawing</td>
<td>Minneapolis D</td>
</tr>
</tbody>
</table>
SUNDAY, JUNE 12, 2022

8:00 A.M. - 11:30 A.M.

PLENARY
WELCOME AND INTRODUCTION
William Stoops, University of Kentucky; CPDD 2022 President

RESEARCH ON DRUG ABUSE AND ADDICTION: PROGRESS, OPPORTUNITIES AND CHALLENGES
Nora Volkow, National Institute on Drug Abuse

Scientific advances continue to broaden our understanding of the biological, developmental, and environmental elements underlying drug use and addiction and to accelerate efforts to develop targeted strategies for their prevention and treatment. At the same time, the challenges confronting the field have grown both in number and in magnitude. This presentation will highlight such challenges as the growing use of fentanyl by itself or in combination with other opioids or stimulant drugs like cocaine and methamphetamine and the staggering number of overdose deaths that result. It will also focus on how NIH researchers have been using scientific advances to address the opioid crisis amidst the COVID pandemic, which includes the development of new medications and formulations to help treat opioid use disorders and overdoses; prevention strategies to mitigate an individual’s vulnerability to addiction; and implementation science to guide optimal deployment of therapeutic interventions including the use of telehealth in diverse settings (healthcare, justice setting, rural communities). Also to be addressed is the disproportionate impact that the COVID-19 pandemic has had on some drug abusing populations; and some of the relevant policy and research initiatives currently being supported by NIDA and the National Institutes of Health (NIH) to help address some of the most pressing challenges the field has ever faced.

NIAAA UPDATE: CLOSING THE TREATMENT GAP
George Koob, National Institute on Alcohol Abuse and Alcoholism

Alcohol misuse and alcohol use disorder (AUD) cause an enormous amount of human suffering, loss of productivity and cost to our medical care system and the nation’s economy all of which have been exacerbated by the COVID-19 pandemic. Recent developments include a 26% increase in alcohol-related deaths, 34% increase in the prevalence of hospital visits for alcohol withdrawal, and a 51% increase in hospitalizations for alcohol-associated hepatitis during the COVID-19 pandemic in the United States. In addition, there continues to be a significant treatment gap where less than 10% of individuals in need of treatment receive treatment for AUD and less than 2% receive one of the 3 FDA approved medications for treatment of AUD. Ongoing challenges include the increased drinking to cope with stress exacerbated by the COVID-19 pandemic, interaction of alcohol with mental health, the role of alcohol in women’s health, alcohol and health in older adults, and research on recovery from AUD. Current priorities and challenges for closing the treatment gap include promoting medications development, expanding NIAAA resources for the public, development of a heuristic definition of recovery, expanding the uptake of screening, brief intervention and referral to treatment (SBIRT), exploring and expanding a role for telehealth in treatment, addressing stigma, addressing diversity, equity and health disparities in the alcohol field, and supporting the next generation of alcohol researchers. Addressing such challenges will facilitate the implementation of evidence-based treatment for AUD in primary care, mental health, and other health care settings.
AWARD PRESENTATION: 2022 EDDY LECTURE
LEVERAGING THE REINFORCEMENT PROCESS TO PROMOTE HEALTH: APPLICATIONS TO SUBSTANCE USE DISORDERS AND OTHER CHRONIC CONDITIONS
Stephen Higgins, University of Vermont, 2022 Eddy Awardee

This presentation will underscore how the reinforcement process that plays such a fundamental role in the genesis and maintenance of substance use disorders can also be applied effectively to promote healthy behavior change. Research from clinical laboratory and randomized clinical trials will be reviewed. Interventions designed to impact the behavior of individual patients and populations will be discussed.

1:30 P.M. - 2:30 P.M.

PRESIDENTIAL SYMPOSIUM
William Stoops, University of Kentucky; 2022 CPDD President

THE HISTORICAL ROLE OF ANIMAL RESEARCH IN ADDICTION SCIENCE
Katherine Serafine, The University of Texas at El Paso

Animal research has served as an essential component in our understanding of substance use disorder, and factors that contribute to disease etiology, vulnerability, addiction liability and potential treatments. Understanding the historical impact of animal research in addiction science is essential for those advocating for continued investments in this life-saving field of study. This presentation will focus on an overview of the historical and current roles of animal research in exploring the neurobiology of addiction and vulnerability factors, as well as the development of effective pharmacotherapeutics for substance use disorders including methadone, naltrexone and varenicline. This presentation will also describe how these historical examples can be used to advocate for the critical role of animal research to further understand and treat human diseases, including substance use disorder.

THE FUTURE OF ANIMAL RESEARCH ON ADDICTIONS: PROMISE AND PERILS
J. David Jentsch, Binghamton University

Though animal research has been crucial to the effort to identify the mechanisms of action of drugs with addiction liability, the discovery of the pathophysiological mechanisms underlying addictions and the successful translation of those biological mechanisms into actionable treatment targets, there clearly is much left to do if we are to address many currently unmet needs. The animal research community is developing more powerful, rigorous and sophisticated approaches that have exceptional promise for closing the remaining gaps, yet a number of forces place those advances at risk. Because of the actions of animal rights extremist groups, politically connected lobbyists and elected officials themselves, this vital research is at peril. This presentation will focus on the future for animal research on addiction and the need for a broader set of actions we must all take to support it.
Marian Fischman served as a role model to many young clinical investigators during her exceptional career. Her wisdom and support led to the success of many of the current leaders (and particularly women) in the addiction field. This talk will initially focus on “lesson learned” from my personal experience being mentored by Marian, followed by highlights of some of the research that I have conducted over the past 30+ years and additional “lessons learned.”

MONDAY, JUNE 13, 2022

The large-scale implementation of genetic knowledge represents one of the next major scientific challenges to improve health. Although much work to date has focused on using genetic information to identify diseases and define treatment options in fields such as cancer, the next frontier is to expand our genetic knowledge base to a wider range of disorders including substance use disorder. Smoking cessation is an ideal target for testing the implementation of a genetic intervention to enhance behavioral change. There remains a massive preventable burden of morbidity and mortality related to smoking and there are well identified genetic variants that drive smoking behaviors as well as smoking related diseases. A precision health effort focused on smoking behaviors will test the utility of a genetic informed intervention to drive behavioral change and study the implementation, optimization, and integration of smoking related genetic knowledge in the goal of improved population health. Personalized genetic results can inform individual health decisions, optimize treatment choices, and potentially motivate smoking cessation. Let’s challenge the dominant model of incremental, stepwise research questions and undertake multi-faceted efforts that test the effects of returning genomic information about smoking and smoking-related disease risk directly to individuals, in a manner that promotes future scalability to large-scale implementation.
ABSTRACT

SUNDAY, JUNE 12, 2022

3:00 P.M. - 4:00 P.M. WORKSHOP

1. TEST OF TWO IMPLEMENTATION SCIENCE STRATEGIES TO INCREASE MEDICATIONS FOR OPIOID USE DISORDERS (MOUD) IN JAIL SETTINGS

Chair: Faye Taxman, George Mason University
Co-Chair: Todd Molfenter, University of Wisconsin - Madison

This session describes the initial experiences of a trial testing use of NIATx Coaching and the ECHO model to increase use of medication for opioid use disorders (MOUDs) in jail settings located in California, Florida, Hawaii, Maine, Virginia, Wisconsin, and Washington. The NIATx model has been supported by 30+ research publications and used by community-based treatment provider settings to increase MOUD use. This session will describe the key operational components of the NIATx model and how the model was adjusted to accommodate jail workplace practices.

Project ECHO is a collaborative model of medical education that uses video-conferencing sessions, a panel of subject matter experts to provide short educational lectures, then participants present clinical cases and receive feedback from peers and experts. This model was utilized to offer education and support in the delivery of MOUD to health professionals from the participating trial sites. The session will describe the ECHO structure, the educational topics presented, a summary of cases presented, and preliminary lessons learned.

NIATx Coaching and ECHO asked participants to use workflow improvement strategies to increase use of MOUD. For workflow improvement, jails tended to follow the MOUD cascade of care model and focused on improving certain steps of the cascade. This session will describe the cascade of care and where the greatest opportunities to strengthen the cascade of care exist based on jail self-assessments. The session will conclude with a concentration on the role external coaching and ECHO can play in the jail MOUD policy setting and implementation process.

1.1 Project Echo for Dissemination of Clinical Education in Jail settings: Lessons Learned
Elizabeth Salisbury-Afshar, University of Wisconsin - Madison

1.2 Test of Two Implementation Science Strategies to Increase Medications of Opioid Use Disorders (MOUD) in Jail Settings.
Todd Molfenter, University of Wisconsin - Madison

1.3 Test of Two Implementation Strategies to Increase Medications for Opioid Use Disorder (MOUD) in Jail Settings
Lynn Madden, APT Foundation

4:30 P.M. - 6:00 P.M. SYMPOSIUM

2. BEYOND DELTA-9-THC: THE BLOSSOMING OF MINOR CANNABINOIDS

Chair: Jenny Wiley, RTI International
Co-Chair: Inna Belfer, Laboratory of Neurogenetics, NIAAA, NIH

The cannabis plant (Cannabis sativa/indica) has long been used for medicinal purposes. In addition to its major psychoactive constituent delta-9-tetrahydrocannabinol (THC), cannabis contains over 100 phytocannabinoids
as well as over 500 other identified chemicals, including the terpenoids that give cannabis its distinctive flavoring and aroma. The degree to which these minor plant constituents contribute to the psychoactive and medicinal effects of cannabis is under active investigation. The speakers in this symposium will provide an overview of their work with selected minor cannabinoids, ranging from molecular pharmacology to preclinical studies and clinical trials. The symposium will begin with an examination of interactions of minor cannabinoids with CB1 and CB2 receptors and continue with assessment of the effects selected cannabis constituents in a mouse model of THC-like subjective effects and in rodent models of pain and inflammation. A translational viewpoint will follow, linking an initial finding that the minor cannabinoid cannabidiol (CBD) showed promise in the treatment of heroin use disorder in an animal model with later supportive data from human clinical trials. A final presentation will focus on results of analysis of cannabinoid constituent profiles of products from medical cannabis patients enrolled in a longitudinal, observational study and will explore the potential impact of these profiles on clinical variables. The moderated discussion period will begin with a brief description of NCCIH programmatic priorities and funding opportunities for minor cannabinoids research. Together, these presentations will provide the audience with a broad overview of the pharmacology and potential medicinal uses of cannabis.

2.1 Minor Phytocannabinoid Interactions With CB1 and CB2 Receptors
Jenny Wiley, RTI International

2.2 Evaluation of Analgesic and Protective Effects of Minor Cannabinoids in Animal Models
Sara Jane Ward, Lewis Katz School of Medicine, Temple University

2.3 Translating Cannabidiol for Opioid Use Disorder and Related Phenotypes
Yasmin Hurd, Icahn School of Medicine at Mount Sinai

2.4 A Major Role for Minor Cannabinoids? Examining Real World Products From Medical Cannabis Patients
Staci Gruber, McLean Hospital, Harvard Medical School

4:30 P.M. - 6:00 P.M. SYMPOSIUM

3. USING BEHAVIORAL AND BRAIN BIOTYPES TO ENHANCE TREATMENT OUTCOMES IN ADDICTION MEDICINE

Chair: Amy Janes, National Institute on Drug Abuse
Co-Chair: Hamed Ekhtiari, University of Minnesota

Drug and alcohol use disorders are dynamic processes, affecting a wide variety of individuals for a wide variety of reasons. Despite widespread appreciation for this variability, our current treatment regimens are fairly uniform. In an effort to catalyze a new chapter in patient-tailored addiction treatment, this symposium will feature a group of experts who are working at the intersection of uniting behavioral and brain based phenotyping with improved pharmacological and neuromodulatory treatment outcomes. Dr. Witkiewitz will present data from three clinical trials on phenotypic variation in drinking motives in treatment-seeking individuals with Alcohol Use Disorder, who could be characterized into ‘reward’ or ‘relief drinkers’. Each type responded best to differential pharmacological treatments, driven by distinct underlying learning mechanisms. Dr. Zilverstand will demonstrate that this framework extends to individuals with other SUD (e.g., cannabis, cocaine Use Disorder), by presenting an empirically derived addiction-general three domain model of neurobehavioral function. Individuals who use substances could be characterized as either ‘reward’, ‘relief’ and ‘low functioning’, demonstrating distinct behavioral profiles and brain function during resting-state. In addition
to using behavioral phenotypes to make decisions about pharmacological treatment, recent studies show that brain based phenotypes can influence brain stimulation treatment outcomes. Dr. Ekhtiari will demonstrate that it is possible to tailor transcranial electrical stimulation to individual patients through the use of brain functions and structure. Dr. Hanlon will bring these themes together by demonstrating unique brain activity patterns in “reward” and “relief” subtypes and that they differentially respond to transcranial magnetic stimulation strategies.

3.1 Phenotyping Individuals With Alcohol Use Disorder: Implications for Precision Medicine
Katie Witkiewitz, University of New Mexico

3.2 An Empirically Derived Neurobehavioral Three-Domain Model Underlying Addiction-General Subtypes: Implications for Personalized Addiction Medicine
Anna Zilverstand, University of Minnesota

3.3 Optimization in Transcranial Electrical Stimulation, Implications for Precision Addiction Medicine
Hamed Ekhtiari, University of Minnesota

3.4 Using Behavioral and Brain Biotypes to Influence TMS Protocol Selection
Colleen Hanlon, Wake Forest Health Sciences

7:15 P.M. - 9:15 P.M. WORKSHOP

4. ADVANTAGES AND CHALLENGES OF BIG DATA APPROACHES TO DETECT NOVEL BIOLOGY UNDERLYING SUBSTANCE USE DISORDERS

Chair: Susan Wright, NIDA/NIH

Incorporating data science as a tool for the study of substance use disorders is gaining popularity and plays a critical role in data-driven decision making. Advanced computational methods to extract knowledge and insights from increasingly large and/or complex datasets in addiction research improves our understanding of the genetic, chemical, neurobiological and behavioral mechanisms of drug use disorders and their long-term consequences and informs prevention and treatment. However, there are also some challenges, such as biases embedded in data or in machine learning algorithms, and ethical, legal, and social implications are important considerations. This session will highlight cutting-edge research such as the performance of different substance use outcome measures in predicting longer-term improvement in psychiatric and social functioning and algorithms and methods for high-dimensional and high-throughput -omics data, including artificial intelligence/machine learning approaches. This session will also caution how biases in both data and algorithms may inadvertently lead to racial disparities being perpetuated and exacerbated, which is of particular importance for addiction, which carries stigma and potential discrimination.

4.1 Empirically Identifying and Validating Predictors of Longer-Term Improvement in Patients With Substance Use Disorders
Laura Brandt, Columbia University Irving Medical Center and New York State Psychiatric Institute

4.2 Empirically Comparing Opioid Use Disorder Treatment Outcomes
Gabriel Odom, Florida International University
5. CONDUCTING PRAGMATIC TRIALS OF INTERVENTIONS TO IMPROVE CARE FOR SUBSTANCE USE IN MEDICAL SETTINGS: LESSONS FROM 4 TRIALS

Chair: Morgan Justice Fuoco, Kaiser Permanente Washington Health Research Institute
Co-Chair: Judith Tsui, University of Washington

Few patients with substance use disorders (SUDs) receive treatment. Routine substance use screening, outreach, care management, and digital therapeutics may improve access and outcomes among the 90% of patients with SUDs who do not receive treatment. To understand whether these interventions reach patients and increase SUD care, each must be evaluated in real world settings with appropriate comparison groups, through pragmatic, implementation, or hybrid trials. Such trials are relatively new and can pose challenges in design, site recruitment and engagement, health systems partnerships, Institutional Review Board considerations, and implementation. They also rely on data for outcome measures from diverse secondary electronic sources, such as apps, patient-report measures in electronic health records, prescription monitoring programs, and health information exchanges. This symposium highlights lessons learned from four such studies. These include: 1) a study to improve primary care of teens using tobacco, alcohol, cannabis and other drugs, which will describe a 3-clinic pilot and a future pragmatic trial to evaluate implementation across 30 other clinics; 2) the DIGITS trial, which will share results of a pilot of reSET/reSET-O implementation in primary care and present the design of an ongoing cluster-randomized, hybrid type-III implementation trial; 3) the PROUD trial, which will highlight lessons from a cluster-randomized, hybrid type-III implementation trial of opioid use disorder (OUD) treatment in primary care; and 4) the MI-CARE trial of collaborative care for OUD and depression, which will describe the challenges of encouragement (Zelen) trials whereby patients are randomized before consent.

5.1 Design and Pilot Implementation of Opportunistic Substance Use Screening into Routine Primary Care: Unique Challenges for Teens
Gwen Lapham, Kaiser Permanente Washington Health Research Institute

5.2 Digital Therapeutics for Opioids and Other Substance Use Disorders (DIGITS Trial) in Primary Care: Results of a Quality Improvement Pilot and Study Protocol for a Hybrid Type-III Implementation Trial
Joseph Glass, Kaiser Permanente Washington Health Research Institute

5.3 The Primary Care Opioid Use Disorders Treatment (PROUD) Trial: Strengths and Challenges of a Pragmatic, Cluster-Randomized, Hybrid Type III Implementation Trial Using Real World, Electronic Health Record Data
Paige Wartko, Kaiser Permanente Health Research Institute

5.4 More Individualized Care: Assessment and Recovery Through Engagement (MI-CARE) Trial: Lessons Learned Regarding Rigorous Design and Implementation of an Encouragement Trial
Morgan Justice Fuoco, Kaiser Permanente Washington Health Research Institute
ABSTRACT

7:15 P.M. - 9:15 P.M. WORKSHOP

6. EPIDEMIOLOGY AND PUBLIC HEALTH RESEARCH METHODS

Chair: Howard Chilcoat, Indivior, Inc.
Co-Chair: Maria Parker, Indiana University - Bloomington

This proposal is for a continuation of the annual CPDD Epidemiology and Public Health Research Methods evening workshop series that was launched more than 10 years ago. These workshops have featured a series of methodologic approaches of interest to those conducting epidemiologic, prevention, and clinical research in the field of substance use and related disorders. This year’s workshop will focus on methods that can be applied in behavioral economic research on drug substance use and how these methodologic approaches can be used in population-based research. Presentations will discuss on delay discounting as a key behavioral economic indicator related to substance use and associated behaviors,

6.1 The Nuts and Bolts of Delay Discounting Assessment, and its Relevance for Substance Use Research
Richard Yi, University of Kansas

6.2 Behavioral Economic Methods to Understand Intersecting COVID-19 and Substance Use Epidemics
Justin Strickland, Johns Hopkins University School of Medicine

6.3 Statistical Methods for Subgroup Identification: An Application to Opioid Use Disorder Recovery
Allison Tegge, Virginia Tech Carilion Research Institute

7:15 P.M. - 9:15 P.M. WORKSHOP

7. NEWS YOU CAN USE: MEDIA RELATIONS 101

Chair: Chelsea Shover, David Geffen School of Medicine at UCLA

Talking to the press can seem intimidating, but mass media is an excellent platform to get your research in front of a wider audience. Engaging with media is also an effective way to influence health policy. This workshop will demystify media relations for scientists, with an opportunity to practice via mock pitches and interviews. Dr. Shover, formerly a journalist, uses insight into media relations to amplify her work as an epidemiologist, most recently when her study was on the front page of the Los Angeles Times. Dr. Vest, a formerly incarcerated scholar, will discuss techniques to contribute to media that advances a public health - rather than criminal legal - response to substance use disorders. Presentations will cover best practices for pitching your work to news outlets, talking with reporters, evaluating interview requests, cultivating relationships with editors to become a go-to source, and working with public relations teams at your university or organization. We will cover your rights and expectations as someone being interviewed. This workshop will cover nuts and bolts like talking points, quote checks, when to go “off the record” versus “on background,” and what to do if you get misquoted. We will also share tips of the trade to appear in your best light and make sure your work shines through compellingly and accurately. Attendees will then have the opportunity to practice in mock pitches (telling a media outlet why they should cover their work) and mock interviews (discussing your findings for a general audience).
ABSTRACT

7.1 Reporting With Conviction: A Formerly Incarcerated Scholars Perspective on Media Relations
Noel Vest, Stanford University School of Medicine

7.2 How’s and Why’s of Talking to Reporters
Chelsea Shover, David Geffen School of Medicine at UCLA

7:15 P.M. - 9:15 P.M. WORKSHOP

8. ACADEMIC/COMMUNITY PARTNERSHIPS AS A STRATEGY FOR REDUCING HEALTH DISPARITIES IN SUBSTANCE USE

Chair: A. Kathleen Burlew, University of Cincinnati
Discussant: Ayana Jordan, NYU Langone Medical Center

The integration of evidence-based interventions into racial/ethnic communities has often been challenging in part due to the lack of fit between the intervention and the target group. Community-engaged research leverages the knowledge and expertise of both community and academic members, can directly target community needs, and often results in more culturally relevant interventions. The aim of this workshop is to share alternative approaches for academic/community partnerships. Members of the Minority Interest Group of NIDA’s Clinical Trials Network (CTN) will present on community engagement activities either conducted within or inspired by the CTN. These partnerships include work with community partners on recruitment (Dr. Haeny), prevention (Dr. McCuistian) and treatment (Dr. Cain). Dr. Haeny will describe a partnership with the community to recruit individuals who use cocaine into treatment. Dr. McCuistian will describe the formation of an academic/community partnership within a residential community that worked together on all phases of a project aimed at culturally adapting a prevention intervention to increase its effectiveness for Blacks. Dr. Cain will describe the development of a partnership with churches and other community sites to provide more effective substance use treatment for opioid users. Ms. Delanie Jordan, a peer recovery guide, will offer a community perspective.

Following the presentations, Dr. Ayana Jordan who collaborates with churches to provide more effective treatment, will serve as the discussant. She will also encourage audience discussion on other models for community engagement.

8.1 Using Community Engaged Approaches to Recruit Participants Who Self-Changed From Cocaine Use Disorder
Angela Haeny, Yale University School of Medicine

8.2 Collaborating With Community Members on Cultural Adaptation: Overview of the CCCA Model
Caravella McCuistian, University of California, San Francisco

8.3 Engaging a Diversity of Community Partners to Reduce Disparities in Substance Use Disorder Treatment
Gloria Cain, Howard University College of Medicine

8.4 Engaging a Diversity of Community Partners to Reduce Disparities in Substance Use Disorder Treatment
Dephanie Jordan, Howard University College of Medicine
9. THE BEST OFFENSE IS DEFENSE! BLOCKING AND TACKLING STIMULANTS IN THE PERIPHERY TO PREVENT CNS ACTION

Chair: Katrina Foster, NIH/NIDA/DTMC
Co-Chair: David White, National Institute of Drug Abuse, National Institutes of Health

Stimulant use is a significant public health concern in the United States. In 2019, approximately 1.4 million persons age 18 and up reported past month stimulant use (2019 National Survey on Drug Use and Health). Further, there is an urgent need for reversal agents for stimulant overdose. According to CDC data, stimulants were involved in approximately 33,000 overdose deaths in 2019. There are currently no FDA-approved interventions for the treatment of stimulant use disorder (SUD) or overdose. The most effective treatment options available to clinicians treating patients with SUD are behavioral therapies, such as Cognitive Behavioral Therapy and Continency Management. Yet, these interventions are only modestly effective with high rates of relapse. Additionally, patients presenting at emergency rooms with symptoms of a stimulant overdose are stabilized by treating only the symptoms but not the root cause(s). As traditional pharmacotherapeutic approaches have yet to yield effective SUD treatments, alternative approaches need to be given serious consideration. This symposium will provide exciting pre-clinical and clinical development efforts for treating SUD and stimulant overdose by preventing or reducing stimulant activity in the CNS.

9.1 A New Therapeutic Approach for Treating Methamphetamine Intoxication
Xinhua Li, Clear Scientific, Inc

9.2 AAV Gene Therapy for Cocaine Abuse
Kah-Whye Peng, Mayo Clinic
W. Michael Hooten, Mayo Clinic

9.3 Adenovirus-Based Vaccines for Addiction
Stephen Kaminsky, Weill Cornell Medical College

9.4 New Results From Phase 2 Trials of IXT-M200, a High Affinity METH Antibody
Brooks Gentry, InterveXion Therapeutics, LLC

10. THE IMPORTANCE OF GENDER, CULTURE AND INTERSECTIONAL ISSUES IN SUBSTANCE USE INTERVENTIONS: LESSONS IN HEALTH DISPARITY RESEARCH IN SOUTH AFRICA AND THE U.S.

Chair: Felicia Browne, RTI International
Co-Chair: Wendee Wechsberg, RTI International

There is a dearth of evidence-based interventions that explicitly address substance use for populations of African descent. Moreover, evidence has shown that interventions that are intersectional and more comprehensive have greater impact with substance use outcomes. The specific aims of the symposium are to (1) share the stages
of intervention research and lessons learned conducting NIH-funded cross-cultural and global collaborative research, including community and youth advisory boards and key populations who use substances, and (2) present the process and outcome evaluation data from evidence-based substance use interventions for young women, women who are pregnant and couples of African descent. In addition, this symposium will allocate time for an interactive discussion about how these projects have offered professional and career development for a diversity of investigators, students and staff.

The first presentation will report on a clustered randomized trial that reached female adolescents who use drugs in South Africa and have left school early and live in underserved communities.

The second presentation will discuss outcomes from a randomized trial in the U.S. South testing the delivery of a substance use intervention among African American women in emerging adulthood.

The third presentation will share formative research from a new study in South Africa reaching young couples who use drugs and alcohol to adapt a risk-reduction intervention for couples and address community stigma.

The fourth presentation will report findings from analysis of a study addressing maternal drug and alcohol use and preventing fetal alcohol spectrum disorders and adverse infant outcomes in South Africa.

10.1 Intervening With Teens in the Cape Flats in South Africa Who Use Alcohol and Other Drugs and Report Other Risk Behaviors: What Works?
Wendee Wechsberg, RTI International

10.2 Outcomes From a Randomized Trial Reaching Young African American Women Who Use Drugs and Alcohol
Felicia Browne, RTI International

10.3 Multilevel Strategies for Young Couples Who Use Alcohol & Other Drugs in Cape Town, South Africa: Formative Research Findings to Adapt a Biobehavioural Intervention for Couples and Address Community Stigma
Tara Carney, South African Medical Research Council

10.4 Addressing Maternal Alcohol and Substance Use and Preventing Adverse Infant Outcomes in South Africa
Yukiko Washio, RTI International

Moderator: Courtney Bonner, RTI International

10:00 A.M. - 11:30 A.M. SYMPOSIUM

11. FROM BENCH TO BEDSIDE TO POLICY: UPDATING OUR UNDERSTANDING OF KRATOM

Chair: Kirsten Smith, National Institute on Drug Abuse, Intramural Research Program
Co-Chair: Oliver Grundmann, University of Florida

Use of kratom, a botanical indigenous to Southeast Asia, has increased dramatically in the U.S. since 2006 with products proliferating rapidly. This is noteworthy, as kratom leaves contain bioactive alkaloids of which at least four act as partial, seemingly biased, agonists at mu opioid receptors and with activity at other neurotransmitter receptors. We are only just beginning to scientifically uncover kratom’s therapeutic and effect profile, primarily through preclinical studies, self-report, and case presentations. Accumulating evidence is beginning to reveal that kratom produces clinically relevant opioid-like effects that have implications for policy decisions. This translational symposium will feature four talks from kratom experts focused on unique aspects of this complex psychoactive plant and its heterogenous population of consumers. First, trends in real-world kratom use derived from survey and social media data, that include dependence and misuse, as well as clinical anecdote on kratom’s use as an opioid substitute among persons with substance use disorders, will be discussed. Second,
an overview of kratom’s role as a self-treatment for psychiatric and pain symptoms will be presented using national and international survey findings. Third, the molecular structure of kratom’s best studied alkaloids, their pharmacological effects, and variability of kratom leaves and products will be reviewed. Lastly, kratom regulation and policy will be discussed in light of current scientific understanding and within the broader context of intersecting opioid, pain, and psychiatric health epidemics in the U.S. Discussion of key scientific and clinical considerations on kratom and attendee engagement will be facilitated by the symposium’s moderator.

11.1 Real-World and Clinical Characteristics of Kratom Use
Kirsten Smith, National Institute on Drug Abuse, Intramural Research Program

11.2 The Who, Why, and What: Kratom User Profiles in the US
Oliver Grundmann, University of Florida

11.3 Alkaloid Chemistry and Pharmacology of Kratom
Christopher McCurdy, University of Florida

11.4 Kratom Policy in the Context of Abuse Potential and Public Health
Jack Henningfield, Pinney Associates, Inc.

Moderator: Kelly Dunn, Johns Hopkins University School of Medicine

10:00 A.M. - 11:30 A.M. SYMPOSIUM

12. DOSE-DEPENDENT SUBJECTIVE EFFECTS OF THC AND CANNABIS CONCENTRATES: FROM NATURALISTIC INVESTIGATION TO POPULATION ANALYSIS

Chair: Adrianne Wilson-Poe, Legacy Research Institute
Co-Chair: Ziva Cooper, UCLA Cannabis Research Initiative

The subjective and intoxicating effects of cannabis are well-established. However, much of this evidence relies on cannabis supplied by the National Institute on Drug Abuse, which has important chemical differences compared to cannabis products sold in regulated markets. Because of these differences, it is important to characterize the abuse liability and psychoactive effects of cannabis sold in regulated markets. The excessive use of cannabis is also well-characterized, and is associated with negative health outcomes such as psychosis-like symptoms, Cannabis Use Disorder, and cannabinoid hyperemesis syndrome. These negative outcomes are largely mediated by cannabis’ primary psychoactive constituent, delta-9-THC, which is also involved in the euphoric and rewarding effects of cannabis. The THC potency of both regulated and illicit cannabis products around the world has been steadily increasing in recent years. In fact, cannabis concentrates (purified resin from the cannabis plant), which make up 9.5% of the regulated U.S. cannabis market, can contain 80% THC or more. Despite the increased prevalence and health risks of high-potency cannabis products, their subjective effects and safety are poorly characterized. This session will focus on the subjective effects of high potency cannabis products and cannabis concentrates, with an emphasis on young adults. Dose-dependent effects of THC will be discussed, as well as harm reduction opportunities to support public health. This symposium also features innovative data collection methods to characterize the effects of high potency cannabis products sold in state-regulated markets.

12.1 The Appeal and Use of Cannabis among Adolescents and Young Adults
Jessica Barrington-Trimis, University of Southern California
12.2 Aroma, But Not THC Potency Mediates the Subjective Appeal of Cannabis Flower  
Adrianne Wilson-Poe, Legacy Research Institute

12.3 Acute Effects of High Potency Cannabis Flower and Concentrates  
Carrie Cuttler, Washington State University

12.4 Cannabis Concentrates: Cannabis Exposure & Intoxication  
L. Cinnamon Bidwell, University of Colorado Boulder

12:00 P.M. - 2:00 P.M. HUMAN FORUM

13. RESUMING RESEARCH ON SUBSTANCE USE DISORDERS AFTER LIFTING COVID-19 DISTANCING MEASURES: CHALLENGES AND OPPORTUNITIES

Chair: Omayma Alshaarawy, Michigan State University College of Human Medicine  
Co-Chair: Elizabeth Santa Ana, Medical University of South Carolina and Charleston VAMC

The College on Problems of Drug Dependence Human Research Committee (HRC) presents a forum focusing on challenges and opportunities related to resuming research on substance use disorders after lifting many COVID-19 distancing measures. In 2020, the emerging pandemic necessitated the halting of all non-essential human subject research. This pause was the focus of the HRC 2021 forum, where ethical considerations related to retention of study participants, adapting research methodologies, and investigator burnout were discussed. In 2021, COVID-19 vaccines became widely available, significantly reducing risks associated with COVID-19 infection and allowing paused research programs to resume in-person activities. However, these rapidly shifting regulations have created additional challenges for investigators who need to re-adjust their protocols to protect participants and staff (e.g., mask policies, reducing interactions with participants, transition to virtual platforms, preference of some research participants to maintain the virtual format without face-to-face contact). In 2022, HRC forum speakers will present an overview of these adjustments, implementation barriers, and risk-benefit assessments. Furthermore, a wealth of COVID-19 misinformation has continued to spread, including the usefulness of masks or vaccines. Investigators engaged in human subject research are well placed to help counter falsehoods about the pandemic. Speakers will discuss opportunities for integrating SBIRV (Screening, Brief Intervention, and Referral for Vaccine) with substance use research. In summary, the forum will provide attendees with different perspectives and best practices to conduct substance use research in the era of global pandemics.

13.1 Addressing Provider and System Level Barriers to Opioid Use Disorder Treatment via Telehealth: Findings From a Mixed-Methods Investigation in the Veteran's Health Administration  
Ursula Myers, Ralph H. Johnson VA Medical Center

13.2 The Association Between COVID-19 and Alcohol Use Among a Trauma Exposed Sample: Future Directions for Participant Outreach in the Post Pandemic World  
Elizabeth Santa Ana, Medical University of South Carolina and Charleston VAMC

13.3 The Challenges and Opportunities of Online-Only Trials in the Post-Covid Era  
Steven Ondersma, Michigan State University

13.4 Screening, Brief Intervention and Referral for Vaccine for Researchers Engaged in Drug Use Research  
Maureen Reynolds, University of Pittsburgh
14. GABAPENTIN, FRIEND OR FOE? EMERGING TRENDS, USE BEHAVIORS, AND ADVERSE EVENTS

Chair: Matthew Ellis, Washington University in St. Louis
Co-Chair: Mance Buttram, University of Arkansas

Gabapentin is an anti-convulsant prescribed for the treatment of epilepsy and neuralgia, but off-label, its use is increasing in the treatment of opioid use disorder (OUD). Reports of non-medical use (NMU) and overdose involvement are growing, particularly in combination with opioids. The aim of this mini symposium is to describe newly emerging national trends related to polysubstance use involving gabapentin. Data are drawn from three long-running nationally representative surveillance programs that will present a comprehensive picture of non-medical gabapentin use through different, yet linked, lenses. First, quantitative and qualitative data from newly admitted patients in treatment for opioid use disorder shed light on the concomitant NMU of gabapentin and opioid agonist therapies such as buprenorphine and methadone, including motivations, perceived benefits, and consequences. Second, data from US poison centers in 48 states will describe recent trends in gabapentin-involved poison center exposure cases, co-occurring substances present in each case, and related direct deaths. Finally, data from law enforcement agencies in 49 states who report diversion cases and use trends in their jurisdictions will report describe national rates of gabapentin diversion along with qualitative data from law enforcement investigators which describe polysubstance trends and behaviors in their justifications.

These presentations represent some of the first national-level reports of polysubstance trends involving gabapentin. Although gabapentin may have some harm reduction benefits in the self-treatment of OUD, negative consequences of NMU in combination with opioids can be severe and contribute to fatal overdoses. Continued surveillance of gabapentin in the context polysubstance use is needed.

14.1 Co-Occurring Use of Gabapentin and Opioid Agonist Therapies: Prevalence and Motivations
Matthew Ellis, Washington University in St. Louis

14.2 National Trends in Gabapentin Diversion and Qualitative Descriptions of Polysubstance Use
Mance Buttram, University of Arkansas

14.3 Perils of Polysubstance Use: Tales and Trends of Gabapentin From US Poison Centers
Janetta Iwanicki, Rocky Mountain Poison and Drug Safety

1:00 P.M. - 2:00 P.M. MINI-SYMPOSIUM

15. CATCHING UP ON SLEEP: INSIGHTS INTO THE BIDIRECTIONAL RELATIONSHIP BETWEEN DRUG USE AND SLEEP IMPAIRMENTS, AND RELAPSE POTENTIAL

Chair: Robert Gould, Wake Forest School of Medicine
Co-Chair: Lais Berro, University of Mississippi Medical Center

Substance use disorders (SUDs) show a high degree of comorbidity with sleep problems, with drug abuse profoundly impairing sleep at all phases of addiction. Conversely, sleep disruption also may affect the course of drug addiction: Individuals with a history of sleep problems are at higher risk for the development of substance use disorders and are more likely to relapse during treatment. Taken together, these observations suggest a bidirectional relationship between effects of drugs of abuse and sleep impairment that may be
critical for developing effective treatments. In this symposium, we will discuss recent studies indicating that SUDs and sleep disorders are intricately interconnected, including evidence across the translational pipeline. While decades of research have shaped our understanding of circuits/mechanisms regulating homeostatic sleep and neurobiological changes following chronic drug exposure, less research has demonstrated a causal relationship between the two. Speakers will cover topics including mechanisms underlying sleep and how neurobiological changes associated with SUD may contribute to altered sleep, pre-clinical and translational research investigating progressive and persistent sleep impairment in animals self-administering drugs, and clinical studies showing a clear role of sleep in SUDs. This symposium will cover a range of topics in a field that is of high relevance to both basic and clinical scientists.

15.1 Progressive Sleep Alterations Following Cocaine or Oxycodone Self-Administration in Rats.
Robert Gould, Wake Forest School of Medicine, Department of Physiology/Pharmacology

15.2 Sleep Disturbances and Dopamine Adaptations During Cocaine Abstinence
Rodrigo España, Drexel University College of Medicine

15.3 Nonhuman Primates as a Translational Model to Study the Effects of Methamphetamine on Sleep
Lais Berro, University of Mississippi Medical Center

3:45 P.M. – 5:15 P.M. SYMPOSIUM

16. “EXTENDING” THE BENEFITS OF EXTENDED (VIRTUAL AND AUGMENTED) REALITY TO SUD PATIENTS

Chair: Leonardo Angelone, DHHS/National Institute on Drug Abuse

Extended reality (XR) can be defined as an artificial environment which is experienced through sensory stimuli (such as sights and sounds) provided by a computer and in which one’s actions partially determine what happens in the environment. XR approaches are diverse and currently include augmented reality (AR), virtual reality (VR) and mixed reality (MR). While the use of XR as a therapeutic has been initially proposed over 20 years ago, only recently the technology has become robust enough to be applied to medical devices. Exponential improvement of computational and graphic capabilities and emergence of peer-reviewed XR research led to attempts to leverage this technology for surgical and radiology applications, and more recently as therapeutic solutions for pain and substance use disorders (SUDs).

XR-based products are characterized by broad flexibility of content, adaptable design to address diverse patient needs, ability to address high or low digital literacy, and a wide price range. Speakers will discuss ongoing research efforts in the XR as a medical device area, with specific attention to patient-centric study design. Panelists will also discuss existing regulatory hurdles for XR devices and opportunities to ensure that developed solutions are accessible to SUD patients of diverse socio-economic backgrounds, including underrepresented and vulnerable populations.

16.1 Opportunity for Self-Administered VRx to Reduce Opioid Use With Chronic Pain Sufferers
Matthew Stoudt, AppliedVR, Inc.

16.2 Virtual Reality for Opioid-Sparing Chronic Pain Management
Celine Tien, Tamade Inc. (dba Flowly)
17. PAIN RELIEF WITHOUT OPIOIDS: IS THE FUTURE NOW?

Chair: Nathan Appel, National Institute on Drug Abuse, National Institutes of Health
Co-Chair: Jane Acri, National Institute of Drug Abuse, National Institutes of Health

Opioid receptor agonists acting primarily at mu opioid receptors, are widely prescribed to treat pain. They are effective analgesics, but they carry liabilities that include dependence, tolerance, respiratory depression, nausea, somnolence, constipation, and abuse potential. Moreover, opioid analgesics are less effective for treating certain pain modalities such as inflammatory and neuropathic pain. The NIDA Medications Development Program in concert with the NIH HEAL (Helping to End Addiction Long-termSM) Initiative is supporting research to develop effective new analgesics that lack all, or some of the liabilities of mu opioid receptor agonists. In this symposium, we will present preclinical and clinical progress on NIDA-supported efforts to develop safer analgesics. Drs. Jane Acri and Nathan Appel will then moderate a discussion on how novel non-opioid analgesics can inform treatment and potentially reduce exposure to opioids for both new and existing patients with acute and chronic pain conditions.

17.1 Arylepoxamides: A New Class of Potent, Safer Analgesics
Jeffrey Reich, Sparian Biosciences, Inc.

17.2 Nav1.7 Selective Inhibitors for the Treatment of Acute and Chronic Pain
John Hunter, Site One Therapeutics

17.3 A Novel Chemical Entity That is an Effective, Safe, Non-Addictive Peripheral Anti-Hyperalgesic
Paula Hoffman, University of Colorado Anschutz Medical Campus

17.4 Agonist Targeting of TRPV1 for Pain Treatment
Andrew Mannes, Clinical Center, NIH

3:45 P.M. - 5:15 P.M. SYMPOSIUM

18. NDEWS METHODS TO DETECT NEW AND EMERGING PSYCHOACTIVE SUBSTANCES PRESENTED BY NEW AND EMERGING SCIENTISTS

Chair: Linda Cottler, University of Florida
Co-Chair: Marsha Lopez, National Institute of Drug Abuse, National Institutes of Health

In 2020, NIDA funded the second iteration of the National Drug Early Warning System (NDEWS) to address the shifting landscape of drug use in the US, particularly the proliferation of new psychoactive substances (NPS) such as fentanyl and its analogs, synthetic cathinones, and synthetic cannabinoids. Real-time surveillance is needed to detect early signals of new and emerging drug trends and inform prevention efforts, and the new iteration
ABSTRACT

of NDEWS has established multiple data sources to provide an integrated and comprehensive characterization of drug use and availability. This workshop will discuss the NDEWS Scientific Advisory Group, Sentinel Sites, Weekly Briefings, and four methods for surveillance, including: 1) Rapid Street Reporting, on-the-ground rapid surveys of NPS use in Sentinel Site locations, pairing self-report methods with hair sampling; 2) assessment of real-time, substance-related 911 dispatch data; 3) collaborations with High Intensity Drug Trafficking Area (HIDTA) programs and RADARS for monitoring of drug seizures and exposures reported to national Poison Control Centers; and 4) real-time web monitoring of drug-related discussion forums. Trainees from the University of Florida NIDA T32 Predoctoral Training Program and Florida Atlantic University spearheading these NDEWS projects will present their methods and ongoing surveillance findings at this symposium. The audience will be asked to link to a brief survey at the end of the symposium to obtain feedback on the topics important to them.

18.1 Rapid Street Reporting: Identifying Emerging Drugs and Their Adverse Effects in the Field
Nae Won, University of Florida, College of Medicine

18.2 Drug Seizures and Poisoning Exposures: Collaborations with HIDTA and RADARS for Monitoring Trends in Drug Use and Availability in the U.S.
Nicole Fitzgerald, University of Florida

18.3 Real-Time 911 Dispatch Data to Monitor Overdose Events in the U.S.
Andrew McCabe, University of Florida

18.4 Web Monitoring of New Psychoactive Substance Trends in Drug Subreddit Discussion
Paul Morris, Center for Complex Systems and Brain Sciences, Florida Atlantic University

Moderator: Anna Wang, University of Florida

7:00 P.M. - 9:00 P.M. WORKSHOP

19. EARLY CAREER MEMBER COMMITTEE: NAVIGATING A CAREER IN ADDICTION SCIENCE

Chair: Lia Smith, University of Houston
Co-Chair: Denise Vidot, University of Miami

Despite the many career paths available to addiction scientists, the knowledge on how to navigate a given career can be limited. This gap in knowledge may often be a function of available mentorship and/or resources. Opportunities may exist for emerging addiction scientists that are suited for their skillsets or expertise but are otherwise inaccessible due to a lack of institutional knowledge on how to pursue certain career paths. The purpose of this workshop is to provide early career attendees the opportunity to hear from a diverse group of addiction scientists pursing a range of professions in academia, industry, and government agencies. This workshop will provide valuable information to early career attendees about skill sets, experiences, and expertise required to be successful in various careers as addiction scientists. Our speakers include preclinical, clinical, and epidemiological addiction scientists with experience in industry (Pew Charitable Trust, Canopy Growth Inc.), government (FDA), and academic (research institute, teaching institute and clinic-based research) agencies. Presenters will share experiences that prepared them for success, describe their day-to-day work entails, and discuss available growth opportunities. The workshop will also include breakout groups with each speaker that will allow early career attendees to ask directed questions about specific career paths. CPDD is successful, in part, because of dedicated addiction scientists with careers in academia, industry, and government.
who collaborate to advance the understanding of addiction science. This workshop will provide critical insights for early career attendees, facilitate unique networking opportunities, and will ultimately enrich the future membership of CPDD.

19.1 Navigating Substance Use Disorder Careers Outside of Academia  
Alexandra Duncan, The Pew Charitable Trusts

19.2 Drug Abuse Research at a Primarily Undergraduate Institution: Balancing the Classroom and Laboratory  
Ryan Lacy, Franklin and Marshall College

19.3 The “Ins” and “Outs” of a Typical Workday for a Regulatory Scientist on the FDA Controlled Substance Staff  
Jovita Randall-Thompson, US Food and Drug Administration

19.4 The Role of the Psychiatrist in Academic Research  
Denis Antoine, Johns Hopkins University School of Medicine

19.5 Trading Paces: One Perspective on the Journey From Academia to Industry  
Erica Peters, Canopy Growth Corporation

7:00 P.M. - 9:00 P.M. WORKSHOP

20. 28TH ANNUAL CONTINGENCY MANAGEMENT WORKING GROUP

Chair: Diann Gaalema, University of Vermont

The Contingency Management (CM) Working Group, held annually during the CPDD convention, is an opportunity for the discussion and dissemination of current research regarding the use of CM interventions to promote behavior change and reduce drug use. CM is a behavioral treatment strategy that has demonstrated consistent success in promoting abstinence from a wide-range of drugs and across many different treatment populations. It is also being used to promote change in behaviors impacting the course of other chronic diseases (e.g., obesity, diabetes). At the 28th annual meeting of the CM Working Group, junior and senior researchers will present preliminary data from ongoing studies involving CM. The goal for this working group is to provide an informal outlet for discussion of ongoing CM research, with an emphasis on developing or improving research strategies by seeking audience input, and providing opportunities for junior and senior researchers to interact. As the goal for this working group has always been to provide an informal outlet for discussion of CM data, names of presenters are not included with this submission. Rather, participants and topics will be chosen during the Spring of 2022 in order to capture the most current data in contingency management for presentation at our annual working group.

20.1 Contingency Management to Promote Health-Related Behaviors  
Diann Gaalema, University of Vermont

20.2 Promoting Abstinence From Commonly Abused Drugs  
Forrest Toegel, Northern Michigan University
Over the past 20 years, drug-related epidemics have expanded from metropolitan areas into rural areas. This workshop is designed to strengthen participants’ capacities to plan and conduct rigorous research with people who use drugs (PWUD) and live in rural areas.

Methods to study drug use and drug-related harms were often created in, and for, cities, and so must be adapted or replaced in rural environments because of urban/rural differences in population dynamics, technology access and use, travel distances, and the distribution of resources. Venue-based sampling, for example, may encounter challenges because low densities of rural populations are usually accompanied by low densities of medical and public health organizations. Moreover, local knowledge and relationships may be required to identify and gain entrée to organizations serving PWUD because they are purposely hidden from populated areas. Further, the lack of history with research may make it more difficult to establish the relationships necessary to gain local knowledge and entrée.

We will draw on learnings from the first years of eight NIDA-funded Rural Opioid Initiative projects to share, and critically reflect on, promising strategies for engaging and studying PWUD in a variety of rural areas. Speakers will discuss COVID-era challenges to these strategies, and ways to overcome them.

Sessions:
- **21.1 Historical & Sociocultural Drug-Use Contexts in Rural America: A Multi-Site Qualitative Study**
  Vivian Go, University of North Carolina

- **21.2 Recruitment & Retention of Rural PWUD: Lessons From Appalachian Kentucky**
  Thomas Stopka, Tufts University School of Medicine

- **21.3 Epidemiologic, Policy & Vulnerability Scans for Rural Opioid-Related Risks**
  Mai Pho, The University of Chicago

- **21.4 Maximizing Benefits & Avoiding Pitfalls When Collaborating With Rural Health Departments for Harm Reduction**
  William Zule, RTI International

- **21.5 Epidemiologic, Policy & Vulnerability Scans for Rural Opioid-Related Risks**
  April Young, University of Kentucky, College of Public Health
22. A PATH LESS TRAVELED: BECOMING A MEDICAL DEVICE DEVELOPER FOR THE SUBSTANCE USE DISORDERS

Chair: Leonardo Angelone, DHHS/National Institute on Drug Abuse
Co-Chair: Stephanie Carreiro, University of Massachusetts Medical School

The alarming increase of drug overdose-related deaths highlights the continuous public health emergency faced by patients, their families, and caregivers. There is an urgent need for safe and effective solutions for Substance Use Disorders (SUDs), not fully addressed by existing pharmacologic and psychological treatments. Medical devices offer promising means to monitor, diagnose, and treat SUDs. The paths to become a medical device developer in SUD field are often unexplored and unique for each investigator. The symposium offers the opportunity to learn from four speakers about their unique experience and journey to become a medical device developer. Panel members include executives and academic partners from some of the most disruptive and innovative companies in today’s healthcare ecosystem. The speakers have exceptional and diverse background, including emergency medicine, toxicology, epidemiology, anesthesiology, computational neuroscience, and business administration. Their research interests include a broad spectrum of applications for SUD patients, such as digital biomarkers, wearables, mobile health, neurofeedback, or stochastic vibration used as therapy for neonatal abstinence syndrome. They are pioneers in their field, building an ecosystem that includes the scientific community, regulators, payers, and patients. And they share common goals: to develop novel safe and effective technologies for SUD patients, design these products to address specific needs of the patients and their caregivers, and ensure access to these novel solutions for all patient populations.

22.1 Using Smart Devices to Detect Opioid Overdose
Jacob Sunshine, University of Washington School of Medicine

22.2 A Curious Journey to Help Opioid-Exposed Newborns, My Benjamin Button Like Story
John Konsin, Prapela, Inc

22.3 From the University Lab to the Market: Digital Biomarker-Based SUD Intervention Development From the Academic Investigator’s Perspective
Stephanie Carreiro, University of Massachusetts Medical School

22.4 Unplugged: Lessons Learned Taking Drug Craving Neuromarkers Out of the Lab and Into the Clinic
Scott Burwell, Neurotype Inc.
Unfortunately, most individuals living with a SUD do not receive treatment. Peer recovery coaching services involve a form of nonclinical, peer support aimed at helping individuals with SUDs to achieve and maintain recovery. These services are provided by recovery coaches, individuals with lived experience with substance use and a successful recovery. Recent studies have shown the effectiveness of utilizing peer recovery services into different settings, including emergency department and outpatient settings. This workshop will bring together researchers, peer recovery specialists, and clinicians who will provide insight into the implementation of peer recovery services in a variety of settings including clinical trials, inpatient and outpatient services, and emergency departments. More specifically, Dr Pericot-Valverde will describe the implementation of peer recovery coaching in randomized clinical trials. Dr Roth will describe the implementation of peer recovery coaching in inpatient settings departments. Dr Byrne will describe the utilization of recovery coaching services in inpatient and outpatient settings. Finally, Ms. Melling will describe her experience as a specialist peer recovery coach. Focusing on prior experiences from a multidisciplinary team, the workshop will help researchers and clinicians interested in implementing peer recovery coaches for research and treatment purposes.

23.1 Results of Inpatient Linkage to Peer Recovery Coaching on Engagement in Recovery Outcomes and Hospital Utilization
Kaileigh Byrne, Clemson University

23.2 Implementation of Inpatient Peer Recovery Coaching Into the Hospital System
Prerana Roth, Prisma Health-Upstate

23.3 What Are Peer Recovery Coaches and What Do We Do? Input From a Peer Recovery Professional
Trisha Melling, Prisma Health

23.4 Applying Peer Recovery Coaching in Clinical Trials
Irene Pericot-Valverde, Clemson University

TUESDAY, JUNE 14, 2022

10:00 A.M. - 11:30 A.M. SYMPOSIUM

24. CIRCADIAN AND SLEEP FACTORS IN SUBSTANCE USE DISORDERS: ROLE OF THE EXTRACELLULAR MATRIX

Chair: Barbara Sorg, Legacy Research Institute
Co-Chair: Harry Pantazopoulos, University of Mississippi Medical Center

Sleep and circadian rhythms are disrupted in individuals with substance use disorders (SUDs). This session will cover recent findings showing that extracellular matrix components, including perineuronal nets, may serve as key mechanistic links between SUDs and disrupted sleep and circadian rhythms. Dr. Ryan Logan will discuss transcriptomic results in the prefrontal cortex (PFC) and nucleus accumbens (NAc) of humans with opioid use disorder (OUD), demonstrating association of rhythmic transcripts with changes in glutamatergic, GABAergic, and extracellular matrix signaling, and with sleep and insomnia. He will also present evidence for the role of microglia, proinflammatory cytokines, and ECM signaling in OUD. Dr. Harry Pantazopoulos will provide the first evidence of altered PNNs and PNN-surrounded parvalbumin neurons in the hippocampus of humans with SUDs and will discuss the link between these changes with altered expression of clock genes and synaptic markers. Dr. Barbara Sorg will discuss diurnal rhythms of PNNs and surrounded parvalbumin neurons. She will
also discuss how PNNs in the PFC guide cocaine-associated memories in a rodent addiction model, and how depleting PNNs in the PFC alters brain oscillations between the PFC and hippocampus. Dr. Jonathan Wisor will discuss the consequences of manipulating the sleep/wake cycle to address whether the diurnal pattern of PNNs is linked to or is independent of daily variations in the sleep/wake cycle. Collectively, this mini-symposium will highlight changes in the extracellular matrix as an important driver of altered plasticity that links SUDs with disrupted sleep and circadian rhythms.

24.1 Transcriptional Rhythms in Human Brain Reveal Roles for Extracellular Matrix and Microglia in Opioid Use Disorder
Ryan Logan, Boston University School of Medicine

24.2 Extracellular Matrix and Molecular Clock Abnormalities in the Hippocampus of Subjects With Substance Use Disorder
Harry Pantazopoulos, University of Mississippi Medical Center

24.3 Perineuronal Nets: Diurnal Changes and Cocaine Memories
Barbara Sorg, Legacy Research Institute

24.4 Sleep and Circadian Modulation of Perineuronal Nets
Jonathan Wisor, Washington State University

10:00 A.M. - 11:30 A.M. SYMPOSIUM

25. INNOVATIVE APPROACHES FOR EXPANDING ACCESS TO PHARMACOTHERAPY FOR OPIOID USE DISORDER

Chair: Stacey Sigmon, University of Vermont
Co-Chair: Sharon Walsh, University of Kentucky

Innovative approaches are desperately needed to continue the expansion of OUD treatment access. In this session, presenters will share their recent scientific efforts to develop and evaluate novel approaches for expanding delivery of pharmacotherapy and harm reduction. First, Dr. D’Onofrio will discuss innovative strategies for ED-initiated buprenorphine, including the options of high-dose buprenorphine and a 7-day injectable, extended-release buprenorphine formulation which may allow for immediate induction while concurrently surmounting logistic and other barriers that often impede uptake. Second, Dr. Lee will present on his team’s efforts to expand MOUD in CJS settings and populations, which will include NIDA-funded research findings and real-world implementation efforts on recent and current clinical trials and MOUD expansion strategies focused on criminal justice facilities and re-entry populations. Thirdly, Dr. Freemen will discuss the role of pharmacists in substance use disorder treatment and harm reduction. This will include recent efforts by pharmacists to initiate dispensing of naloxone, establish opioid and alcohol use disorder treatment services with long-acting naltrexone injection, and sell syringes over-the-counter to persons who inject drugs. Finally, Dr. Sigmon will present primary outcomes from two recently-completed randomized clinical trials (1 rural, 1 non-rural setting) evaluating the efficacy of a technology-assisted buprenorphine treatment for reducing illicit opioid use and other risk behaviors. Dr. Walsh will moderate this session. Taken together, we aim to share updates on recent scientific efforts to expand avenues for increasing access to life-saving opioid treatment.

25.1 Innovative Strategies for ED-Initiated Buprenorphine
Gail D’Onofrio, Yale University School of Medicine
Early life adversity (ELA) is a term that is being used to describe traumatic events that occur during childhood which have the potential to alter normal development and increase risks for a spectrum of physical and mental health in adulthood, including substance use disorders (SUDs). Accumulating evidence has shown associations between ELA and risk behaviors, drug misuse, more rapid transition from misuse to use disorders, and poor treatment outcomes in humans. These findings have mirrored those of preclinical studies demonstrating the consequences of early life manipulations on behaviors that reflect aspects of drug reward or tendency to relapse after abstinence. Nevertheless, ELA is only beginning to be taken into consideration in the development of individualized prevention and treatment strategies and there is a need for better understanding of the neurobiological processes that promote vulnerability or resilience in ELS-exposed individuals. This symposium will begin with a presentation by Dr. Khan who will discuss the role of ELAs in substance abuse risks, highlighting current findings on mediating pathways that may help to inform intervention strategies. Dr. al’Absi will then review evidence of neurobiological mechanisms that underlie risks for addiction, focusing on the physiological stress system. Dr. Nugent will present her findings showing effects of ELA on behavior depression and motivational properties of morphine and its relationship to habenula activity in a rat model. Finally, Dr. Hales will discuss the impact of ELA on nociception in mice and their response to morphine and its implications for opioid treatment of chronic pain.

26.1 The Role of Childhood Traumatic Events in Substance Use Risk Across the Lifecourse: Considerations of Mediating Paths and Intervention Possibilities
Maria Khan, New York University School of Medicine

26.2 Neurobiological Mechanisms of Early Adverse Experience, Blunted Stress Reactivity and Risk for Addiction
Mustafa al’Absi, University of Minnesota Medical School

26.3 Maternal Deprivation-Induced Lateral Habenula Dysfunction Promotes Anhedonia and Alters Morphine Self Administration Acquisition in Rats
Fereshteh Nugent, Uniformed Services University

26.4 The Impact of Early Life Adversity on Pain and Responses to Opioids
Tim Hales, University of Dundee

Moderator: Erin Winstanley, West Virginia University
10:00 A.M. - 11:30 A.M. SYMPOSIUM

27. CROSS-CULTURAL CANNABIS SCIENCE: LESSONS LEARNT AND HOW TO MOVE FORWARD

Chair: Janna Cousijn, Erasmus University Rotterdam
Co-Chair: Francesca Filbey, University of Texas at Dallas

Today’s world is experiencing shifts towards lenient cannabis policies and similar shifts in public opinion. However, the knowledge base of both harms and benefits is still poor and integration of evidence is complicated by substantial variability in cannabis products, route of administration, and regional differences therein. For example, European cannabis users often smoke cannabis with tobacco, while this is uncommon in US users. Moreover, the strength of cannabis is highly variable between regions, and how others perceive cannabis use will likely impact the social problems a cannabis user experiences. This symposium will describe what we currently know about the impact of long-term cannabis use and dependence on brain and behaviour. Taking a cross-cultural and cross-jurisdictional perspective, we will critically evaluate the role of different user characteristics and the environment. We will discuss novel findings from neuroimaging research investigating the role of cannabis culture, as well as cannabis policy research. Moreover, we will discuss important knowledge gaps and evaluate novel tools to globally harmonise cannabis research.

27.1 Cannabis Use, Dependence and the Brain: What Do We know?
Janna Cousijn, Erasmus University Rotterdam, The Netherlands

27.2 The Role of Cannabis Cultural Attitudes and Norms on Cannabis Approach Tendencies in Individuals With Cannabis Use Disorder
Lauren Kuhns, University of Amsterdam

27.3 Assessing Cannabis Consumption and Policy-Relevant Outcomes at the Population Level
David Hammond, University of Waterloo

27.4 Bridging the Gaps: New Developments in Measuring Cannabis Use Across International and Multidisciplinary Settings
Valentina Lorenzetti, Australian Catholic University

12:00 P.M. - 2:00 P.M. ANIMAL FORUM

28. GETTING THE WORD OUT: STRATEGIES FOR EFFECTIVE COMMUNICATION ABOUT ANIMALS IN RESEARCH

Chair: James Rowlett, University of Mississippi Medical Center

Animal research plays a vital role in our understanding of substance use disorders (SUDs), contributing to topics ranging from genetic/molecular mechanisms to complex social interactions. As with most research endeavors with animals, misrepresentations about the importance of animal research in SUDs research has grown over the years due to the actions of animal rights extremists, who are remarkably effective at affecting public opinion. As an organization, CPDD supports animal research, and a key strategy for growing this support beyond the scientific community is to engage in effective communication that: (a) informs the public at large about the issues and misinformation propagated by the modern animal rights extremism movement, and (b)
informs the public at large about the factual role animal research plays in scientific advancement of the field. To discuss these issues, Dr. Sangeeta Panicker (American Psychological Association) will provide an overview of the strategies and recent successes of the animal rights movement in the modern era. Next, Dr. Allyson Bennett (University of Wisconsin—Madison) will discuss communication strategies for all scientists to engage both scientific and non-science audiences alike. The overall goal of this Forum is to make the membership aware of the urgent issues regarding the animal research environment and to provide important resources for addressing these critical issues.

28.1 Not Just Science: Talking About Ethics, Animals, and Public Benefit
Sangeeta Panicker, Public Responsibility in Medicine and Research (PRIM&R)

28.2 Why Are We Still Doing This? Making the Basic to Applied Relationship Clear
Allyson Bennett, University of Wisconsin-Madison

1:00 P.M. - 3:00 P.M. POLICY FORUM

29. IMPACT OF COVID-19 OPIOID TREATMENT PROGRAM POLICY RELAXATIONS ON PATIENT OUTCOMES

Chair: Sandra Comer, Columbia University and NYSPI
Co-Chair: Dennis McCarty, Oregon Health and Science University
Discussant: Gavin Bart, University of Minnesota

The 2022 CPDD Policy Forum examines the COVID-19 relaxation of methadone treatment regulations. In addition, the Policy Forum will include a Friends of NIDA update and a review of pending federal legislation.

Optimal Policies to Improve Methadone Maintenance Adherence Long-term (OPTIMMAL)
Arthur Robin Williams, MD
The study examined pre-pandemic OTP operations and patient outcomes (e.g., clinic dosing visits, take-home doses, retention in care) with post-pandemic operations and patient outcomes. Approximately 2,500 patient charts were reviewed across 10 OTPs participating in the National Drug Abuse Treatment Clinical Trials Network.

Multi-state Survey of Opioid Treatment Program Leaders Assessing COVID-19 Changes
Ximena Levander, MD
A multi-state survey of OTP leaders’ responses to COVID-19 related policy changes assessed 1) how OTPs changed take-home methadone provisions, 2) factors considered in determining patient stability, and 3) concerns surrounding expanded take-homes. The two most common factors for determining stability were ongoing non-prescribed opioid use (52%) and sedative use (52%).

Impacts of COVID-19 Relaxation of Methadone Policies in Rural Oregon Opioid Treatment Programs (Oregon HOPE study)
Todd Korthuis, MD, MPH
Oregon’s OTPs reported a 50% decline in patient visits and a 97% increase in take-home doses after implementation of relaxed policies. In two rural OTPs, the rate of opioid positive urine screens did not increase and interviews identified three themes: 1) patients felt trusted with increased responsibility; 2) repurposed time spent traveling to the clinic with other activities supportive of recovery; and 3) less exposure to individuals who hampered recovery.
29.1 The Optimal Policies to Improve Methadone Maintenance Adherence Longterm OPTIMMAL CTN Study
Arthur Robin Williams, Columbia University Division on Substance Use Disorders

29.2 Multi-State Opioid Treatment Program Leader Survey of COVID-19 Policy Changes
Ximena Levander, Oregon Health and Science University

29.3 Impacts of COVID-19 Relaxation of Methadone Policies in Rural Oregon Opioid Treatment Programs (Oregon Hope Study)
P. Todd Korthuis, Oregon Health and Science University

2:00 P.M. - 3:00 P.M. JOURNALS

30. JOURNALS: DRUG AND ALCOHOL DEPENDENCE AND DRUG AND ALCOHOL DEPENDENCE REPORTS

Steve Shoptaw, University of California Los Angeles
Teresa Franklin, University of Pennsylvania
Erin McClure, Medical University of South Carolina

In this one-hour Oral Session, the Editor-in-Chiefs for Drug and Alcohol Dependence (DAD; Dr. Steve Shoptaw) and Drug and Alcohol Dependence Reports (DADR: Dr. Teri Franklin) will make a brief presentation on their perspectives for the next year for the journals.

1. Vital stats of DAD and DADR: submission rate/acceptance rate/impact factor
2. Snapshots of the most important papers published over the last year in DAD and DADR
3. What puts a submission on track to be the ‘best’ published of the year?
4. What causes a submission to be rejected without review and authors’ next steps
5. Role of reviewers: what makes a review helpful to authors; what can be learned by being a reviewer?
6. Ensuring diversity and inclusion in peer reviewed journals

30.1 Gender Parity and Homophily in the Drug and Alcohol Dependence Editorial Process
Erin McClure, Medical University of South Carolina

3:30 P.M. - 5:30 P.M. WORKSHOP

31. EVENT-RELATED POTENTIALS AND SUBSTANCE USE DISORDERS: IDENTIFYING CLINICALLY RELEVANT METRICS TO INFORM THERAPEUTICS

Chair: Vaughn Steele, Yale University School of Medicine
Co-Chair: Ingmar Franken, Erasmus University Rotterdam

Substance use disorders (SUDs) are exemplified by dysregulated cognitive functions such as heightened drug cue reactivity, attentional bias, and executive control. Uncovering the underlying mechanisms related to these cognitive functions is important for understanding the chronic, relapsing brain disease of SUDs necessary to develop effective therapeutics. Recent studies show exciting progress in this area and reveal how event-related potentials (ERPs) can inform our understanding of basic brain processes involved in SUD behaviors, predict the onset and development of these behaviors, and provide objective markers for treatment outcome evaluation. In the symposium we present state-of-the-art of ERP studies focused on how ERPs facilitate
prediction, prevention, treatment outcomes, and therapeutic development. Specifically, Dr. Parvaz will present results related to ERPs-based tracking changes in reactivity to cocaine-related cues in cocaine use disorder as a function of abstinence duration as well as with volitional down-regulation of the affective response to these cues. Mr. Butler will present time-frequency ERP measures of attentional processes dysregulated in SUD. Dr. Steele will present ERP measures of dysregulated response inhibition and error-monitoring and outline how these are targets for therapeutic interventions to treat SUDs. Finally, Dr. Franken will present recent and ongoing studies of error-processing in SUD as highlighted in a large-scale study of adolescents to predict the development of substance use disorders. Together, these presentations will highlight how robust and versatile ERP measures inform clinical outcomes and therapeutic development.

31.1 Electrophysiological Tracking of Drug Cue-Reactivity and Changes Therein With Abstinence and Self-Regulation
Muhammad Parvaz, Icahn School of Medicine at Mount Sinai

31.2 Delta and Theta Activity From an 3-Stimulus Oddball Task Provide Shared and Unique Sensitivity to Alcohol and Cocaine Use Disorders
Devin Butler, University of Maryland - College Park

31.3 Identifying Treatment Targets Related to Dysregulated Circuits in Substance Use Disorders With Event-Related Potential Measures of Response Inhibition and Error-Monitoring
Vaughn Steele, Yale University School of Medicine

31.4 Electrophysiological Indices of Error Processing in Substance Use Disorders
Ingmar Franken, Erasmus University Rotterdam

3:30 P.M. - 5:30 P.M. WORKSHOP

32. DID YOU HEAR ABOUT THE LOOMING GLOBAL FENTANYL CRISIS?: A QUICK START FOR ADDICTION SCIENTISTS ACROSS THE WORLD

Chair: Francesca Filbey, University of Texas at Dallas
Co-Chair: Dace Svikis, Virginia Commonwealth University

Illegally sourced fentanyl is no longer just a problem for the United States. Despite disruptions in supply chains for illicit drugs during the COVID-19 pandemic, we have witnessed an increase in fentanyl-related drug fatalities, and fentanyl is now also being shipped to Canada, Europe, and other destinations. How will these complex developments be different from the U.S. opioid epidemic and are there lessons learned that can be applied to evolving contexts and settings? What strategies from different countries can be effective in fending off an emerging global fentanyl crisis?

Towards the goal of providing current data and resources for an international audience to address this growing worldwide public health concern, this workshop will be structured in two parts. Part 1 (80 minutes) will consist of 20-minute panel presentations: (1) Thom Browne from the Colombo Plan will discuss various fentanyl compounds (and other novel synthetic opioids) and existing international controls; (2) Paul Griffiths from the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) will present scientific evidence on the fentanyl crisis in the EU as well as the impacts of medical and legal policies; (3) Kim Johnson, Director of the International Consortium of Universities for Drug Demand Reduction (ICCUDDR) will describe how ICCUDDR’s mission of supporting addiction professionals can be leveraged to meet the challenges of this global crisis; and (4) Steve Gust, Director of NIDA International Program, will describe existing NIDA mechanisms to advance international collaborations on addiction research. Part 2 (40 minutes) will be an interactive Q and A session.
Among individuals with a current substance use disorder (SUD), 90% did not receive any substance use treatment in the past year. Despite the existence of evidence-based interventions addressing SUDs and their impact on the greater community, the availability of a well-trained workforce to deliver such services is severely limited. This workshop will educate participants on the latest efforts to develop and evaluate training initiatives designed to meet the demand for accessible evidence-based services that address SUDs. Dr. Jessica Chou will first present on a Health Resources and Services Administration (HRSA) Opioid Workforce Expansion Program (OWEP) to train graduate students to provide services to children, adolescents, and families impacted by opioid use disorder in Ohio and Pennsylvania, two states experiencing some of the highest rates of opioid fatalities in the United States. Dr. Paul Sacco will then present on the University of Maryland, Baltimore Behavioral Health Workforce Integration Service and Education (BHWISE) Fellowship programs, highlighting an interdisciplinary OWEP designed to train clinicians who are committed to working with underserved communities. Dr. Kenneth Carpenter will next present on a national parent-to-parent peer support network by describing the feasibility and acceptability of training parents of a child who has a substance use disorder in evidence-based principles and strategies who in turn provide phone coaching to other parents seeking help for their children. Finally, Drs. McCarthy and Chou will lead an interactive discussion on next steps to expand our ability meet the unmet need for addiction treatment.

33.1 Online Family Systems Training for Graduate Students Working With Adolescents & Families Impacted by Opioid Use Disorder
Jessica Chou, Drexel University

33.2 Training the Next Generation of Substance Use Disorder Clinicians Committed to Working With Underserved Communities
Paul Sacco, University of Maryland Baltimore

33.3 Parent-To-Parent Phone Coaching for Families Experiencing a Substance Use Disorder
Kenneth Carpenter, New York State Psychiatric Institute, Columbia University
3:30 P.M. - 5:30 P.M. WORKSHOP

34. ENGAGING COMMUNITIES TO DELIVER EFFECTIVE OPIOID USE PROGRAMS FOR NATIVE AMERICANS

Chair: Daniel Dickerson, UCLA Integrated Substance Abuse Programs

The opioid epidemic is having a profound impact on the health and well-being of American Indian/Alaska Native (AI/AN) people. Effective relationships between researchers, clinical delivery systems and Native American communities are needed in order to create a system of opioid treatment delivery that is sustainable and culturally appropriate.

The first part of this workshop will include brief presentations. First, Dr. Daniel Dickerson (Inupiaq) will describe the development of a new opioid prevention intervention for urban AI/AN emerging adults. Next, Dr. Claradina Soto (Najavo/Pueblo) will describe a comprehensive assessment of California Tribal Health Programs, Urban Indian Health Programs, and AIAN culturally centered residential treatment, and sober living facilities. Next, Dr. Carrie Johnson (Wahpeton Dakota), will provide a clinical perspective in the implementation and delivery of opioid prevention and treatment. Lastly, a community elder (to be determined) will provide a community perspective with regard to the delivery of opioid interventions for AI/ANs.

The second part of this workshop will include an interactive exercise that will involve the development of a new “hypothetical” opioid use treatment program for Native Americans. The audience will be separated into three groups: 1) an AI/AN community advisory board, 2) opioid use intervention researchers, and 3) clinic administrators and providers. Following a brief description of this community, each group will discuss potential strategies that may need to be considered. Lastly, a broader discussion with the whole group will be conducted to identify some potential collaborative strategies that can help develop this new program.

34.1 The Development of a New Opioid Prevention Intervention for Urban Native American Emerging Adults
Daniel Dickerson, UCLA Integrated Substance Abuse Programs

34.2 An Overview of a Comprehensive Assessment of Opioid Treatment Programs for Native Americans in California
Claradina Soto, Keck School of Medicine University of Southern California

34.3 Engaging Communities to Deliver Effective Opioid Use Programs for Native Americans
Carrie Johnson, United American Indian Involvement

34.4 Engaging Communities to Deliver Effective Opioid Use Programs for Native Americans
George Funmaker, State of California, Department of Corrections and Rehabilitation

3:30 P.M. - 5:30 P.M. WORKSHOP

35 ADVANCES IN ADOLESCENT RECOVERY RESEARCH AND THE SOCIETY FOR ADOLESCENT SUBSTANCE ABUSE TREATMENT EFFECTIVENESS (SASATE)

Chair: Michael Dennis, Chestnut Health Systems
Co-Chair: Doug Smith, University of Illinois Urbana-Champaign

The process of substance use disorder (SUD) recovery is difficult for adolescents and young adults. It often involves multiple episodes of treatment and relapse. While adolescents is the primary person of substance use
onsite and SUD prevalence peaks during young adult, treatment and recovery support systems are generally geared towards older adults. In the past two decades there has been a growing body of research on how to facilitate and sustain recovery. More recently this research has begun to focus on adolescents and youth adults. Presentations on recovery related research with adolescents and young adults and will include presentations by: Dr. Douglas Smith on, “Coming of Age in Recovery: The prevalence and correlates of recovery status among a large statewide sample of adolescents”; Dr. John Kelly on “Independent Effects of entering recovery as a young versus older adult on long-term functioning and quality of life: Results from a National Survey on Recovery”; Dr. Emily Hennessy on, “Social Influence in Youth Recovery and the use of Social Identity Mapping to Examine Recovery Processes”; Dr. Michael Dennis on “Preliminary Findings from the Smartphone Addiction Recovery Coach (SARC) experiment with Young Adults”; and Robert M. Vincent facilitating a discussion.

35.1 Coming of Age in Recovery: The Prevalence and Correlates of Recovery Status Among a Large Statewide Sample of Adolescents
Doug Smith, University of Illinois Urbana-Champaign

35.2 Social Influence in Youth Recovery and the Use of Social Identity Mapping to Examine Recovery Processes
Emily Hennessy, Massachusetts General Hospital and Harvard Medical School

35.3 Independent Effects of Entering Recovery as a Young Versus Older Adult on Long-Term Functioning and Quality of Life: Results From a National Survey on Recovery
John Kelly, Harvard Medical School

35.4 Preliminary Findings From the Smartphone Addiction Recovery Coach (SARC) Experiment With Young Adults
Michael Dennis, Chestnut Health Systems

Moderator: Robert Vincent, Substance Abuse and Mental Health Administration (SAMHSA)

WEDNESDAY, JUNE 15, 2022

10:00 A.M. - 11:30 A.M. SYMPOSIUM

36. THE OREXIN SYSTEM IN ADDICTION

Chair: Scott Lane, University of Texas Health Science Center, McGovern Medical School
Co-Chair: Mark Greenwald, Wayne State University

Accumulating evidence demonstrates that the hypocretin/orexin (ORX) neuropeptide system and its constituent CNS receptors play a significant role in the development and maintenance of substance use disorder (SUD). The biobehavioral components through which ORX contributes to SUD are still being elucidated; regulation of motivational, stress/anxiety, sleep and energy homeostasis systems are strongly implicated. The present symposium will provide an update on mechanisms and treatment interventions involving the ORX system in addiction. Presentations will include both preclinical and human studies and feature investigations covering a range of abused substances.

36.1 Cocaine-Suvorexant Interactions: A Human Laboratory Study
William Stoops, University of Kentucky
36.2 Dual Orexin Receptor Antagonism During Opioid Withdrawal  
Andrew Huhn, Johns Hopkins University School of Medicine

36.3 The Orexin System in Addiction  
Brooke Schmeichel, East Tennessee State University, James H. Quillen College of Medicine

36.4 Orexin System Plasticity Following Cocaine in Rats: Therapeutic Opportunities  
Morgan James, Rutgers University

10:00 A.M. - 11:30 A.M. SYMPOSIUM

37. THROUGH THE LOOKING GLASS: METACOGNITION, INTEROCEPTION, HALLUCINOGENS, AND NON-ORDINARY STATES AS POTENTIAL AVENUES FOR NOVEL ADDICTION TREATMENTS.

Chair: Albert Garcia-Romeu, Johns Hopkins University School of Medicine

Metacognition issues in addiction lead to problems in social functioning and may contribute to low treatment success rate and high levels of relapse. Research into the role of interoception in drug and alcohol use is also growing. Interoceptive “fingerprints” could be a part of predisposition endophenotype, and also may change under the influence of drugs and alcohol, or through targeted treatment. Data on emerging treatment modalities using hallucinogens suggest the potential for rapid insight and behavior change, possibly through inducing non-ordinary states that can alter metacognition and interoceptive processes. These interventions may present novel avenues to overcoming barriers in addiction treatments, while improving social cognition and functionality.

37.1 Moderated Discussion: Hallucinogens and Non-ordinary States in Addiction Treatment  
Albert Garcia-Romeu, Johns Hopkins University School of Medicine

37.2 Metacognition in Mental health: A Hierarchical and Transdiagnostic Framework  
Tricia Seow, UCL, London

37.3 Interoceptive Correlates of Alcohol Administration and Future Clinical Avenues  
Mateo Leganes-Fonteneau, Center of Alcohol and Substance Use Studies, Rutgers University

37.4 Down a Rabbit Hole? The Role of Metacognition and Interoception in Establishing Addiction Phenotypes  
Lori Keyser-Marcus, Virginia Commonwealth University

37.5 Interrupted by the Ineffable: The Role of Ketamine-Occasioned Non-Ordinary Experiences in Facilitating Cognitive, Perceptual, and Existential Reappraisal in SUDs  
Elias Dakwar, Columbia University
Cannabis is the most commonly used federally illicit drug in the United States (U.S.) (SAMHSA, 2019) and the prevalence of cannabis use and cannabis use disorder (CUD) has increased in the US over the past two decades, but the majority of users do not develop CUD. High levels of exposure to cannabis increases the likelihood that young adults will experience deleterious psychosocial and behavioral consequences, as well as substance use disorders. Given widespread legalization and increased rates of use, it is important to identify the biopsychosocial risk processes that are most relevant to distinguishing those who will develop hazardous use and/or cannabis use disorder. This symposium will present findings on neurophysiological, biological, and psychosocial risk factors for hazardous use and cannabis use disorder. Research presented will employ multiple modalities including laboratory paradigms of stress reactivity, EEG, cue reactivity, intensive repeated measurement of stress biomarkers and self-report, and longitudinal designs over 3-6 months that will highlight key risk factors in the process of increasingly hazardous cannabis use, consequences from cannabis use, and cannabis use disorder. The aim of this session is to review several biopsychosocial risk processes with a focus on modalities of cannabis use, stress and cannabis cue motivation, and sex differences in cannabis users that may underlie patterns of problematic use. Implications for prevention of risk and treatment will be discussed.

38.1 Associations Between Modes of Cannabis Use in Daily Life With Concurrent and Longitudinal Hazardous Use and Consequences
Margaret Bedillion, Penn State University

38.2 Electrophysiological Markers of Cannabis Cue Reactivity in Regular Cannabis Users: Impact of CUD Severity and Acute Stress
Richard Macatee, Auburn University

38.3 Investigating Real-World Subjective Responses and Cortisol in Individuals With Cannabis Use Disorder Relative to Recreational Cannabis Users: An In-Field, Within-Person Intensive Monitoring Study
Stephanie Wemm, Yale School of Medicine

38.4 Sex Differences in Risk Mechanisms Underlying Hazardous Cannabis Use
Emily Ansell, Penn State University

Moderator: Margaret Haney, Columbia University Irving Medical Center
The number of adults age +65 years is expected to more than double over the next 30 years and for the first time ever older adults will make up nearly a quarter of the US population. At the same time, there is evidence that substance use disorders (SUDs) among older adults are increasing including drug-related overdoses. Older adults who use psychoactive substances are at heightened risk for harm including exacerbation of chronic health issues such as cardiovascular disease and cancer.

The primary aim of this symposium is to promote discussion around how to increase the representation of older adults who use psychoactive substances in research, treatment, and health policy and the special considerations pertaining to an older adult population. Four presentations will 1) provide critical analysis of tobacco smoking prevalence in the US across over last 30+ years using data from the National Health Interview Survey, 2) present survey data characterizing cannabis use, risk perceptions, and symptom management among patients with a cancer diagnosis, 3) describe patterns of comorbidities and healthcare utilization among older adults with opioid use disorder, and 4) critically examine co-occurring opioid use, cannabis use, and dual-use of these substances among older adults with chronic pain. Given the broad focus of this symposium across methods and substances of use, we expect that it will be of great interest to clinical researchers, healthcare providers, and health policy organizations to promote the inclusion of older adults in all areas of SUD research and treatment.

39.1 Age and Race Disparities in Tobacco Smoking Prevalence in the United States: Over 50 Years and Counting
Betha Kleykamp, BAK and Associates, LLC

39.2 Opioid Use Disorder Among Older Adults: Addressing Multimorbidity and Geriatric Conditions
Benjamin Han, University of California - San Diego

39.3 Characterizing Chronic Pain and Co-Occurring Substance Use in a Community Sample of Younger and Older Adults
Marilyn Horta, University of Florida

39.4 Assessing Patterns of Cannabis Use, Risk Perceptions, and Symptom Management Among Older Adults With a Cancer Diagnosis
Margaret Fahey, Medical University of South Carolina
11:30 A.M. - 1:30 P.M. MEDIA FORUM

40. MEDIA FORUM - HARNESSING YOUR EXPERTISE: CPDD MEDIA TRAINING WITH REPORTING ON ADDICTION

Chair: Bethea Kleykamp, BAK and Associates, LLC

Mainstream news media perpetuates many problematic narratives about drug use and addiction that increase stigma, discrimination, and bad policy. One way to address these shortcomings is to increase the coverage of evidence-based approaches to addiction treatment and recovery, including well-designed research studies, in the news through collaborative efforts with subject matter experts. However, many experts are not trained to interact with journalists in today’s media environment. Thus, this forum is designed to offer customized, in-person training that can help support effective interactions between CPDD attendees and The Media. The Media Forum will be open to all attendees, including graduate-level and early career CPDD attendees for whom this forum could serve as a valuable training experience. The 120-minute forum will be broken down into three components: 1) how The Media works (30 minutes); 2) how you can work with the media (30 minutes); 3) trainer-led small-group didactic and practice sessions (one hour). The small-group trainer sessions will help attendees generate social media-friendly video content for CPDD to promote the sharing of cutting-edge research in the field. Topics covered include how to prepare for interviews, how to disseminate press releases, and how to pitch ideas or op-eds to The Media. In addition, in the weeks following the annual conference, Reporting on Addiction, a cutting-edge collaboration designed to facilitate the communication of substance use research findings, will promote this content to journalists interested in the topic areas covered.

40.1 Media Forum - Harnessing Your Expertise: CPDD Media Training With Reporting on Addiction
Ashton Marra, Reporting on Addiction

40.2 Reporting on Addiction - A Collaborative Approach to Working With the Media to Reduce Stigma
Jonathan Stoltman, Opioid Policy Institute

1:30 P.M. - 2:30 P.M. MINI-SYMPOSIUM

41. FACILITATING COMPASSIONATE AND CONSISTENT CARE FOR WOMEN AND NEONATES AFFECTED BY OPIOIDS

Chair: Dennis Hand, Thomas Jefferson University
Co-Chair: Ekaterina Burduli, Washington State University

Opioid use during pregnancy remains a significant public health concern with 8.2:1000 births including an opioid-related diagnosis. Whether perinatal opioid use consists of a medication for opioid use disorder (OUD) or unauthorized use, all mothers and neonates deserve compassionate and highest quality care. The voices of perinatal women with OUD must be heard to understand their needs and to address stigmatization and discrimination that undermine health during the vulnerable perinatal period. Healthcare providers have frequent interactions with mother-child dyads in the perinatal period and their needs, barriers, and facilitators must be understood to improve the care provided. The studies in the present symposium include qualitative and quantitative analyses of feedback from perinatal women with OUD and the providers who care for them and their neonates. In the first study, pregnant women and nurses identified barriers and facilitators to care, such as compassion fatigue and burnout when seeking medication for OUD. In the second, perinatal women
and healthcare providers identified the importance of self-advocacy while navigating the healthcare and social systems and the importance of communicating expectations in a way which is empowering women. In the final study, nurses and caregivers tested a digital therapeutic care diary with embedded decision support for improving consistency of care in two forms of neonatal abstinence syndrome care, the Finnegan Neonatal Abstinence Scoring Tool and Eat, Sleep Console. Overall, these studies provide critical information for researchers designing educational and technological interventions to improve care for perinatal women with OUD and their neonates.

41.1 Primary Stakeholder Evaluation of Acute Care Induction Period Women Entering Substance Use Treatment
Meghan Gannon, Thomas Jefferson University

41.2 Supporting Perinatal Women With Opioid Use Disorder and Their Newborns Experiencing Neonatal Abstinence Syndrome: Impressions From Perinatal Women and Providers
Ekaterina Burduli, Washington State University

41.3 Development of a Neonatal Abstinence Syndrome (NAS) Primer, Reference and Decision Support Tool
Crystal Smith, Washington State University

1:30 P.M. - 2:30 P.M. MINI-SYMPOSIUM

42. USING BIG DATA TO OPTIMIZE BENZODIAZEPINE PRESCRIBING AND DEPRESCRIBING ACROSS THE LIFESPAN

Chair: Kevin Xu, Washington University School of Medicine
Co-Chair: Laura Bierut, Washington University School of Medicine

This mini-symposium will illustrate the potential for large-scale administrative claims research (“big data”) to examine important clinical questions across the lifespan that are difficult to study via conventional clinical trials, such as the prescribing of benzodiazepines. While benzodiazepines are powerful short-term treatments for anxiety disorders and insomnia, they are associated with longer-term addictive potential and overdose risk, culminating in a September 2020 boxed warning by the FDA. A major gap in the research base is that real-world studies examining the long-term risks of prescribing are lacking, especially in vulnerable populations such as children, geriatric patients, and people with opioid use disorder. Thus, the overarching goal of this mini-symposium is to highlight state-of-the-art research shedding light on benzodiazepine prescribing and overdose risk in these understudied groups. Leading pharmaco-epidemiologists will present new data encompassing 1) adolescents and young adults (“Leveraging Healthcare Claims Data to Study Benzodiazepine Overdose Risk in Adolescents and Young Adults”), 2) adolescents and adults with opioid use disorder (“Novel Methods for Comparative Effectiveness Research: Towards Rational Benzodiazepine Prescribing in Adolescents and Adults with Opioid Use Disorder”), and 3) older adult populations (“Prescription Characteristics Associated with Increased Overdose Event Risk Among Older Adults Prescribed Benzodiazepines”). The use of datasets such as Medicaid, Medicare, and IBM MarketScan commercial claims will be discussed, in addition to cutting-edge analytical methods such as parallel cohort analyses, propensity score estimation, and case-crossover study design.

42.1 Novel Methods for Comparative Effectiveness Research: Towards Rational Benzodiazepine Prescribing in Opioid Use Disorder
Kevin Xu, Washington University School of Medicine
42.2 Leveraging Healthcare Claims Data to Study Benzodiazepine Overdose Risk in Adolescents and Young Adults
Greta Bushnell, Rutgers University

42.3 Prescription Characteristics Associated With Increased Overdose Event Risk Among Older Adults Prescribed Benzodiazepines
Donovan Maust, University of Michigan

2:45 P.M. - 3:45 P.M. MINI-SYMPOSIUM

43. USE OF TECHNOLOGY TO FACILITATE TRANSLATIONAL SUBSTANCE USE DISORDER RESEARCH

Chair: Kathryn Polak, Virginia Commonwealth University
Co-Chair: Dace Svikis, Virginia Commonwealth University

Technology-based tools have demonstrated feasibility with various Substance Use Disorders (SUDs), populations (from pregnant women to individuals with chronic pain), providers (from case managers to medication-assisted treatment prescribers), and settings (from primary care clinics to out-of-treatment direct-to-consumer). Use of technology as part of SUD treatment can promote access to care, personalized medicine, measurement-based care, recovery, and wraparound care. This symposium will explore novel and innovative utilization of technologic tools to serve in addictions healthcare. First, Dr. Polak will present recent findings examining efficacy of a fully-automated contingency management app targeting self-monitoring of pain symptom severity and prescription opioid use in a sample of individuals with chronic pain. Next, Dr. Ingersoll will discuss the application of an mHealth platform deployed by HIV care clinics to increase treatment engagement in substance users vs. non-substance users. Finally, Dr. Ondersma will discuss the development and implementation of a digital platform facilitating tailored SUD interventions.

43.1 Use of Technology to Facilitate Translational Substance Use Disorder Research
Kathryn Polak, Virginia Commonwealth University

43.2 CIAS: A Digital Intervention Development Platform for Accelerating Translational Science
Steven Ondersma, Michigan State University

43.3 Comparison of 3 Year HIV Clinical Outcomes Among mHealth Platform Users for People With and Without Substance Use Histories: A Clinical Quality Improvement Project
Karen Ingersoll, University of Virginia School of Medicine
SUNDAY, JUNE 12, 2022

POSTER SESSION 1

S1. Association of Phosphotidylethanol (PEth) Levels With Severity of Dependence in Alcohol Dependent Patients- A Cross-Sectional Study
Abhishek Gupta*, Raka Jain¹, Biswadip Chatterjee¹
¹AIIMS DELHI

S2. Associations Among Perceived Risk, Age of Marijuana and Alcohol Onset, and DSM-IV Alcohol Use Disorder and Marijuana Use Disorder in a Sexual Minority Population
Corrine M. Schwarting*, Sean Esteban McCabe², Sterling M. Hubbard¹, Brenna Klesel¹, Brooke Arterberry²

S3. Driving Under the Influence of Alcohol, Marijuana, and Select Illegal Drugs by Sexual Identity and Gender
Raymond Moody*, Justin Knox², Dustin Duncan¹, Silvia Martins²
¹Columbia University, Mailman School of Public Health, ²Columbia University

S4. Longitudinal Patterns and Demographic, Family History, and Psychopathology Predictors of Substance Use Initiation in the ABCD Study Cohort
Ryan Sullivan*, Natasha Wade², Alexander Wallace¹, Christine Kaiver¹, Mary Heitzeg³, Krista Lisdahl¹
¹University of Wisconsin-Milwaukee, ²University of California, San Diego, ³University of Michigan

S5. Sex-Specific Associations in Patients With Alcohol Use Disorder Admitted for Hospital Detoxification
Daniel Fuster*, Xavier Garcia-Calvo², Ferran Bolao³, Paola Zuluaga², Julia Casado², Anna Hernández-Rubio², Robert Muga¹
¹Hospital Universitari Germans Trias i Pujol, ²Internal Medicine Service. Hospital Universitari Germans Trias i Pujol, ³Internal Medicine Service. Hospital Universitari Bellvitge.

S6. The Effect of Comorbid Alcohol Use Disorder on Major Depressive Disorder Treatment Outcomes: A STAR*D Analysis
Victor Tang*, Dengdeng Yu², Cory Weissman³, Brett Jones⁴, Guan Wang⁵, Daniel Blumberger⁶, Zafiris Daskalakis⁷, Bernard Le Foll⁹, Daphne Voineskos⁶
¹University of Toronto, Centre for Addiction and Mental Health, ²University of Texas at Arlington, ³UC San Diego Health, ⁴University of Toronto, ⁵Dalla Lana School of Public Health, University of Toronto, ⁶Centre for Addiction and Mental Health

S7. Alcohol Use Disorder is Associated With Lower Receipt of Direct-Acting Antiviral Hepatitis C Treatment: A Cohort Study
Lamia Haque*, David Fiellin¹, Denise Esserman¹, Debika Bhattacharya², Adeel Butt³, Stephen Crystal⁴, E. Jennifer Edelman¹, Adam Gordon⁵, Joseph Lim¹, Christopher Rentsch⁶, Jeanette Tetrault¹, Emily Williams⁷, Kendall Bryant⁸, Amy Justice⁹, Vincent Lo Re III¹⁰, Janet Tate⁹, Kathleen McGinnis¹¹
¹Yale University School of Medicine, ²David Geffen School of Medicine, University of California, Los Angeles, ³Weill Cornell Medical College, ⁴Rutgers University, ⁵University of Utah School of Medicine; Veterans Affairs Salt Lake City Healthcare System, ⁶London School of Hygiene and Tropical Medicine, Veterans Affairs Connecticut Healthcare System, ⁷University of Washington School of Public Health; Veterans Affairs Puget Sound Health Services Research and Development, ⁸National Institute of Drug Abuse, National Institutes of Health, ⁹Yale University School of Medicine; Veterans Affairs Connecticut Healthcare System, ¹⁰Perelman School of Medicine, University of Pennsylvania, ¹¹VA Connecticut Healthcare System
S8. Harms From Other’s Drinking: Risk Factors and Help-Seeking Behaviors in Taiwan
Ren-Hao Chen*1, I-An Wang2, Wei J. Chen3, Chuan-Yu Chen1
1National Yang Ming Chiao Tung University, 2Center of Neuropsychiatric Research, National Health Research Institutes, 3National Taiwan University College of Public Health

S9. High-Throughput LC-QTOF-Mass Method for Determination of Phosphatidylethanol (PEth) in Whole Blood for Monitoring Alcohol Consumption in Alcohol Dependent Subjects
Raka Jain*1, Abhishek Gupta2, Sachin Rana2, Biswadip Chatterjee2, Arun Kumar2
1All India Institute of Medical Sciences, 2National Drug Dependence Treatment Centre, All India Institute of Medical Sciences

S10. Negative Mood Symptoms and Alcohol Use in Firefighters: The Moderating Effects of Drinking Motives
Krista Miloslavich*1, Margaret Wardle1, Anka Vujanovic2
1University of Illinois at Chicago, 2University of Houston

S11. Perceived Stigma, Self Stigma and Barriers to Treatment in Alcohol Dependent Individuals
Richa Tripathi*1, Samant Singh1, Manoj Prithviraj2, Amit Nair1
1All India Institute of Medical Sciences

S12. Races, ACEs, and Places: The Interaction Effects of Race, Childhood Adversity, and Neighborhood Disadvantage on Alcohol Use Disorder
Skye Bristol*1, Elzbieta Wiedbusch1, Enya Vroom2, Micah Johnson1
1University of South Florida, 2University of Florida

S13. Correlates and Consequences of Anxiety and Depressive Symptom Trajectories During Early Treatment for Alcohol Use
Jill Rabinowitz*1, Jennifer Ellis2, Justin Strickland2, Jonathan Wells3, Andrew Huhn2, Brion Maher1
1Johns Hopkins Bloomberg School of Public Health, 2Johns Hopkins University School of Medicine, 3Virginia Commonwealth University

S14. Fine Particulate Matter Exposure in Neighborhood is Associated to Early Substance Use Initiation in Youth
Julia Harris*1, Gabriella Navarro1, Evelyn Doan1, Ryan Sullivan1, Krista Lisdahl1
1University of Wisconsin-Milwaukee

S15. Nicotine Does Not Speed the Development of Recovery-Like Behavior in a Rat Model of Alcohol Use and Recovery Following Chronic Ethanol Exposure
Haley DeWitt*1, Lyra Seaborn2, Richard J. Lamb1, Brett Ginsburg1
1University of Texas Health Science Center at San Antonio, 2Davidson College, Davidson NC

S16. Racial Differences in the Effects of Parent and Sibling Alcohol Misuse on the Odds of Alcohol Misuse Among Justice-Involved Adolescents
Elzbieta Wiedbusch*1, Micah Johnson1, Enya Vroom2, Skye Bristol1, Zahra Akbari1, James-Angelo Suarez2
1University of South Florida, 2University of Florida

S17. Racial Differences in the Relationship Between Treatment Completion and Optimism Among Opioid Users in the Juvenile Justice System
Angitha Reji*1, Micah Johnson1
1University of South Florida
S18. Reductions in Blood Alcohol Concentration During the First 90 Days of a Telehealth Program for Alcohol Use Disorder
Gantt Galloway*, Kevin Hallgren², Katie Witkiewitz³, Paul Linde¹, Robert Nix¹, Tom Nix¹, John Mendelson¹
¹Ria Health, ²University of Washington, ³University of New Mexico

S19. A Casual Model of Risk Factors Underlying Onset of Alcohol Use in Childhood
Andrea Maxwell*, Gregory Niklason¹, Leyla Brucar¹, Reed Evers¹, Karina Quevedo¹, Anna Zilverstand¹
¹University of Minnesota,

S20. A Rapid Procedure to Assess Shifts in Discriminative Control Over Drinking During Recovery-Like Behavior
Acacia Nawrocik-Madrid*, Richard Lamb¹, Brett Ginsburg¹
¹The University of Texas Health Science Center at San Antonio

S21. Open Board

S22. Perspectives of Health Consumers With HIV on Integration of Pharmacological Mental Health and Substance Use Treatment in HIV Care
Erin Cox¹, Suzanne Singer², Felicia Browne¹, Wendee Wechsberg¹, Courtney Bonner*¹
¹RTI International, ²University of North Carolina Chapel Hill

S23. US Treatment Admissions for Alcohol Use Disorder by Gender and Reproduction 2015-2019
Mishka Terplan*¹, Kelly Young-Wolff², Karen Alexander¹, Erin Kelty³, Elizabeth Krans⁴, Sara Wallhed-Finn⁵
¹Friends Research Institute, ²Kaiser Permanente Northern California, ³The School of Population and Global Health, The University of Western Australia, ⁴University of Pittsburgh, ⁵Karolinska Institute

S24. Evaluation of the Adverse Effects of Synthetic Cathinones in Mice: Dependence and Toxicity
Masahiko Funada*¹, Tomiyama Kenichi²
¹National Institute of Mental Health, ²National Center of Neurology and Psychiatry

S25. Contraceptive Literacy and Utilization Among Illegal Drugs-Involved Women in Community
Rosetta Siew*¹, I-An Wang², Chuan-Yu Chen¹
¹National Yang Ming Chiao Tung University, ²Center of Neuropsychiatric Research, National Health Research Institutes

S26. Methylone Pre-Exposure Differentially Impacts the Aversive Effects of MDMA, MDPV and Fluoxetine in Male and Female Sprague-Dawley Rats
Hayley Manke*, Katharine Nelson², Shihui Huang¹, Jacob Bailey¹, Sara Bowman¹, Robert Jones¹, Sydney Cerveny¹, Kenner Rice², Anthony Riley³
¹American University, ²Medical University of South Carolina, ³National Institute of Drug Abuse, National Institutes of Health, ⁴The American University

S27. Trends in Drug Use Among Nightclub/Festival Attendees as a Potential Bellwether for Drug-Related Outcomes in the General Population
Joseph Palamar*¹, Austin Le²
¹New York University School of Medicine, ²New York University College of Dentistry
Beatrice Setnik*1, Denise Milovan1, Megan Shram2, Cynthia Arons3, Talar Hopyan4, Catherine Mills1, Himanshu Upadhaya5, Thomas Hudzik6, Michael Klein7
1Altasciences, 2Altreos Research Partners Inc.; University of Toronto, 3Pfizer, 4Syneos Health, 5Eli Lilly and Company, 6BlueRock Therapeutics, 7Controlled Substance Scientific Solutions LLC

S29. Use of Plant-Based Hallucinogens and Dissociative Agents: U.S. Time Trends, 2002-2019
Claire Walsh*1, Ofir Livne2, Dvora Shmulewitz3, Deborah Hasin3
1Columbia University and New York State Psychiatric Institute, 2Columbia University Mailman School of Public Health, 3Columbia University

S31. Exploring the Heteromeric Interface of the Serotonin 5-HT2A:5-HT2C Receptor Complex In Vitro
Joshua Zamora*1, Scott Gilbertson2, Noelle Anastasio1, Kathryn Cunningham1
1University of Texas Medical Branch, 2University of Houston

S32. Open-Access Clinical Care and Intervention in the Setting of Overprescribing of Benzodiazepines in a Community Sample
Gretchen Hermes*1, Dexter Louie1, Olayinka Olaniyi1, Fabiola Arbelo-Cruz1, Scott Farnum2, Declan Barry1, Kathryn Eggert1, Kimberly DiMeola2, Erica Cannata2, Lynn Madden2
1Yale University School of Medicine, 2APT Foundation, Inc.

S33. Human Abuse Potential Study Results in the Context of Abuse Detected Postmarketing
Yohanka Caro*1, Silvia Calderon1, Ling Chen1, Saranrat Wittayankorn1, Sara Karam1, Sheheryar Muhammad1, Modupeola Adereti1, Rajdeep Gill1, Rose Radin1, E. Gregory Hawkins1, Chad J. Reissig1, Dominic Chiapperino1
1US Food and Drug Administration

S34. Ketamine Non-Medical Use Versus Medical Use in the United States’ General Population
Alexis Krause*1, Annika Czizik1, Joshua Black1, Paula Bernander1, Richard Dart1, Janetta Iwanicki1
1Rocky Mountain Poison and Drug Safety, Denver Health and Hospital Authority

S35. Perspectives of People Who Use Illicit Stimulants on Prospective Pharmaceutical Stimulant Substitution Treatments: A Qualitative Study
Taylor Fleming*1, Andrew Ivsins2, Allison Barker2, Manal Mansoor2, Ryan McNeil3
1The University of British Columbia, 2British Columbia Centre on Substance Use, 3Yale University School of Medicine

S36. Abuse Potential of Zuranolone in Nondependent, Recreational Users of Central Nervous System Depressants: A Randomized, Double-Blind, Active- and Placebo-Controlled, Crossover Study
Joi Dunbar*1, Robert Lasser1, Nilanjana Rana1, Haihong Li1, Naama Levy-Cooperman2, James Doherty1, Kathleen Brady3
1Sage Therapeutics, 2Altreos Research Partners Inc., 3Medical University of South Carolina

S37. The Association Between Childhood Trauma, Intimate Partner Violence and Perceived Parental Competence Among Women Abusing Amphetamine Type Stimulant
Suzaily Wahab*1, Rubini Sivarajah2, Amirul Danial Azmi1, Norliza Chemi2, Raynuha Mahadevan1
1Universiti Kebangsaan Malaysia Medical Centre, 2Kajang Hospital, Selangor
S38. The Risk Factors of One-Year Relapse Among Methamphetamine Users Referred From Criminal Justice System for Mandatory Treatment
Lian-Yu Chen¹, Su-Chen Fang², Ming-Chyi Huang¹
¹Taipei City Hospital, ²Mackay Medical College

S39. The Safety and Feasibility of Lisdexamfetamine for the Treatment of Acute Methamphetamine Withdrawal: Preliminary Results of an Open Label Pilot Study
Liam Acheson*¹, Nadine Ezard¹, Nicholas Lintzeris², Adrian Dunlop³, Jonathan Brett¹, Craig Rodgers¹, Anthony Gill¹, Michael Christmass⁴, Rebecca McKetin⁵, Michael Farrell⁶, Steve Shoptaw⁶, Krista Siefried⁷
¹St. Vincents Hospital, ²South Eastern Sydney Local Health District, ³Hunter New England Local Health District, ⁴Next Step Drug and Alcohol Services, ⁵National Drug and Alcohol Research Centre, UNSW, ⁶University of California, Los Angeles, ⁷The National Centre for Clinical Research on Emerging Drugs (NCCRED)

S40. Trajectories of Prescription Stimulant Misuse and Substance Use Disorder Symptoms From Ages 18 to 50: US National Panel Data
Sean Esteban McCabe¹, John E. Schulenberg¹, Ty S. Schepis¹, Rebecca J. Evans-Polce¹, Timothy E. Wilens¹, Vita V. McCabe¹, Philip Veliz*¹
¹Center for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan School of Nursing

S41. What’s Driving the Increases in Methamphetamine Overdose Deaths That Do Not Involve Opioids?
Dalia Khoury*¹, William Zule¹, Caitlin Hennessy¹
¹RTI International

S42. Is Age of Onset and Duration of Stimulant Medication Therapy for ADHD Associated With Stimulant Misuse During Adolescence? A Multi-Cohort National Study
Sean Esteban McCabe¹, Olivia Figueroa¹, Vita V. McCabe¹, Ty S. Schepis¹, John E. Schulenberg¹, Phil T. Veliz¹, Kennedy S. Werner¹, Timothy E. Wilens¹
¹Center for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan School of Nursing

S43. Novel Pharmacotherapies for Young People With Methamphetamine Use Disorder: The MASKOT and CALM Studies
Alexandre Guerin*¹, Edward Mullen², Emily Karanges¹, Amelia Quinn¹, Orli Schwartz¹, Shalini Arunogiri¹, Colleen Loo⁴, Andrew Chanen¹, Enrico Cementon², Paul Amminger¹, Gillinder Bedi¹
¹University of Melbourne, ²Orygen, ³Monash University, ⁴University of New South Wales

S44. Prevalence of Stimulant Use Disorder and Co-Occurring Substance Use Disorders Among Medicaid Enrollees With Stimulant Use Disorder in 2017-2018
Thanh Lu*¹, Sean Murphy¹
¹Weill Cornell Medical College

S45. Open Board
S47. The Influence of Cocaine Use Disorder, Drug Cues and Sex on Decision-Making  
Miranda Ramirez*, Joshua Lile, Joshua Beckmann, Joseph Alcorn, Skylar Mays, Craig Rush, William Stoops, Preston Tolbert, Michael Wesley  
1University of Kentucky, College of Arts and Sciences, 2University of Kentucky, College of Medicine, 3University of Kentucky

S48. Central Nervous System Activity of Kappa Opioid Receptor Ligands 5' And 6'-Guanidinonaltrindole  
Michelle Morochnik*, Yuli Kim, Brian Reed  
1The Rockefeller University

S49. Prevalence and Correlates of Active Amphetamine-Type Stimulants (ATS) Use Among Full-Service Women Sex Workers in Malaysia  
Courtney J. Pedersen, Jeffrey A Wickersham, Antoine Khati, Francesca Maviglia, Frederick A. Altice, Adeeba Kamarulzaman, Kaveh Khoshnood, Britton A. Gibson, Roman Shrestha*  
1Brown University, 2Yale University, 3University of Connecticut, 4University of Malaya

S50. Psychosocial and Drug Use Characteristics of Individuals With Stimulant Use Disorder in New York City  
Gabriella Horton*, Suky Martinez, Allen Yang, Jermaine Jones  
1Columbia University and New York State Psychiatric Institute

S51. Risk of First Episode Psychosis or Mania With Prescription Amphetamine Use  
1Harvard Medical School, McLean Hospital, 2McLean Hospital, 3Harvard Medical School, Massachusetts General Hospital, 4Harvard Medical School, Massachusetts General Hospital/McLean Hospital

S52. Treatments for the Fourth Wave: Association of Bupropion, Naltrexone, and Opioid Agonist Therapies With Stimulant-Related Events in Opioid Use Disorder  
Kevin Xu*, Carrie Mintz, Ned Presnall, Laura Bierut, Richard Grucza  
1Washington University School of Medicine, 2St. Louis University School of Medicine

S53. Utilizing a Nonhuman Primate Model to Examine the Importance of Sleep/Wake Architecture in Treating Substance Use Disorder  
Christina LaValley*, Robert Gould, Michael Nader  
1Wake Forest School of Medicine

S54. Voluntary Exercise Prevents Long-Term Incubation of Cocaine Craving in Female and Male Rats  
Marilyn Carroll*  
1University of Minnesota

S55. Addiction Severity and Language-Based Temporal Perspective in Cocaine Use Disorder  
Jennifer Hoots*, Christopher Holden, Scott Lane, Joy Schmitz, Margaret Wardle  
1University of Illinois Chicago, 2University of Illinois College of Medicine, 3University of Texas Health Science Center, McGovern Medical School, 4University of Texas Health Science Center
S56. Associations Between Prescription and Illicit Opioid and Stimulant Use in the United States, 2015-2019
Riley Shearer*, Abenaa Jones2, Benjamin Howell3, Joel Segel4, Tyler Winkelman5
1The University of Minnesota, 2Penn State, 3Yale University School of Medicine, 4Health, Homelessness, and Criminal Justice Lab, Hennepin Healthcare Research Institute

S57. Causal Association Between Recent Methamphetamine Use and Unsuppressed HIV Viral Load Among People Living With HIV Who Inject Drugs in Hai Phong, Vietnam
Jonathan Felemyer*, Don Des Jarlais2, Nicolas Nagot3, Huong Duong Thi4, Oanh Khuat Thi Hai2, Pham Minh khue4, Giang Hoang Thi4, Thanh Nham Thi Tuyet6, Charles Cleland4, Kamyar Arasteh2, Ellen Caniglia7, Yu Chen1, Gavin Bart8, Jean-Pierre Moles3, Vinh Vu Hai9, Roselyne Vallo2, Catherine Quillet3, Delphine Rapoud3, Mai Le Sao10, Laurent Michel11, Didier Laureillard3, Maria Khan1
1New York University School of Medicine, 2New York University School of Global Public Health, 3University of Montpellier, 4Hai Phong University of Medicine and Pharmacy, 5Centre of Supporting Community and Development Initiatives, 6SCDI, 7Perelman School of Medicine, University of Pennsylvania, 8University of Minnesota, 9Infectious Diseases Department, Viet Tiep Hospital, 10Mental Health Department, 11Centre Pierre Nicole

S58. Elevated Brain Lactate Levels in Female Methamphetamine Users
Young-Hoon Sung*, Xianfeng Shi1, Yasmin Peralta1, Deborah Yurgelun-Todd2, Perry Renshaw2, Douglas Kondo2
1The University of Utah, 2The University of Utah, Rocky Mountain VISN 19 MIRECC

S59. Impact of Ketamine or Propranolol During a Novel Retrieval Session on Cue-Induced Reinstatement of Cocaine Self-Administration in Rats
Angela Gonzalez*
1Washington State University, Vancouver

S60. Motivation for Change and Duration of Inpatient Treatment Among Patients With Cocaine Use Disorder
Kristine Chestnut1, Bonnie Starkes1, Kyle Kampman*
1University of Pennsylvania

S61. Observed Increase in Methamphetamine Use Risk Among Vietnamese Methadone Patients: 2018-2021 Repeated Surveys
Trang Nguyen*, Diep Bich Nguyen1, Thuy Dao1, Anh Vu1, Van Hoang1, Michael Li2, Steve Shoptaw2, Giang Le1
1Hanoi Medical University, 2University of California, Los Angeles

Dustin Lee*, Mary Sweeney1, Labos Breanna1, Roland Griffiths2
1Johns Hopkins University School of Medicine, 2Johns Hopkins University

S63. Open Board

S64. Beliefs About Medications for Opioid Use Disorder Among Healthcare Practitioners and Community Stakeholders in Rural New England
Sarah Heil*, Nathaniel Schafrick1, Julia Shaw1, Valerie Harder1, Andrea Villanti1, Mary Smith2, Jeanne Ryer3, Stacey Sigmon1
1University of Vermont, 2University of Southern Maine, 3University of New Hampshire
S65. Body Image Dissatisfaction Among Patients Receiving Methadone Maintenance Treatment
Zachary Mannes*, Meagan Carr, Lindsay Oberleitner, David Oberleitner, Mark Beitel, Marina Gaeta Gazzola, Lynn Madden, Xiao Zheng, Declan Barry
1Columbia University, Mailman School of Public Health, 2Yale University School of Medicine, The APT Foundation, Oakland University William Beaumont School of Medicine, 4University of Bridgeport, The APT Foundation, 5Yale University School of Medicine, The APT Foundation

S66. Characterizing Opioid Withdrawal Experiences Among a Sample of Opioid Using People Who Inject Drugs (PWID)
Kelsey Simpson*, Maria Bolshakova, Matt Kirkpatrick, Ricky Bluthenthal
1University of Southern California, Keck School of Medicine

S67. Differences in Sociodemographic Profiles and Drug Use Patterns of Individuals With Current Opioid Use Disorder Depending on Opioid Use Preference
Allen Yang, Suky Martinez, Gabriella Horton, Sandra Comer, Jermaine Jones
1Columbia University and New York State Psychiatric Institute, 2Columbia University Vagelos College of Physicians and Surgeons, 3Columbia University Irving Medical Center and the New York State Psychiatric Institute, 4Columbia University Irving Medical Center

S68. Disparities in Opioid Use Disorder Related Hospital Use Among Postpartum Virginia Medicaid Members
Caitlin Martin*, Erin Britton, Hannah Shadowen, Chethan Bachireddy, Ashley Harrell, Xue Zhao, Peter Cunningham
1Virginia Commonwealth University, 2Virginia Department of Medical Assistance Services

S69. Emergency Department Initiated Buprenorphine/Naloxone Intervention for Problematic Opioid Use: Retention Rates and Predictors, and Health Outcomes at 3 and 6 Months
Nathan Schwab*, Nicholas Ferrigno, Roz King, Miles Lamberson, Richard Rawson, Daniel Wolfson, Sanchit Maruti, Scott Mackey
1University of Vermont College of Medicine, 2UCLA Integrated Substance Abuse Programs

S70. Evaluating the Rate of Reversal of Fentanyl-Induced Respiratory Depression Using cNLX-NP, a Novel Long-Acting Naloxone Nanoparticle
Michael Raleigh, Andrew Kassick, Diego Luengas, Pedro Silva, Marco Pravetoni, Saadyah Averick
1University of Minnesota, 2Allegheny-Singer Research Institute Center for Neurosciences Research, 3University of Minnesota Medical School

S71. Factors Associated With COVID-19 Testing Among People Who Inject Drugs: Missed Opportunities for Reaching Those Most at Risk
Samantha Yeager, Daniela Abramovitz, Alicia Harvey-Vera, Carlos Vera, Angel Algarin, Laramie Smith, Maria Gudelia Rangel Gomez, Irina Artamonova, Thomas Patterson, Angela Bazzi, Emma Brugman, Steffanie Strathdee
1University of California - San Diego, 2University of California - San Diego, School of Medicine, 3Comisión de Salud Fronteriza México-EEUU, Sección México

S72. Fentanyl's Rising Presence in Oregon's Drug Supply and Knowledge, Attitudes, and Behaviors Among People Who Use Drugs
Kate LaForge, Sarah Shin, Erin Stack, Gillian Leichtling, Christopher Blazes, Dan Hoover, Andrew Seaman, P. Todd Korthuis
1Comagine Health, 2Oregon Health and Science University
S73. Frequency of Opioid Response Network Technical Assistance Requests Addressing Substance Use Disorder Stigma
Jermaine Jones*, 1, Brent Moore 2, Holly Hagle 3, Michael Knabel 3, Nathan Driskill 3, Nicholas Canning 4, Laurie Krom 3, Shelby Webb 3, Zuleyma Serpas 4, Zoey Logan 4, Kerri Hayes 4, Michele Baker 3, Frances Levin 5, Kathryn Cates-Wessel 4
1 Columbia University Irving Medical Center, 2 Yale University School of Medicine, 3 University of Missouri-Kansas City, 4 Opioid Response Network, American Academy of Addiction Psychiatry, 5 Columbia University Irving Medical Center/ New York State Psychiatric Institute

S74. Health-Related Quality of Life in Patients With Opioid Use Disorder Initiating Medication Assisted Treatment in Primary Care
Michelle Lent*, 1, Karen Dugosh 2, Emily Rey 1, Hannah Callahan 1, Richard Saitz 3
1 Philadelphia College of Osteopathic Medicine, 2 Public Health Management Corporation, 3 Boston University School of Public Health

S75. Impact of Anxiety Severity on Retention in Opioid Agonist Therapy: A Secondary Analysis of the Optima Trial
Anees Bahji*, 1, Paxton Bach 2, Eugenia Socías 2
1 University of Calgary, 2 University of British Columbia

S76. Impact of COVID-19-Related Health Care Disruptions and Regulatory Changes on Nationwide Access to Buprenorphine
Payel Roy*, 1, Katherine Kim 2, Katie Suda 2, Jing Luo 1, Xiaoming Wang 3, Jane Liebschutz 1
1 UPMC/University of Pittsburgh, 2 University of Pittsburgh, 3 National Institute on Drug Abuse

S77. Long-Term Mortality Among Hospitalized Medical Patients Seen by a Substance Use Disorder (SUD) Consultation Service
Jan Gryczynski*, 1, Courtney Nordeck 2, Christopher Welsh 3, Shannon Mitchell 1, Robert Schwartz 1
1 Friends Research Institute, 2 Johns Hopkins Bloomberg School of Public Health, 3 University of Maryland School of Medicine

S78. Modelling Buprenorphine Mitigation of Fentanyl-Induced Respiratory Depression
Celine Laffont*, 1, Erik Olofsen 2, M. Hyke Algera 2, Laurence Moss 3, Robert Dobbins 1, Geert Jan Groeneveld 3, Monique van Velzen 2, Marieke Niesters 2, Albert Dahan 2
1 Indivior, Inc., 2 Leiden University Medical Center, 3 Leiden University Medical Center; Centre for Human Drug Research

S79. New Federal Guidelines for Buprenorphine DEA-30 Patient Waivers: Will the States Support?
Anita Silwal*, 1, Jeffery Talbert 2, Jordan Kelsch 3, Christopher Cook 3, Michelle Lofwall 4
1 University of Kentucky, College of Communication and Information, Substance Use Priority Research Area, 2 University of Kentucky College of Medicine, College of Pharmacy, 3 University of Kentucky, Substance Use Priority Research Area, 4 University of Kentucky, College of Medicine, Center on Drug and Alcohol Research (CDAR)

S80. Opioid Agonist Treatment for Prescription Opioids Dependence: An Updated Systematic Review and Meta-Analysis
Suzanne Nielsen*, 1, Wai Chung Tse 1, Briony Larance 2, Louisa Degenhardt 3
1 Monash University, 2 University of Wollongong, 3 UNSW Sydney
S81. Opioid and Alcohol Inpatient Treatment Admissions During the COVID-19 Pandemic
Mohammad Sibai1, Vartika Parashar1, Gail Koshorek1, Joshua Smith1, Mark Greenwald2, Timothy Roehrs1
1Henry Ford Health System, 2Wayne State University, Dept of Psychiatry and Behavioral Neurosciences

S82. Preliminary Findings From a Tool for Calculating the Effects of Replacing High Dead Space Syringes in Naloxone Kits With Reduced Dead Space Alternatives
William Zule1, Dalia Khoury1, Caitlin Hennessy1, Delesha Carpenter2, Bayla Ostrach3, Georgiy Bobashev1
1RTI International, 2University of North Carolina, 3Boston University School of Medicine

S83. Prescription Drug Monitoring Program and the Opioid Use Disorder Cascade of Care Model: Opportunities for West Virginia
Anthony Eller1, Elizabeth DiDomizio2, Kimberly Johnson3, Lynn Madden4, Jennifer Oliva5, Frederick Altice1
1Yale University School of Medicine, 2Yale University, 3University of South Florida, 4APT Foundation, 5Seton Hall University

S84. Preventing Opioid Relapse Among American Indian Women: A Community Based Participatory Approach to Develop a Facebook Intervention
Sydney Kelpin1, Anne Roche2, Pamela Sinicrope2, Gavin Bart3, Lisa Marsch4, Aimee Campbell5, Kamilla Venner6, Cuong Pham7, Antonia Young8, Nicole Reinicke2, Corinna Sabaque2, Christi Patten2
1Behavioral Health Research Program, 2Health Research Program, Mayo Clinic, 3Hennepin Healthcare, 4Dartmouth College, 5Columbia University Irving Medical Center and New York State Psychiatric Institute, 6Center on Alcohol, Substance Use and Addictions, University of New Mexico, 7University of Minnesota

S85. Proximity to Treatment and Post-Release Treatment Engagement Rates Among Adults Who Participated in a Comprehensive MOUD Program at the Rhode Island Department of Corrections, 2016-2018
Ariel Hoadley1, Gerald Stahler2, Jeremy Mennis2, Courtney Delacuesta1, Jennifer Clarke3, Rosemarie Martin4
1Brown University, 2Temple University, 3Rhode Island Department of Health, 4Brown University School of Public Health

S86. Readmission and Comorbidities Associated With Patient-Directed Discharges Among Surgical Patients With and Without Opioid Use Disorder
Rachel French1, Ashish Thakrar1, Peggy Compton2, Matthew McHugh3, J. Margo Brooks Carthon3
1University of Pennsylvania, 2University of Pennsylvania, School of Nursing, 3University of Pennsylvania, Center for Health Outcomes and Policy Research

S87. Recent Opioid Use Impedes Range Adaptation in Reinforcement Learning in Human Addiction
Maëlle Gueguen1, Hernan Anlló2, Darla Bonagura1, Julia Kong1, Sahar Hafezi1, Stefano Palminteri3, Anna Konova1
1UBHC, and Brain Health Institute, Rutgers University – New Brunswick, 2School of Fundamental Science and Engineering, Waseda University - Tokyo, 3Institut National de la Santé et Recherche Médicale, and Ecole Normale Supérieure - Paris

S88. Relative Risk of Opioid-Involved Death Following Exposure to Treatments for Opioid Use Disorder, Connecticut, 2017
Robert Heimer1, Anne Black1, Hsiu-ju Lin2, Benjamin Howell3, Grau Lauretta4, David Fiellin5, Gail D’Onofrio5, Kathryn Hawk1, William Becker1
1Yale University, 2State of Connecticut, 3Yale University School of Medicine, 4Yale School of Public Health
S89. Risks of Overdose Events for Patients Undergoing Opioid Use Disorder Treatment
Laura Brandt¹, Mei-Chen Hu², Ying Liu², Felipe Castillo³, Gabriel Odom⁴, Raymond Balise⁵, Daniel Feaster⁶, Edward Nunes³, Sean Luo²
¹Columbia University Irving Medical Center, ²Columbia University, ³Columbia University and New York State Psychiatric Institute, ⁴Florida International University, ⁵University of Miami, ⁶University of Miami Miller School of Medicine

S90. Running to Stand Still: Exaggerated Aversive Salience in Individuals With Opioid Use Disorder
Jennifer Stewart*, Chrysantha Davis¹, Mary Kate Dykes¹, Natosha Markham¹, Tulsa 1000 Investigators¹, Rayus Kuplicki¹, Martin Paulus¹
¹Laureate Institute for Brain Research

S91. Concordance Between Self-Report and Hair Analysis in the ABCD Study: Self-Report With Hair Analysis Detects Additional 10% of Substance Users
Natasha Wade*, Ryan Sullivan², William Pelham¹, Krista Lisdahl², Susan Tapert¹, Marilyn Huestis³, Frank Haist¹
¹University of California, San Diego, ²University of Wisconsin-Milwaukee, ³National Institute of Drug Abuse, National Institutes of Health

S92. Considerations for Defining a Modified Completer Population in Human Abuse Potential Studies
Ling Chen*, Shalini Bansil¹, Qianyu Dang¹, Joshua Lloyd¹, Dominic Chiapperino¹
¹US Food and Drug Administration

S93. Prospective Effects of Financial Insecurity on Frequency of Substance Use
Sarah Gutkind*, Deborah Hasin¹
¹Columbia University

S94. Reinforcer Pathology’s Anhedonia Hypothesis: An Examination Among Those in Recovery From Substance Use Disorder
Devin Tomlinson*, Liqa Athamneh², Roberta Freitas-Lemos¹, Allison Tegge², Warren Bickel³
¹Fralin Biomedical Research Institute at Virginia Tech Carilion, ²Virginia Tech Carilion Research Institute, ³Fralin Biomedical Research Institute at VTC

S95. Cannabis Use and Mental Health Among Transition Age Youth Receiving Care in a Large Urban Healthcare System 2019-2020
Marjan Javanbakht*, Howard Padwa², Whitney Akabike³, Lawrence Dardick³, Yu-Hsiang Lin³, Steve Shoptaw², Lillian Gelberg³
¹University of California Los Angeles, Fielding School of Public Health, ²University of California Los Angeles, Integrated Substance Abuse Programs, ³University of California Los Angeles

S96. Shifting State-Level Cannabis Policies and Health Equity for Racial and Ethnic Minority Young People: A Qualitative Exploration
Morgan Philbin*, Heather Wurtz¹, Adrian Guta², Benjamin Lane³, Pia Mauro¹
¹Columbia University Mailman School of Public Health, ²University of Windsor, ³Columbia University Irving Medical Center
Deborah Hasin*, Andrew Saxon1, Carol Malte2, Katherine Keyes4, Mark Olfson5, Melanie Wall5
1Columbia University, 2Veterans Affairs Puget Sound Healthcare System, 3Center of Excellence in Substance Abuse Treatment and Education, Veterans Affairs Puget Sound Health Care System, 4Columbia University Mailman School of Public Health, 5Columbia University and NYSPI

MONDAY, JUNE 13, 2022

POSTER SESSION 2

M1. Augmenting a Low-Level Implementation Strategy to Address Co-Occurring Substance Use and Mental Health Disorders: Outcomes From the Adaptive Implementation of Effective Programs Trial (ADEPT)
Andria Eisman*, E. Whitney Moore1, Michaila Paulateer1, Shawna Smith2, Amy Kilbourne3
1Wayne State University, 2University of Michigan, 3University of Michigan Medical School

M2. Open Board

M3. COVID Wariness, Protective Behaviors, Smoking, and Cigarette Purchasing Patterns Among Vulnerable Populations
Rhiannon Wiley*, Janice Bunn1, Anthony Barrows1, Jennifer Tidey2, Dustin Lee3, Stacey Sigmon1, Diann Gaalema1, Sarah Heil1, Andrea Villanti1, Stephen Higgins1
1University of Vermont, 2Brown University, 3Johns Hopkins University School of Medicine

M4. Flavor Compounds Modulate Oral Nicotine Consumption and Preference in Mice
Ketki S. Pawaskar1, Shaydel Engel*, Cassandra Win1, Fayzeh K. El Banna1, Anna M. Lee1
1University of Minnesota

M5. Interactive Effects of Financial Strain and Distress Tolerance on Pre-Quit Tobacco Withdrawal Symptoms in Smokers Preparing to Initiate a Quit Attempt
Mariel Bello*, Raina Pang2, Suzanne Colby3, Adam Leventhal4, Michael Zvolensky5, Kirsten Langdon6
1Brown University, Alpert Medical School, 2University of Southern California, 3Brown University Center for Alcohol and Addiction Studies, 4Keck School of Medicine, University of Southern California, 5University of Houston, 6Rhode Island Hospital

M6. Pattern of Tobacco Use and Nicotine Dependence in Patients With Psychiatric Disorders
Amit Nayak*, Richa Tripathi1
1All India Institute of Medical Sciences

M7. Youth Susceptibility to Tobacco-Free Oral Nicotine Products in Comparison to Cigarettes and E-Cigarettes
Erin Vogel*, Jessica Barrington-Trimis1, Alyssa Harlow1, Melissa Wong1, Junhan Cho1, Dae-Hee Han1, Adam Leventhal1, Alayna Tackett1
1University of Southern California

M8. Association Between Electronic Cigarette and Combustible Cigarette Use With Cardiometabolic Risk Biomarkers Among U.S. Adults
Emeka Okafor*, Nkechinyere Okafor2, Catherine Kaliszewski1, Liang Wang1
1Baylor University, 2Essen Healthcare
M9. Changes in Smoking From 2018 to 2020 Among Older Adults in the US: Implications for COVID-19
Pia Mauro*1, Sarah Gutkind1, Erin Annunziato2, Daniel Giovenco1
1Columbia University, 2Columbia Mailman School of Public Health

M10. Characterization of Nicotine Pharmacokinetics and Pharmacodynamics During Use of Five Commercially Available Nicotine Pouches and Two Nicotine Lozenges in Adult Cigarette Smokers
Jesse Rensch1, Jianmin Liu1, Jingzhu Wang1, Andrea Vansickle1, Jeffery Edmiston*1, Maria Gogova1, Mohamadi Sarkar1, Joshua Karelitz1
1Altria Client Services LLC

M11. Pulsed Intravenous Nicotine Infusions as Model for Inhaled Tobacco Use in Humans
Joao De Aquino*1, Ralitza Gueorguieva1, Mehmet Sofuoglu2
1Yale University School of Medicine, 2Yale University

M12. The Relationship Between Nonsystematic Delay Discounting and Low-Quality Survey Responses in a Sample of Smokers: ROC Curve Analysis
Yu-Hua Yeh*1, Devin Tomlinson1, Roberta Freitas-Lemos1, William Craft1
1Fralin Biomedical Research Institute at Virginia Tech Carilion

M13. Tobacco, Alcohol, Cannabis, and Other Drug Use in the U.S. Before (2016-2019) and During (2020) the COVID-19 Pandemic: Findings From the Path Study
Kerry Flannagan1, Marushka Silveira1, MeLisa Creamer1, Heather Kimmel1, Moana Kanel1, Carlos Blanco1, Wilson Compton1
1National Institute on Drug Abuse/NIH

Hailey Wirtz*1, Ryan Sullivan1, Krista Lisdahl1
1University of Wisconsin-Milwaukee

M15. Open Board

M16. Characterizing Prevalence of Tobacco Product Type and Effects on Abstinence Among Individuals With Serious Mental Illness Enrolled in a Pragmatic Randomized Trial
Joanna Streck*1, Kristina Schnitzer2, Kevin Potter2, Lindsay Neilson2, Anne Eden Evins2
1Harvard Medical School, 2Massachusetts General Hospital/Harvard Medical School

M17. Discrepancies in the Relation Between Smoking and Performance Across Different Tests of Executive Function
Brian Katz*1, Diann Gaalema1, Jennifer Tidey2, Stacey Sigmon1, Sarah Heil1, Dustin Lee3, Michael DeSarno1, Stephen Higgins1
1University of Vermont, 2Brown University, 3Johns Hopkins University School of Medicine

M18. Does Risky Substance Use Modify the Relationship Between Intensity of Nicotine Dependence and Motivation to Stop Smoking During COVID-19?
Jesse Boggis*1, Elizabeth Saunders1, Lisa Marsch1, Nico Agosti1, Alan Budney1, Shea Lemley1
1Geisel School of Medicine at Dartmouth
M19. Loss Aversion, Substance-Free Reward, and Risk for Cigarette Smoking and Other Substance Use
Eric Thrailkill*, Michael DeSarno1, Stephen Higgins1
1University of Vermont

Brandon Newmyer1, Joshua Karelitz*2, Jeffery Edmiston2, Diana McKinney2, Elizabeth Becker2, Stephanie Plunkett2, Mohamadi Sarkar2
1Formally Altria; now JUUL, 2Altria Client Services

M21. Sexual Identity Differences in Perceived Risk of Tobacco and Marijuana Use Among U.S. Young Adults
Rebecca Evans-Polce*, Megan Schuler2
1University of Michigan, 2RAND

M22. Validating Self-Reported Electronic Nicotine Delivery System Use With Biochemical and Topographical Measures
Merideth Addicott*, Eryn Matich2, Katherine Wallis2, Ping-Ching Hsu2
1Wake Forest University, School of Medicine, 2University of Arkansas for Medical Sciences

M23. An Exploratory Analysis of Tobacco Use and Demographic Characteristics Among Treatment-Seeking Adult Dual Users Who Prefer to Quit Cigarettes Only Vs. Cigarettes and E-Cigarettes Simultaneously
Marc Jerome Feinstein*, Shaun Meyers1, Joan Skelly2, Elias Klemperer1
1Univ. of Vermont College of Medicine, 2Univ. of Vermont

M24. Assessment of Actual Use Behavior for Flavored Nicotine Pouches Relative to Original Nicotine Pouches
Hui Cheng*, Jennifer Lewis1, Lai Wei1, Elizabeth Becker1
1Altria Client Services, LLC

Robert A Freitas-Lemos*, Allison N. Tegge1, Jeffrey S. Stein1, Warren K. Bickel1
1Fralin Biomedical Research Institute at Virginia Tech Carilion

Alyssa Harlow*, Erin Vogel1, Alayna Tackett1, Junhan Cho1, Dae-Hee Han1, Melissa Wong1, Adam Leventhal2, Jessica Barrington-Trimis1
1University of Southern California, 2Keck School of Medicine, University of Southern California

M27. Racial Disparities in Awareness of Cigar Health Warnings by Cigar Type
Alisha Crump*, Brian Fairman1
1University of Arkansas for Medical Sciences

M28. Risk Factors Associated With E-Cigarette Use Among Adults in North Central Florida
Andrew McCabe*, Linda Cottler1
1University of Florida
Juhan Lee*, Suchitra Krishnan-Sarin†, Grace Kong†
†Yale University School of Medicine

M30. Tobacco Free Nicotine E-Cigarette Use Among Young Adults
Danielle Davis*, Krysten Bold†, Meghan Morean*, Deepa Camenga†, Grace Kong†, Asti Jackson†, Juhan Lee†, Lavanya Rajesh-Kumar†, Patricia Simon†, Suchitra Krishnan-Sarin†
†Yale University School of Medicine

M31. Young Adults’ Interest in Using Tobacco-Free Nonmedicinal Oral Nicotine Products to Quit Vaping
Dae Hee Han*, Alyssa Harlow†, Junhan Cho†, Jessica Barrington-Trimis†, Alayna Tackett†, Erin Vogel†, Melissa Wong‡, Adam Leventhal‡
‡University of Southern California

M32. Clouding up Cognition: Secondhand Cannabis and Tobacco Exposure Related to Cognitive Functioning in Youth
Alexander Wallace*, Connor McCabe†, Marybel Gonzalez‡, Eunha Hoh‡, M. Infante‡, Margie Hernandez Mejia†, Frank Haist†, Natasha Wade‡
†University of Wisconsin-Milwaukee, ‡University of Washington, ‡University of California, San Diego, ‡San Diego State University, §San Diego State University/University of California, San Diego

M33. Craving: An Early and Predictive Marker of Addiction? Baseline Results of a Prospective Study
Emmanuelle Baillet*, Fuschia Serre†, Sarah Moriceau†, Lucie Fournet†, Marc Auriacombe†
†University of Bordeaux

M34. Fluctuations of Clinical Insight in Daily Life Influences Craving Intensity in Addiction
Laura Lambert*, Léa Donnadieu†, Bérangère Thirioux‡, Nematollah Jaafari‡, Marc Auriacombe†, Fuschia Serre†
†University of Bordeaux, ‡Université de Poitiers

M35. Delay Discounting Predicts Remission Mediated by Regulatory Flexibility in Substance Use Disorder Recovery
Candice Dwyer*, Allison Tegge†, Liqa Athamneh‡, Devin Tomlinson‡, Warren Bickel‡
†Virginia Tech, ‡Virginia Tech Carilion Research Institute, ‡Fralin Biomedical Research Institute at Virginia Tech Carilion, ‡Fralin Biomedical Research Institute at VTC

M36. Diminished Error-Related Negativity and Error Positivity in Adults With Addiction Problems and Disorders: A Meta-Analysis on Error Processing
Miranda Lutz*, Rianne Kok†, Ilse Verveer†, Marcelo Malbec†, Susanne Koot‡, Pol van Lier‡, Ingmar Franken†
†Erasmus University Rotterdam, ‡Vrije Universiteit Amsterdam

M37. Predicting Choice From Response Latencies: A Potential Treatment Target for Behavioral Allocation Disorders
Haidyn Stark*, Dhariye Dave†, Richard Lamb†, Brett Ginsburg†
†University of Texas Health Science Center at San Antonio
M38. Population Exposure to Marijuana and Illicit Drugs is Increasing While Exposure to Prescription Pain Relievers is Decreasing in the United States
Joshua Black*, Stevan Severtson¹, Richard Dart¹, Janetta Iwanicki¹
¹Rocky Mountain Poison and Drug Safety

Matthew Novak*, August Holtyn¹, Justin Strickland¹, Matthew Johnson¹, Hillary Jackson¹, Albert Garcia-Romeu¹
¹Johns Hopkins University School of Medicine

M40. Effects of the COVID-19 Pandemic on New Cases of Drug Diversion in the United States
Kristen Bernal*, Stevan Severtson¹, Mance Buttram², Richard Dart¹, Janetta Iwanicki¹
¹Rocky Mountain Poison and Drug Safety, ²University of Arkansas

M41. Religiosity, Spirituality and Substance Use Disorders in Young Adulthood: A Developmental Approach
David Saunders*¹, Cristiane Duarte²
¹College of Physicians and Surgeons, Columbia University and NYSPI, ²Columbia University and NYSPI

M42. The Impact of Gender-Neutral and -Specific Normative Perceptions on Substance Use and Other Risky Behavior Among Emerging Adults
Kanila Brown*, Devin Banks¹, Katie Lawson²
¹University of Missouri-St. Louis, ²Ball State University

M43. Gender-Responsive Digital Intervention for Young Adult Women With Substance Use and Co-Occurring Psychiatric Disorders
Dawn Sugarman*, Callie Wang², Shelly Greenfield¹
¹McLean Hospital - Harvard Medical School, ²McLean Hospital

M44. LGBQ Microaggressions and Substance Use Among University Students: The Moderating Role of Mindfulness
Ian Carson*¹, Tamika Zapolski¹
¹Indiana University Purdue University Indianapolis

M45. Gateway to Drugs: Poor School Encouragement as a Pipeline to Substance Use Disorder Among Latinx Adolescents
James-Angelo Suarez*¹, Zahra Akbari¹, Enya Vroom², Elzbieta Wiedbusch¹, Skye Bristol¹, Micah Johnson¹
¹University of South Florida, ²University of Florida

M46. Racial Differences in the Association Between Consequential Thinking and Substance Use Disorder Treatment Adherence Among Justice-Involved Adolescents
Zahra Akbari*¹, Enya Vroom², Skye Bristol¹, Elzbieta Wiedbusch¹, James-Angelo Suarez¹, Micah Johnson¹
¹University of South Florida, ²University of Florida

M47. Assessing Whether a Survey-Driven Tablet-Based Intervention Increased Willingness of Black Women With Substance Use to Attend a Prep Clinic Following an Emergency Department Visit
Mandy Hill*, Angela Heads², Robert Suchting², Charles Green¹, Angela Stotts¹
¹University of Texas Health Science Center, ²The University of Texas Health Science Center at Houston
M48. Emerging Sex Differences in Adolescent Substance Use
Devika Bhatia*, Susan Mikulich-Gilbertson1, Crystal Natvig1, Joseph Sakai1
1University of Colorado School of Medicine

M49. Sex Differences in Military Workplace Victimization and Drug Use Among U.S. Army Reserve/National Guard Service Members
Jessica Kulak*, Kimberly Kamper-DeMarco2, D. Lynn Homish3, Gregory Homish3
1University at Buffalo, 2Buffalo State College, 3State University of New York at Buffalo

M50. Open Board

M51. Assessing Recovery Coach Roles and Responsibilities in Substance Use Recovery
Matt Webster*, Amanda Fallin-Bennett1, Martha Tillson2, Jennifer Becan2, Kevin Knight2, Michele Staton1
1University of Kentucky, 2Texas Christian University

M52. Climate Change and Harmful Substance Use – A Risk Pathway Framework
Francis Vergunst*, Helen Berry2, Kelton Minor3, Nicholas Chadi4
1University of Montreal, 2University of Sydney, 3University of Copenhagen, 4Sainte-Justine University Hospital Centre

M53. Examining Factors Associated With "Lack of Readiness to Stop Using" Among U.S. Adults Needing but Not Receiving Substance Use Treatment
JaNiene Peoples*, Christine Doroshenko1, Philip Baiden2, Erin Kasson2, Nina Kaiser2, Patricia Cavazos-Rehg2
1Brown School of Social Work, Washington University in St. Louis, 2Washington University School of Medicine, 3The University of Texas at Arlington, School of Social Work

M54. Lessons Learned From Adapting Screening and Brief Intervention (SBI) to Prevent Substance Use Dependence Among Primary Care Patients in the New Age of Telehealth
Lillian Gelberg*, Stephanie Sumstine1, Melvin Rico2, Leticia Cazares1, Quynh Vo1, Natalie Martinez1, Whitney Akabike1, Dallas Swendeman1
1University of California Los Angeles,

M55. Principles and Metrics for Evaluating Oregon’s Drug Decriminalization Measure: Centering the Voices of People Who Use Drugs
Alex Kral*, Jules Netherland2, Riona Morgan2, Danielle Ompad Ompad3, Corey Davis4, Haven Wheelock5, Ricky Bluthenthal6, Nabarun Dasgupta7, Michael Gilbert8, Theshia Nadoo2
1RTI International, 2Drug Policy Alliance, 3New York University, 4National Health Law Program, 5Outside In, 6University of Southern California, 7University of North Carolina, 8Booz Allen Hamilton

M56. Telehealth Services for Substance Use Disorders
Siara Sitar*, Kate Gliske2, Justine Welsh1, Jackie Braughton2, Lance Waller3, Quyen Ngo2
1Emory University School of Medicine, 2Hazelden Betty Ford Foundation, 3Emory University Rollins School of Public Health

M57. Characterizing Behavioral Addiction Symptoms in Adults Receiving Inpatient Substance Use Disorder Treatment
Andrew Peckham*, R. Kathryn McHugh2, Margaret Griffin1, Hannah Shapiro2, Roger Weiss2
1Harvard Medical School/McLean Hospital, 2McLean Hospital
**M58. The Impact of National Drug Policy on the Perceptions of Psychoactive Drugs Among Psychiatrists in the United States**
Alan Davis*, Adam Levin†, Paul Nagib†, Selina Deiparine†, Tom Gao†, Justin Mitchell†
†The Ohio State University

**M59. A Qualitative Observational Study of Implementing Trauma-Informed Care as a Prevention/Intervention Strategy for Substance Use and Related Problems Among Juvenile Justice Youth**
Yang Yang*, Elizabeth Joseph†, Elaine Tinius†, Lillyan Shelley†, Erin Razurin†, Danica Knight†
†Texas Christian University

**M60. An Intervention to Address the Self-Stigma of Substance Use and Criminal Involvement: Feasibility, Acceptability, and Preliminary Effectiveness**
Diamond Allen*, Shania Siebert†, Jason Luoma†, Kelly Moore†
†East Tennessee State University, ‡Portland Psychotherapy Clinic, Research, and Training Center

**M61. Associations Between Automated Session Elements and Gold Standard Ratings of Motivational Interviewing**
Matisyahu Shulman*, Kenneth Carpenter‡, Mei-Chen Hu‡, Paul Amrhein§, Edward Nunes‡
‡College of Physicians and Surgeons, Columbia University/NYSPI, ‡New York State Psychiatric Institute, Columbia University, §Columbia University

**M62. Factors Associated With Recovery Housing Availability for Justice-Involved Individuals in the Community**
Amy Mericle*, Katherine Karriker-Jaffe‡, Deidre Patterson†, Meenakshi Subbaraman†, Faye Taxman§
†Alcohol Research Group, ‡RTI, International, §George Mason University

**M63. Improving Access to High-Value, High-Cost Medicines: The Use of Subscription Models in the United States for Hepatitis C Virus Medications**
Samantha Auty†, Kevin Griffith*, Paul Shafer†
†Boston University School of Public Health, ‡Vanderbilt University

**M64. Infant Caregiving and Postpartum Substance Use: A Review of the Literature**
Alicia Allen*, Linnea Linde-Krieger†, McKenna Nelson†, Stacey Tecot†, Lela Williams‡
†University of Arizona, ‡Arizona State University

**M65. Transition to Virtual Addiction Treatment After Onset of the COVID-19 Pandemic Among Adults With Drug Use Problems in an Integrated Healthcare System**
Vanessa Palzes*, Felicia Chi†, Stacy Sterling†, Asma Asyyed‡, Kathryn Erickson-Ridout†, Cynthia Campbell†
†Center for Addiction and Mental Health Research, Kaiser Permanente Northern California, ‡Northern California Addiction Medicine and Recovery Services, The Permanente Medical Group

Danielle Ompad*, Cho-Hee Shrader‡, Kyle Snyder†, Ingrid Walker‡
†New York University School of Global Public Health, ‡ICAP at Columbia University, §University of Washington, Tacoma

**M67. Barriers to Implementation of Substance Use Disorder Care Within a Local Veteran’s Health Administration System**
Kenisha Nisbett*†
†Kaiser Permanente
M68. Availability of HIV, HCV, Substance Use Disorder Treatment and Other Medical Services at U.S. Syringe Service Programs
Czarina Behrends*, 1 Don Des Jarlais2, Xinlin Lu2, Grace Corry1, Sara Glick3, Shashi Kapadia1, David Perlman4, Bruce Schackman1
1Weill Cornell Medical College, 2New York University School of Global Public Health, 3University of Washington, 4Mount Sinai Beth Israel, Icahn School of Medicine at Mount Sinai

M69. Syringe Service Program Staff Experiences and Wellbeing During the COVID-19 Pandemic
Angela Bazzi*, 1 Andrea Wang2, Raagini Jawa3, Sarah Mackin4, Liz Whynott5, Connor Buchholz5, Ellen Childs7
1University of California, San Diego, 2Boston University School of Medicine, 3Boston Medical Center, 4Access, Harm Reduction, Overdose Prevention and Education (AHOPE), 5Tapestry, 6Boston University School of Public Health, 7Abt Associates

M70. Determinants of Willingness to Pay for a Drug/Alcohol Problem-Free Day Over Time, Among HIV+ Individuals Who Use Drug/Alcohol in South Africa
Techna Cadet*, 1 Jessica Magidson2, Jennifer Belus Belus3, Thanh Lu1, Sean Murphy4
1Weill Cornell Medicine, 2Massachusetts General Hospital, Harvard Medical School, 3Swiss Tropical and Public Health Institute

M71. Screening in Trauma for Opioid Misuse Prevention (STOMP): Results From a Prospective Cohort of Victims of Traumatic Injury
Randall Brown*, 1 Brienna Deyo1, Christopher Nicholas1, Amelia Baltes1, Scott Hetzel1, Alyssa Tilhou2, Joseph Glass3, Ann O’Rourke1, Suresh Agarwal4
1University of Wisconsin School of Medicine and Public Health, 2Boston University, 3Kaiser Permanente Washington Health Research Group, 4Duke University

M72. Similarity of Engagement Across Age Groups of Patients Treated With a Prescription Digital Therapeutic for Opioid Use Disorder
Brian Pfister*, 1 Emily Peckham1, Maxine Stitzer2, Heather Shapiro1, Robert Gerwein1, Stephen Braun1, Gigi Shafai1, Brendan Hare1, Yuri Maricich1, Maria Sullivan1
1Pear Therapeutics, 2Friends Research Institute

M73. The Impact of Opioid Agonist Treatment on Hospitalisations for Injecting-Related Diseases: A Retrospective Data Linkage Study
Samantha Colledge*, 1 Nicola Jones1, Sarah Larney2, Amy Peacock1, Dan Lewer3, Thomas Brothers4, Matthew Hickman5, Michael Farrell1, Louisa Degenhardt1
1National Drug and Alcohol Research Centre, 2Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Université de Montréal, 3UCL Collaborative Centre for Inclusion Health, 4Dalhousie University, 5Bristol Medical School, University of Bristol

M74. The Revolving Prison Door for the Newly Released Heroin-Related Offenders in Taiwan: The Role of Community-Based Healthcare
An-Jou Chen*, 1 I-An Wang2, Sheng-Chang Wang3, Chuan-Yu Chen1
1National Yang Ming Chiao Tung University, 2Center of Neuropsychiatric Research, National Health Research Institutes, 3National Health Research Institutes
M75. Transition of Patients Established on Long-Term Transmucosal Buprenorphine Treatment to Monthly Buprenorphine Injection
Frank Gray*1, Bret Ryder1, Celine M. Laffont1
1Indivior, Inc.

M76. Factors Driving Treatment Retention Among People With Opioid Use Disorder and HIV in Vietnam: A Qualitative Study
1School of Medicine Oregon Health and Science University, 2Hanoi Medical University, 3Portland State University - Oregon Health and Science University School of Public Health, 4Oregon Health and Science University, 5University of Minnesota and Hennepin Healthcare, 6Oregon Health and Science University

M77. A Novel Toll-Receptor 7/8 Adjuvant Increases the Immunogenicity of an Anti-Fentanyl Vaccine and Its Efficacy at Attenuating the Reinforcing Effects of Fentanyl in Rats
Mark LeSage*1, Peter Muelken1, Bethany Crouse2, Shannon Miller3, Jay Evans3, Marco Pravetoni2
1Hennepin Healthcare Research Institute, 2University of Minnesota Medical School, 3University of Montana

Elias Klemperer*1, Laura Wreschnig2, Abigail Crocker3, Jessica King-Mohr4, Annie Ramniceanu4, Liz Evans5, Richard Rawson1
1University of Vermont College of Medicine, 2Vermont Agency of Human Services, Blueprint for Health, 3University of Vermont, College of Engineering and Mathematical Sciences, 4Vermont Agency of Human Services, 5University of Massachusetts Amherst

M79. Analyzing Quality of Life Measures Collected in People With Opioid Use Disorder From the NIDA Data Share Initiative: The Implications for Cost-Effectiveness Evidence in Resource Allocation Decisions
Thomas Patton*1, Jan Boehnke2, Steffanie Strathdee1, Annick Borquez1
1University of California, San Diego, 2University of Dundee

M80. Assessing Changes in Cognitive Functioning in Individuals With Opioid Use Disorder Enrolled in a Residential Treatment Program
Jennifer Marton*1, Daniel Farmer1, Autumn Long1, Erin Winstanley1, Victor Finomore1, Ali Rezai1, James Mahoney1
1West Virginia University School of Medicine/Rockefeller Neuroscience Institute

M81. Barriers and Facilitators to No-Cost Pharmaceutical Alternatives to Illicit Drugs During Intersecting COVID-19 and Overdose Health Emergencies in British Columbia, Canada: A Qualitative Study
Ryan McNeil*1, Taylor Fleming2, Samara Mayer2, Allison Barker2, Manal Mansoor2, Alex Betsos2, Tamar Austin2, Sylvia Parusel2, Andrew Ivsins2, Jade Boyd2
1Yale University School of Medicine, 2British Columbia Centre on Substance Use

M82. Buprenorphine Adherence and Its Association With Illicit Opioid Use
Elenore Bhatraju*1, Andrea C. Radick2, Brian G. Leroux2, Theresa Kim3, Jeffrey Samet4, Judith Tsui2
1Harborview, 2University of Washington, 3Boston Medical Center, 4Boston University School of Medicine
M83. Clinically Significant Loneliness Among Individuals With Opioid Use Disorders
Lisham Ashrafioun1, Tracy Stecker2, Nicholas Allan3, Jonathan Umansky1, Tamara Bilinski1
1University of Rochester, 2VA Center of Excellence for Suicide Prevention; Medical University of South Carolina, 3Ohio University

M84. Early-Onset Prescription Opioid Misuse in Indiana Youth
Maria Parker1, Tamika Zapolski2, Mary Waldron3
1Indiana University - Bloomington, 2Indiana University Purdue University Indianapolis, 3Indiana University School of Education

M85. First in Human Trial of the Non-Opioid Selective Orexin-1 Antagonist INDV-2000 in Healthy Volunteers
Robert Dobbins1, Martin Kankam2, Rana Al-Awam1, Malcolm Young1
1Indivior Inc., 2AltaSciences

M86. How Has Ecological Momentary Assessment Been Used With People Who Are in Medication-Based Treatment for Opioid Use Disorder?
Karen Alexander1, Mishka Terplan1, Pilar Sanjuan2, Kenzie Preston3
1Friends Research Institute, 2University of New Mexico, 3National Institute of Drug Abuse Intramural Research Program

M87. Improving Linkage and Ongoing Engagement With Outpatient Treatment in Patients Initiating Medication for Opioid Use Disorder While Hospitalized at an Urban Safety Net Hospital: Results From Project HOUDINI LINK
D. Andrew Tompkins1, Emily F. Dauria2, Alexandra Haas1, Hannah Snyder1, Paula J. Lum1, J. Konadu Fokuo3, Valerie A. Gruber1
1University of California, San Francisco, School of Medicine, 2University of Pittsburgh Graduate School of Public Health, 3University of Illinois At Chicago College of Medicine

M88. Initial Safety and Feasibility of Rapid-Induction Buprenorphine Extended-Release Following Opioid Overdose
Taylor Ochalek1, Brandon Wills1, Lori Keyser-Marcus1, Kirk Cumpston1, Tamas Gal1, F. Gerard Moeller1
1Virginia Commonwealth University

M89. Injection Partnership Characteristics and Hepatitis C Status Associations With Syringe and Equipment Sharing Among People Who Inject Drugs
Mary Mackesy-Amiot1, Leslie Williams2, Carl Latkin3, Maggie Kaufmann2, Basmattee Boodram2
1University of Illinois at Chicago, School of Public Health, 2University of Illinois at Chicago, 3Johns Hopkins School of Public Health

M90. Is Naloxone Distribution Risky? Attitudes About Naloxone Distribution at the Start of Medical School and Two Years Later
Tabitha Moses1, May Chammaa1, Eva Waineo1, Mark Greenwald2
1Wayne State University School of Medicine, 2Wayne State University

M91. Lack of Effect of Different Pain-Related Manipulations on Opioid Self-Administration, Reinstatement of Opioid Seeking, and Opioid Choice in Rats
Sarah Claypool1, E Andrew Townsend2, Javier Orihuel1, Sarah V Applebey3, Matthew L Banks2, Yavin Shaham1, S Stevens Negus2, David J Reiner1
1National Institute on Drug Abuse, 2Virginia Commonwealth University
M92. Long-Term Recovery From Opioid Use Disorder: Identification of Recovery Subgroups and Their Association With Opioid Use, Treatment, and Quality of Life
Allison Tegge1, William Craft2, Hwasoo Shib3, Diana Keith4, Liqa Athamneh1, Jeff Stein1, Marco Ferreira3, Howard Chilcoat5, Anne Le Moigne5, Angela DeVeauh-Geiss5, Warren Bickel6
1Virginia Tech Carilion Research Institute, 2Fralin Biomedical Research Institute at Virginia Tech Carilion, 3Virginia Tech, 4Fralin Biomedical Research Institute at VTC, Roanoke, VA, 5Indivior, Inc., 6Fralin Biomedical Research Institute at VTC

M93. Multidimensional Assessment of Access to Medications for Opioid Use Disorder Across Urban and Rural Communities: A Scoping Review
Paul Joudrey*1, Tanner Bommersbach1, Marissa Justen1, Amanda Bunting2, Melissa Funaro1, Erin Winstanley3
1Yale University School of Medicine, 2New York University School of Medicine, 3West Virginia University

M94. Prevalence of Mental Disorders Among People With Opioid Use Disorder: A Systematic Review and Meta-Analysis
Thomas Santo*, Gabrielle Campbell2, Natasa Gisev1, Daniel Martino-Burke1, Jack Wilson2, Samantha Colledge1, Brodie Clark1, Lucy Thi Tran1, Louisa Degenhardt1
1National Drug and Alcohol Research Centre, UNSW Sydney, 2University of the Sunshine Coast, 3The Matilda Centre, University of Sydney

M95. Project RIDE: Accessible and Acceptable Mobile Strategy for Community-Based Moud Engagement
Cecile Denis*, Kyle Kampman1, Jose Benitez2, Karen Dugosh3, David Metzger1
1University of Pennsylvania, 2Prevention Point Philadelphia, 3Public Health Management Corporation

M96. Prospective Associations of Tobacco Use With Prescription Drug Misuse Among Young People
Moriah Harton*, Ivana Nguyen1, Rebecca Evans-Polce2, Maria Parker1
1Indiana University, 2University of Michigan

M97. The Use of PICC Lines for Treatment of Serious Infections in People Who Inject Drugs: Review and Commentary
Victoria Weaver*, Mary Clare Kennedy2
1University of British Columbia, Faculty of Medicine, 2The University of British Columbia

SBIR POSTER SESSION (SMALL BUSINESS INNOVATION RESEARCH - SBIR)

Novel Digital and Behavioral Health Platform That Combines Opioid Compliance Protocols to Improve Prescriber Confidence, Reduce Liability, and Improve Patient Outcomes
Amy Elliott*, John Bowman2, Abraham Hartzema1
1University of Florida, 2SureMed Compliance

Development of a Digital Application for Patient Self-Management of Opioid Use Disorder: KIOS
Tara Karns-Wright*, Van King2, Gregg Seigel3, H. Richard Priesmeyer4, Leslie Seigel3, Jennifer Potter2
1The University of Texas Health Science Center At San Antonio, 2University of Texas Health San Antonio, 3Biomedical Development Corporation, 4St. Mary's University

Development of CP-Analogs as Novel Treatments for Opioid Use Disorder
Jeffrey Reich*, Susruta Majumdar2, Jay McLaughlin3, Annie Pasternak1
1Sparian Biosciences, Inc., 2St. Louis College of Pharmacy/Washington University, 3University of Florida
Rae (Realize, Analyze, Engage): A Digital Detection and Intervention for Individuals in Recovery from Substance Use Disorder
Stephanie Carreiro¹, Rebecca Leach², Sloke Shrestha³, Joshua Stapp³, Melissa Taylor², Megan Reinhardt⁴, Nicole Gilbertson⁴, Premananda Indic³
¹University of Massachusetts Medical School, ²University of Massachusetts Chan Medical School, ³University of Texas at Tyler, ⁴RAE Health

Introduction to NIDA’s Office of Translational Initiatives and Program Innovations (OTIPI)
Christopher Conrad*¹, Julia Berzhanskaya¹, Sara Lioi¹, Stacie Gutowski¹, Tamara Slipchenko¹, Tam Nguyen¹, Yordan Kostov¹, Victor Prikhodko¹, Leonardo Angelone¹, Elena Koustova¹
¹DHHS/National Institute on Drug Abuse

Mobile Brain Sensing Platform for Detection of Opioid Craving and Treatment Response
Scott Burwell*¹, Justin Anker²
¹Neurotype Inc., ²University of Minnesota

Integrating Augmented Reality (AR) and Immersive Learning Simulation (ILS) for Healthcare Training: Towards a Transmedia Solution to Address the Opioid Crisis
Douglas Nelson*¹, Anya Andrews², Analia Castiglioni²
¹Lumis Corp., ²University of Central Florida College of Medicine

Risk and Protective Factors for Initial Training Completion Among Substance Use Disorder Peer Worker Trainees
Sierra Castedo de Martell*¹, J. Michael Wilkerson², Jason Howell³, Sheryl McCurdy⁴
¹UTHealth School of Public Health, ²The University of Texas Health Science Center at Houston, ³RecoveryPeople, ⁴University of Texas Health Science Center

Identification of Epigenetic Biomarkers Associated With Prenatal Exposure to Substances of Abuse
Aileen Baldwin*¹
¹United States Drug Testing Laboratories, Inc.

Innovative Animal Experiment Design Tool
Ben Fitzpatrick*¹, Yun Wang¹, Kristin Holmbeck-Cannell¹
¹Tempest Technologies

Multivalent Vaccine Strategies Against Polydrug Use in Opioid Use Disorder
Daihyun Song*¹, Bethany Crouse¹, Jennifer Vigliaturo¹, Stefano Persano¹, Marco Pravetoni¹
¹The University of Minnesota

Overdose Deaths Involving Non-Bzd Hypnotic/Sedatives in the USA: Trends Analyses
Vitor Tardelli*¹, Marina Costa Moreira Bianco², Rashmika Prakash³, Luis Segura³, João Castaldelli-Maia³, Thiago Fidalgo², Silvia Martins³
¹Universidade Federal de Sao Paulo/Centre for Addiction and Mental Health - University of Toronto, ²Universidade Federal de Sao Paulo, ³Columbia University Mailman School of Public Health

Technology Assisted Motivational Interviewing: Developing a Scalable Framework for Promoting Engagement With Tobacco Cessation
Jason Satterfield*¹, Joannalyn Delacruz¹, Ahson Saiyed², John Layton¹, Catherine Bexley¹, Jing Cheng¹, Tatyana Kanzaveli², Maksim Tsvetovat², Brian Borsari¹
¹University of California, San Francisco, ²Open Health Network
Small Business Program: Patient Uptake and Use of a Technological Solution to Support Treatment for Opioid Use Disorder in the Primary Care Setting
Mariah Kalmin*, Bengisu Tulu², Omar Nieto¹, Li Li¹, Dominic Trupiano³, Alycia Quick³, Steve Jenkins³, Steve Shoaptcha¹
¹University of California, Los Angeles, ²Worchester Polytechnic Institute, ³Q2i

Virtual Opioid User: Reproducing Opioid Use Phenomena With a Control Theory Model
Alexander Preiss*, Georgiy Bobashev¹
¹RTI International

TUESDAY, JUNE 14, 2022

POSTER SESSION 3

T1. Arkansas Treatment Admission Trends From 2000 to 2020 for Dual Opioid-Methamphetamine or Opioid-Cocaine Use Problems
Alison Oliveto*, Jeff Thostenson¹, Mary Bollinger¹, Ronald Thompson, Jr.¹, Michael Mancino¹
¹University of Arkansas for Medical Sciences

T2. Childhood Neglect Predicts Perceived Quality of Care in Patients With Co-Occurring Substance Use and Mental Disorders
Karling R. Luciani*, Karina A Thiessen¹, Thomas Wen-Chi Chao¹, Christian Schütz¹
¹University of British Columbia

T3. Craving-Manager App Designed to Manage Craving and Individual Predictors of Substance Use/Addictive Behavior in Addiction: A Randomized Controlled Trial Study Protocol
Fuschia Serre*, Sarah Moriceau¹, Léa Donnadieu¹, Jean Pierre Daulouede², Maurice Dematteis³, Nematollah Jaafari⁴, David Mete⁵, Philippe Nubukpo⁵, Marc Auriacombe¹
¹Université de Bordeaux, ²Bizia, ³Université de Grenoble, ⁴Université de Poitiers, ⁵CHU de La Reunion, ⁶CHU Esquirol de Limoges

T4. Development of the Stop Covid Today Intervention to Increase SARS-CoV-2 Vaccination Among People Who Inject Drugs
Ian Aronson*, Alexander Bennett¹, Mary-Andrée Ardouin-Guerrier¹, German Rivera-Castellar¹, Brent Gibson², Brittney Vargas-Estrella², Sam Santoscoy²
¹New York University, ²New York Harm Reduction Educators

T5. Difficulty in Emotional Regulation is Associated With HIV Risk Related to Drug Use
Fatumastar Adan*, Jeremiah Bertz², Shireen Husami¹, Landhing Moran³, Megan Dwyer², Leigh Panlilio¹, David Epstein¹, Kenzie Preston¹, Karran Phillips⁴
¹NIDA, Intramural Research Program, ²National Institute on Drug Abuse, ³NIDA - Center for Clinical Trials Network, ⁴National Institute of Drug Abuse, National Institutes of Health

T6. Efficacy of Screening and Referral to Targeted Prevention That is Founded on the Liability-Threshold Model
Ty Ridenour*, Daniel Shaw², Chardee Galan³
¹RTI International, ²University of Pittsburgh, ³University of Southern California
T7. Gender Differences in Prescription Medication Misuse in Primary Care
Taylor Crouch*, 1, Caitlin Martin2, Kathryn Polak2, Wally Smith2, Pamela Dillon2, Steven Ondersma2, Dace Svikis2
1Virginia Commonwealth University, School of Medicine, 2Virginia Commonwealth University, 3Michigan State University

T8. HIV Education, Awareness, and Referral and Treatment for Substance Use Disorders (HEARTS): A New Generation of Substance Use Treatment
Adrienne Gilmore-Thomas*, 1, Mandy Hill1, Jane Hamilton2, Angela Heads2
1University of Texas Health Science Center, 2University of Texas Health Science Center Houston

T9. Health Service Utilization Among Hospitalized Patients Experiencing Homelessness in a Randomized Clinical Trial of Patient Navigation Services
Courtney Nordeck*, 1, Robert Schwartz2, Shannon Mitchell2, Christopher Welsh3, Kevin O’Grady4, Jan Gryczynski2
1Johns Hopkins, Bloomberg School of Public Health, 2Friends Research Institute, 3University of Maryland School of Medicine, 4University of Maryland

T10. Illegal Drug Use in Adolescents: A Missed Opportunity for Intervention in Taiwan
Enoch Lee*, 1, An-Jou Chen1, I-An Wang2, Chuan-Yu Chen1
1National Yang Ming Chiao Tung University, 2Center of Neuropsychiatric Research, National Health Research Institutes

T11. Non-Engagement in Substance Use Treatment Among Women With Substance Use Disorders: A Latent Class Analysis on Multidimensional Barriers
Hannah Apsley*, 1, Alexis Santos-Lozada1, Kyler Knapp1, Joy Gray1, Gregory Hard2, Abenaa Jones1
1Pennsylvania State University, 2MGH Institute of Health Professions

T12. Non-Opioid Substance Use Among Patients Receiving Office-Based Buprenorphine Treatment
Karen Dugosh*, 1, Michelle Lent2, Brook Burkley1, Conor Millard1, James McKay3, Kyle Kampman3
1Public Health Management Corporation, 2Philadelphia College of Osteopathic Medicine, 3University of Pennsylvania

T13. One Person’s Needs is Someone Else’s Need Too: Attitudes Towards Harm Reduction and Low-Threshold Healthcare During COVID-19 Among People Who Use Drugs in Rural Southern Illinois
Alex Rains*, 1, Mary York2, Jerel Ezell3, Lawrence J Ouellet4, Wiley Jenkins5, Mai T Pho6
1University of Chicago, Pritzker School of Medicine, 2Southern Illinois University, 3Africana Studies and Research Center, Cornell University, 4School of Public Health, University of Illinois Chicago, 5SIU School of Medicine, 6University of Chicago

T14. Patients With a History of Foster Care Are at Higher Risk for Drug Overdose
Tanisse Teale*, 1, Thomas Wen-Chi Chao1, Christian Schütz1
1University of British Columbia

T15. Prevalence of Substance Abuse Among Out-Of-School Youth in Motor Parks in Ikeja Local Government Area of Lagos State
Olanrewaju Onigbogi*, 1, Modupe Onigbog2
1University of Lagos, College of Medicine, 2University of Texas Health Sciences Houston
T16. The Association Between Socioeconomic Status, Delay Discounting, and Recovery From Substance Use Disorders
Liqa Athamneh*, Allison Tegge¹, Roberta Freitas-Lemos², Warren Bickel²
¹Virginia Tech Carilion Research Institute, ²Virginia Tech Carilion Research Institute at Virginia Tech Carilion

T17. “See The Need, Meet The Need:” Attitudes Toward Trauma-Informed Care Among Juvenile Justice Staff
Elizabeth Joseph*, Lillyan Shelley¹, Yang Yang¹, Danica Knight¹
¹Texas Christian University

T18. Addictive Characteristics of Patients With Cluster Headache
Kelly Hyves¹, Fuschia Serre², Marc Auriacombe², Virginie Corand³
²Bordeaux 2 University, ³Université de Bordeaux, ³Pain Clinic, CHU Bordeaux

T19. COVID-19 Vaccination Status and Concerns Among People Who Use Drugs in Oregon
Erin Stack*, Sarah Shin¹, Kate LaForge¹, Gillian Leichtling¹, Christopher Blazes², Dan Hoover², Andrew Seaman², P. Todd Korthuis²
¹Comagine Health, ²Oregon Health and Science University

T20. Determination of the Cause and the Manner of Death in Post-Mortem Cases in the West Bank in the Years 2011-2021: Mortality Related to Drugs and Toxic Substance Use in Post-Mortem Cases
Ammar Thabaleh*, Rayan Al Ali², Rami Zaghra², Seraj Tijani¹, Omar Saffarini¹, Basma Damiri³
¹School of Medicine and Health Sciences, An-Najah National University, ²Forensic Medicine Institute, An-Najah National University, ³An-Najah National University

Ryan Cook*, Canyon Foot¹, Judith Tsui², Kara Rudolph³, Sean Luo⁴, P. Todd Korthuis¹
¹Oregon Health and Science University, ²University of Washington, ³Columbia University Mailman School of Public Health, ⁴Columbia University

T22. Feasibility of Using Social Media to Deliver an Evidence-Based HIV Prevention Intervention Among Rural Appalachian Women Who Use Drugs
Megan Dickson*, Erika Pike¹, Sean Young², Michele Staton³
¹University of Kentucky, ²University of California, Los Angeles, ³University of Kentucky, College of Medicine

T23. Low Intensity Focused Ultrasound Targeting the Nucleus Accumbens as a Potential Adjunctive Treatment for Substance Use Disorder
James Mahoney*, Marc Haut¹, Jeffrey Carpenter¹, Wanhong Zheng¹, James Berry¹, Jennifer Marton¹, Manish Ranjan¹, Victor Finomore¹, Ali Rezai¹
¹West Virginia University School of Medicine/Rockefeller Neuroscience Institute

T24. Methamphetamine Use and Risky Sex Among Justice-Involved Women With a History of Opioid Use Disorder (OUD)
Michele Staton¹, Martha Tillson*², Matt Webster², Carl Leukefeld², Kathryn McCollister³, Carrie Oser², Sarah Johnson⁴, Katherine Marks²
¹University of Kentucky, College of Medicine, ²University of Kentucky, ³University of Miami Miller School of Medicine, ⁴KY Department of Corrections
T25. Model-Based Decision Making is Related to Reflection Impulsivity: Findings From Exploratory Correlational Analyses Between Computational and Traditional Impulsivity Outcomes
Laura Schmid*, Thomas Wen-Chi Chao1, Stefanie Todesco1, Karina Thiessen1, Christian Schütz1
1University of British Columbia

T26. Predictors of Post Release Service Utilization Among the Formerly Incarcerated With Substance Use Disorders
Sara Beeler-Stinn*, Brett Drake2, Kathleen Bucholz2, Vetta Sanders Thompson2, Tonya Edmond2, Tanya Renn4, Chris Veeh3, Carrie Pettus6
1Jane Addams College of Social Work, UIC, 2Washington University in St. Louis, Brown School, 3Washington University School of Medicine, 4College of Social Work, Florida State University, 5School of Social Work, The University of Iowa, 6Florida State University

T27. Prevalence of Comorbid Health Diagnoses by Body Systems of Persons Presenting in Texas Hospitals With a Substance Use Diagnosis
J. Michael Wilkerson*, Cecilia M Ganduglia Cazaban1, Randa Hamden1, Kathryn R. Gallardo1, David Adzrago1, Henry S Brown1, James J Yang1, Sheryl McCurdy1
1The University of Texas Health Science Center at Houston

T28. Serious Psychological Distress, Substance Use Disorders, and the COVID-19 Pandemic: An Examination of Multiple Mental Health and Social Issues Among Men and Women in the United States in 2020
Joy Gray*, Alexis Santos-Lozada1, Gregory Hard2, Hannah Apsley1, Deirdre O’Sullivan1, Abenaa Jones1
1Pennsylvania State University, 2MGH Institute of Health Professions

T29. Sex Differences in Neural Responses to Stress and Drug Cues is Predictive of Future Substance Use Disorder Relapse Severity
Keisha Smith*, Cheryl Lacadie2, Verica Milivojevic1, Rajita Sinha1
1Yale University School of Medicine, 2Yale University

T30. Sex Work and Overdose Risk Among Women Who Use Drugs in Vancouver, Canada
Miriam Harris*, Shira Goldenberg2, Michelle Cui3, Nadia Fairbairn4, M-J Milloy4, Kanna Hayashi5, Jeffrey Samet6, Alexander Walley4, Seonaid Nolan4
1Boston University, 2San Diego State University, 3British Columbia Centre on Substance Use, 4University of British Columbia, 5Simon Fraser University, 6Boston University School of Medicine

T31. Suicidal Ideation, Planning, and Attempts in Adolescents and Adults During the COVID-19 Pandemic: The Role of Substance Use Disorders and Sex/Gender
Gregory Hard*, Alexis Santos-Lozada1, Joy Gray1, Abenaa Jones1, Hannah Apsley1
1Pennsylvania State University

T32. Survey of Substance Use and Characteristics Associated to Problematic Use in a French Community Structure for People With Mental Disorders
Jean-Marc Alexandre*, Frederique Doneche2, Marc Auriacombe1
1University of Bordeaux, 2Adapei 65

T33. Adolescent Behavioral Responses to COVID-19 and the Development of the Pandemic Response Index
Laura Monico*, Kevin O’Grady2, Jan Gryczynski1, Kaitlyn Garrison1, Tyler Ross1, Shannon Mitchell1
1Friends Research Institute, 2University of Maryland
T34. An Evaluation of Change in Coping Skills From Clinician-Versus Computer-Delivered CBT
Brian Kiluk*, Shannon Schrader1, Tami Frankforter1
1Yale University School of Medicine

T35. Association of Unhealthy Alcohol and Drug Use With Healthcare Utilization Among Adult Primary Care Patients
Leah Hamilton*, Aimee Wahle2, Margaret Kline5, Sarah E. Wakeman3, Timothy Wilens3, Joseph Kannry4, Richard Rosenthal4, Keith Goldfeld5, Angelina Adam5, Sarah Farkas5, Carmen Rosa6, Seth Pitts2, John Rotrosen7, Jennifer McNeely8
1Kaiser Permanente, Washington Health Research Institute, 2The Emes Corporation, 3Massachusetts General Hospital, 4Icahn School of Medicine at Mount Sinai, 5New York University School of Medicine, 6National Institute of Drug Abuse, National Institutes of Health, 7NYU Langone School of Medicine, 8New York University Grossman School of Medicine

T36. Causal Relationships Between High Levels of Substance Use, Emotions, and Social Support
Katherine Harrison*, Andrea Maxwell1, Anna Zilverstand1
1University of Minnesota

T37. Distinguishing Differences in Polysubstance Use by Sex Among Persons Who Use Cocaine
Anna Wang*, Nicole Fitzgerald1, Yiyang Liu1, Barry Setlow1, Lori Knackstedt1, Catherine Striley1, Linda Cottler1
1University of Florida

T38. Gender Differences in Substance Use, Eating, and Other Addictive Behaviors Among Bariatric Surgery Patients
Rachel Arnold*, Jaclyn Sadicario1, Hayley Bray1, Abirami Marimuthu1, Navilia Gottipati1, Leila Islam2, Mary Loos1, Dace Svikis2
1Virginia Commonwealth University, 2VCU Health

T39. Incarcerated Individuals With Co-Occurring Stimulant and Opioid Use Disorder in Rural Massachusetts: Needs and Use of Medications to Treat Opioid Use Disorder
Amelia Bailey*, Calla Harrington1, Liz Evans2
1University of Massachusetts, 2University of Massachusetts Amherst

T40. Treatment Retention, Return to Use, and Recovery Support Following Post-COVID-19 Relaxation of Methadone Take-Home Dosing in Two Rural Opioid Treatment Programs: A Mixed Methods Analysis
Kim Hoffman*, Canyon Foot1, Ximena Levander1, Ryan Cook1, Javier Ponce Terashima2, John McIlveen3, P. Todd Korthuis1, Dennis McCarty1
1Oregon Health and Science University, 2University Hospitals Cleveland Medical Center, 3Oregon Health Authority

T41. Patterns of Past-Month and Lifetime Polysubstance Use are Associated With Co-Occurring Psychosocial Stress, Co-Cooccurring Psychiatric Disorders, and Overdose in Persons Seeking Treatment for Substance Use Disorders
Jennifer Ellis*, Jill Rabinowitz2, Orrin Ware1, Jonathan Wells3, Kelly Dunn1, Andrew Huhn1
1Johns Hopkins University School of Medicine, 2Johns Hopkins Bloomberg School of Public Health, 3Virginia Commonwealth University
T42. Perceived Impact of COVID-19 on Substance Use and Mental Health in People Who Use Opioids (PWUO) in Syringe Services Programs (SSPs) in Southeast U.S. Cities
Mary Hatch¹, Tanja Laschober², Melissa Ertl¹³, Margaret Paschen-Wolff³, Lynette Wright⁴, Daniel Feaster⁵, Susan Tross⁶
¹University of Washington, ²University of Washington, Addictions, Drug and Alcohol Institute, ³Columbia University Medical Center, ⁴University of Washington Alcohol and Drug Abuse Institute, ⁵University of Miami Miller School of Medicine, ⁶Columbia University

T43. Psychoactive Substance Use and Road Traffic Accidents Among Commercial Passenger Vehicle Drivers: A Scoping Review Protocol
Tekendra Rai*¹, Nae Won¹, Nancy Schaefer², Linda Cottler³
¹University of Florida, College of Medicine, ²University of Florida, Health Science Center Libraries, ³University of Florida

T44. Religiosity, Religious Coping and Substance Use for Young Black Men After Trauma
Carolyn Bazan*¹, Alexandria Bauer¹
¹Rutgers University

T45. Social-Emotional Skills and Polysubstance Use Patterns Among Adolescents in Detention Facilities
Samay Shah*¹, Sami Habboub¹, Micah Johnson¹
¹University of South Florida

T46. Substance Use Treatment Utilization Among Individuals With Substance Use Disorders in the United States During the COVID-19 Pandemic: The Role of Polysubstance Use Criminal Justice Involvement
Abenaa Jones*¹, Hannah Apsley¹, Joy Gray¹, Gregory Hard¹, Alexis Santos-Lozada¹
¹Pennsylvania State University

T47. The Association Between Drug Use, Stressful Life Events, and Chaos With Participant Enrollment in Health Research: A Comparison of Two Person-Centered Approaches
Nicole Fitzgerald*¹, Krishna Vaddiparti¹, Catherine Striley¹, Linda Cottler¹
¹University of Florida

T48. Trends in the Concurrent Use of Nicotine and Cannabis Among Adults, United States, 2013-2019
Danielle Smith*¹, Cheryl Rivard¹, Erin McClure², Pete Driezen², Shannon Gravely³, Karin Kasza¹, David Hammond³, Andrew Hyland¹
¹Roswell Park Comprehensive Cancer Center, ²Medical University of South Carolina, ³University at Waterloo

T49. “The Talk to Me Like I Am a Human Being:” A Mixed Methods Analysis of Hepatitis Care Experience at Syringe Exchange Programs
Yesenia Aponte-Melendez*¹, Pedro Mateu-Gelabet¹, Chunki Fong¹, Benjamin Eckhardt², Shashi Kapadia³, Kristen Marks³, Alicia Rodriguez¹, Melinda Pai³
¹CUNY Graduate School of Public Health, ²NYU Langone Health, ³Weill Cornell Medicine

T50. Barriers and Facilitators to COVID-19 Vaccination Among People Who Inject Drugs in San Diego County
Chad Valasek¹, Heather Pines², Samantha Streuli¹, Maria Luisa Mittal¹, Steffanie Strathdee¹, Carlos Vera¹, Alicia Harvey-Vera¹, Angela Bazzi*¹
¹University of California - San Diego, ²San Diego State University
Steven Steine¹, Anne Skinstad*¹
¹University of Iowa

T52. Best Practices for Substance Misuse Research Education Programs to Promote Diversity, Equity, and Inclusion
Chantae Ciceron*¹, Micah Johnson¹
¹University of South Florida

T53. Concurrent Sleep-Motivated Non-Medical Use of Prescriptions and Substance Use: A Latent Class Analysis
Alyssa Falise*¹, Carolin Hoeflich¹, Catherine Striley¹, Catalina Lopez-Quintero¹
¹University of Florida

T54. Internalized Stigma Among Legal-System Involved Women in Substance Use Disorder Treatment
Verlin Joseph*¹, David Moniz-Lewis¹, Dylan Richards¹, Matthew Pearson², Jason Luoma³, Katie Witkiewitz¹
¹University of New Mexico, ²Center on Alcohol, Substance Use, and Addictions (CASAA), ³Portland Psychotherapy Clinic, Research, and Training Center

T55. Leaving the Military in the Context of Mental Health Problems: Does It Increase Risk for Drug Use?
Bonnie Vest*¹, Rachel Hoopsick², D. Lynn Homish¹, Gregory Homish¹
¹State University of New York at Buffalo, ²University of Illinois Urbana-Champaign

T56. Major Depressive Episodes Among U.S. Adults Who Use Kratom (Mitragyna Speciosa): Concurrent Substance Use Patterns and Sociodemographic Differences
Carolin Hoeflich*¹, Alyssa Falise¹, Sara Nutley¹, Catherine Striley¹
¹University of Florida

T57. Perceived Link Between COVID-19 and Substance Use and Mental Health: Findings From Men Who Have Sex With Men Who Use Substances Visiting Sexually Transmitted Infection Clinics in Southeast U.S. Cities
Tanja Laschober¹, Mary Hatch¹, Melissa Erml*², Margaret Paschen-Wolff³, Lynette Wright¹, Daniel Feaster¹, C. Mindy Nelson⁴, Susan Tross⁵
¹University of Washington, Addictions, Drug and Alcohol Institute, ²Columbia University and New York State Psychiatric Institute, HIV Center for Clinical and Behavioral Studies, ³Columbia University Medical Center, ⁴University of Miami Miller School of Medicine, ⁵Columbia University

T58. Racial Differences in the Association Between Family Functioning and Substance Use Disorder Treatment Completion Among Justice-Involved Adolescents
Deja Wilson*¹, Micah Johnson¹
¹University of South Florida

T59. Racial Discrimination, Historical Trauma, Racial Microaggressions and Polysubstance Use in Black Young Adults
Chantel Ebrahimi*¹, Lillian Polanco-Roman¹, Alexandria Bauer², Tanya Saraiya³, Denise Hien⁴
¹The New School, ²Rutgers University, ³Medical University of South Carolina, ⁴Rutgers Center of Alcohol and Substance Use Studies, Graduate School of Applied and Professional Psychology
T60. Resilience During the COVID-19 Pandemic Among Persons Who Use Non-Injected Heroin and Cocaine: Resistance to Injecting, Stable Mental Health, and Reduced Heroin and Cocaine Use
Don Des Jarlais*, Chenziheng (Allen) Weng1, Jonathan Feeleymer1, Anneli Uuskula2, Courtney McKnight1
1New York University School of Global Public Health, 2University of Tartu

T61. Substance Use Trajectories Among Urban College Students: Associations With Symptoms of Stress, Anxiety, and Depression Before and During COVID-19
Laura Brandt*1, Nishanthi J. Anthonipillai2, Teresa López-Castro2, Robert Melara2, Adriana Espinosa2
1Columbia University Irving Medical Center and New York State Psychiatric Institute, 2The City College of New York

Lovelyne Julien*1, Lesia M. Ruglass2, Aimee Campbell3
1The New School, 2The City College of New York, CUNY, 3Columbia University Irving Medical Center and New York Psychiatric Institute

T63. Types of Traumatic Experiences in Drug Overdose-Related Deaths: An Exploratory Latent Class Analysis
Judy Hong1, Constanza de Dios*1, Jessica Balderas1, Sarah Tonkin2, Robert Suchting1, Consuelo Walss-Bass1, Thomas Meyer2
1The University of Texas Health Science Center at Houston, 2University at Buffalo, 3University of Texas Health Science Center

T64. Differences in Substance Class Use Among Driving Under the Influence of Drugs Events Using Real-Time Motor Vehicle Crash Data in the United States From 2019 to 2022
Nae Won*1, Linda Cottler2
1University of Florida, College of Medicine, 2University of Florida

T65. The Association Between Potentially-Traumatic Events and Cocaine, Cannabis, and Alcohol Use Differs by Race
Judy Hong*1, Constanza de Dios1, Adrienne Gilmore-Thomas1, Emma Lathan-Powell1, Jane Hamilton1, Angela Heads1
1The University of Texas Health Science Center at Houston

T66. The Chemokine Antagonists Maraviroc and AMD3100 Reduce Opioid and Stimulant Choice in Rats
Briana Mason*1, Gregory Collins1
1The University of Texas Health Science Center at San Antonio

T67. REL-1017 (Esmethadone; d-Methadone), a Rapid-Acting Antidepressant Has No Meaningful Opioid Abuse Liability in Nonclinical and Clinical Abuse Potential Studies
Jack Henningfield*4, Glen Apseloff2, Charles Gorodetzky3, Marco Pappagallo4, Megan Shram5, Sara De Martin5, Reginaid Fant1, Frank Voci7, Frank Sapienza8, Thomas Kosten9, Jeff Huston1, August Buchhalter1, Judy Ashworth1, Ryan Lainer1, Francesco Bifari10, Franco Foli10, Sady Ribeiro4, Sergio Traversa4, Charles E. Inturrisi4, Paolo L. Manfredi4
1Pinney Associates, Inc., 2Ohio Clinical Trials, 3Consultant in Pharmaceutical Medicine, 4Relmada Therapeutics, Inc., 5Altreos Research Partners, 6University of Padova, 7Friends Research Institute, 8The Drug and Chemical Advisory Group LLC, 9Baylor College of Medicine, MD Anderson Cancer Center, University of Houston, Michael E DeBakey VA Medical Center, 10University of Milano School of Medicine
T68. Racial and Ethnic Differences in Long-Term Outcomes After Randomization to Methadone or Buprenorphine/Naloxone Treatment for Opioid Use Disorder
Yuhui Zhu*, Sarah Clingan1, Larissa Mooney3, Andrew Saxon4, Elizabeth Evans5, Yih-Ing Hser6
1Semel Institute - UCLA, 2University of California, Los Angeles, 3David Geffen School of Medicine, University of California, Los Angeles, 4Veterans Affairs Puget Sound Healthcare System, 5University of Massachusetts Amherst, 6UCLA Integrated Substance Abuse Programs

T69. Self-Reported Substance Use With Clinician Interviewers Versus Computerized Surveys
Lauren Gorfinkel*, Dvora Shmulewitz2, Malka Stohl3, Deborah Hasin2
1The University of British Columbia, 2Columbia University, 3New York State Psychiatric Institute

T70. Sex Differences Among Individuals With Chronic Pain and Opioid Use Disorder Entering Methadone Maintenance Treatment
Olaniyi Olayanja1, Iain Carmichael2, Marina Gaeta Gazzola3, Kimberly Dimeola4, Xiaoying Zheng5, Lynn Madden5, Mark Beitel6, Declan Barry6
1Yale University School of Medicine, 2Brigham and Women’s Hospital, Harvard Medical School, 3The APT Foundation, Yale School of Medicine, 4The APT Foundation, 5The APT Foundation and Yale College, 6The APT Foundation and Child Study Center, Yale School of Medicine

T71. Stimulant Use is Strongly Associated With Return to Opioid Use Following Initiation Onto Medications for Opioid Use Disorder
Canyon Foot*, P. Todd Korthuis1, Judith Tsui2, Sean Luo3, Ryan Cook1
1Oregon Health and Science University, 2University of Washington, 3Columbia University

T72. TRV734 as a Potential Medication for Opioid-Use Disorder: Protocol for a Dose-Finding Pilot and a Proof-Of-Concept Human Laboratory Study
Kirsten Smith*, Leigh Panlilio1, Destiny Schriever1, Lorenzo Leggio1, Karran Phillips2, Kenzie Preston1, Michael Kramer3, Michael Fossler3, David Epstein1, Yavin Shaham2
1National Institute on Drug Abuse, Intramural Research Program, 2National Institute of Drug Abuse, National Institutes of Health, 3Trevena, Inc.

T73. Why Stop a Good Thing? a Qualitative Study of Methadone Discontinuation in the First Year of Treatment for Opioid Use Disorder
Ashish Thakrar*, Jarratt Pytell2, Kenneth Stoller3, Geetanjali Chander3
1National Clinician Scholars Program, University of Pennsylvania, 2Addiction Medicine and General Internal Medicine Fellowships, Johns Hopkins University School of Medicine, 3Johns Hopkins University School of Medicine

T74. The Influence of COVID-19 on Treatment for Opioid Use Disorder Services in Rural Primary Care Settings: Patients’ Perspectives
Sarah Clingan*, Maria Hanano1, Stacy Calhoun1, Allison Ober2, Alex R. Dopp2, Megan E. Curtis1, Megan Black1, Lin Chunqing1, Melissa Salgado1, Katie P. Osterhage3, Laura-Mae Baldwin3, Andrew Saxon4, Emily Hichborn3, Laurie S. Lester3, Lisa Marsch5, Larissa Mooney1, Yih-Ing Hser1
1David Geffen School of Medicine, University of California, Los Angeles, 2RAND Corporation, 3University of Washington, 4Veterans Affairs Puget Sound Healthcare System, Seattle, 5Geisel School of Medicine at Dartmouth
T75. Trends in COVID-19 Testing, Infection, Vaccination and Housing Assistance Among People Who Inject Drugs in Los Angeles, California and Denver, Colorado During the First Year of the Pandemic
Rachel Ceasar¹, Karen Corsi², Jesse Goldshear¹, Patricia Wilkins², Kelsey Simpson¹, Eric Kovalsky², Karina Dominguez Gonzalez³, Ricky Bluthenthal*¹
¹University of Southern California, Keck School of Medicine, ²University of Colorado Denver School of Medicine, ³University of Southern California

T76. Understanding Opportunities and Challenges With Telemedicine-Delivered Buprenorphine During the COVID-19 Pandemic
Kristin Mattocks¹, David Moore², Dora Wischik², Christina Lazar², Marc Rosen*²
¹U Mass Worcester/VA Central Western Mass, ²Yale University/VA Connecticut Healthcare System

T77. Women’s Experiences in Injectable Hydromorphone and Diacetylmorphine Treatment Programs in Vancouver, Canada
Samara Mayer*¹, Jade Boyd², Ryan McNeil³
¹BC Centre on Substance Use and University of British Columbia, ²British Columbia Centre on Substance Use, ³Yale University School of Medicine

T78. “The Opposite of Addiction is Connection”: Syringe Service Program Perspectives on Engaging People Who Use Drugs in Harm Reduction Services During the COVID-19 Pandemic
Elizabeth Austin¹, Maria Corcorran¹, Madeline Frost², Elsa Briggs², Czarina Behrends³, Alexa Juarez¹, Noah Frank¹, Elise Healy¹, Stephanie Prohaska⁴, Paul LaKosky⁴, Shashi Kapadia⁵, David Perlman⁶, Bruce Schackman³, Don Des Jarlais⁷, Emily Williams⁵, Sara Glick¹
¹University of Washington, ²University of Washington School of Public Health, ³Weill Cornell Medical College, ⁴Dave Purchase Project, North American Syringe Exchange Network, ⁵Weill Cornell Medical College, ⁶Mount Sinai Beth Israel, Icahn School of Medicine at Mount Sinai, ⁷New York University College of Global Public Health

T79. A Pilot Randomized Clinical Trial Examining Buspirone as an Adjunctive Medication During Buprenorphine-Assisted Supervised Opioid Withdrawal
Cecilia Bergeria¹, Hongjun Tan², Denis Antoine¹, Elise Weerts¹, Andrew Huhn¹, J. Greg Hobelmann², Kelly Dunn¹
¹Johns Hopkins University School of Medicine, ²Penn State University, ³Ashley Treatment Center

T80. A Randomized Controlled Trial of an Online Training to Reduce Primary Care Clinicians’ Stigma Toward People With Opioid Use Disorder
Stephanie Hooker*¹, Lauren Crain¹, Amy LaFrance¹, Konadu Fokuo², Gavin Bart³, Rebecca Rossom¹
¹HealthPartners Institute, ²University of Illinois Chicago, ³University of Minnesota

T81. Analyzing Whether Social-Emotional Resources Attenuate the Relationship Between Adverse Childhood Experiences and Opioid Misuse Among Justice-Involved Adolescents
Tyre McDowell*¹, Chamanthi Konidala¹, Micah Johnson¹
¹University of South Florida

T82. Best Practices for Drug Testing During Medication for Opioid Use Disorder (MOUD) Treatment Over Telemedicine
Omeid Heidari*¹, Shoshana Aronowitz², Abigail Winiker¹, Sarah Pollock¹, Shereen Sodder¹, Karin Tobin¹
¹Johns Hopkins Bloomberg School of Public Health, ²University of Pennsylvania
T83. Buprenorphine Misuse in Opioid Use Disorders: Subgroups, Motivations, and Opioid Demand
Alexandra Goslow¹, Allison Tagge², Roberta Freitas-Lemos³, Devin Tomlinson³, William Craft³, Angela DeVeau-Geiss⁴, Howard Chilcoat⁴, Warren Bickel³
¹Virginia Tech Carilion School of Medicine, ²Virginia Tech Carilion Research Institute, ³Fralin Biomedical Research Institute at Virginia Tech Carilion, ⁴Indivior, Inc.

T84. Changes In Substance Use Behaviors Among Those Who Use Opioid Analgesics
Stevan Severtson*¹, Joshua Black¹, Janetta Iwanicki¹, Richard Dart²
¹Rocky Mountain Poison and Drug Safety, ²Rocky Mountain Poison and Drug Center

T85. City Streetscapes and Neighborhood Profiles of Fatal Opioid Overdoses Among Unstably-Housed People Who Use Drugs
Elizabeth Nesoff¹, Douglas Wiebe¹, Silvia Martins²
¹Perelman School of Medicine University of Pennsylvania, ²Columbia University

T86. Enhancing Social Determinants of Health Among People With Opioid Use Disorder on Buprenorphine
Irene Pericot-Valverde*¹, Erik Ortiz², Ashely Coleman², Trisha Melling², Quang Pham², Marc Burrows³, Sherry Riggins², Carrie Baldwin², Michelle Bublitz², Jiaying Niu¹, Angelica Perez¹, Moonseong Heo¹, Alain Litwin¹
¹Clemson University, ²Prisma Health, ³Challenges Inc

T87. Experiences With Treatment for Opioid Use Disorder and Substance Use During the COVID-19 Pandemic Among People Who Use Opioids: A Web-Based Survey
Elizabeth Saunders*¹, Grace Janzow², Cassandra Harding², Lisa Marsch¹, Jacob Borodovsky¹, Zev Schuman-Olivier²
¹Geisel School of Medicine at Dartmouth, ²Cambridge Health Alliance

T88. Federal Policy Changes and Buprenorphine Treatment Capacity in the US: An Interrupted Time Series Analysis
Hannah Knudsen*¹
¹University of Kentucky

T89. Gabapentin Levels Impact on Successful Transition to Injectable Naltrexone
Michael Mancino*¹, Jeff Thostenson¹, Azizi Ray¹, Joseph Guise¹, Edward Nunes², Alison Oliveto¹
¹University of Arkansas for Medical Sciences, ²Columbia University and New York State Psychiatric Institute

T90. Impact of Telemedicine on Retention in Medications for Opioid Use Disorder (MOUD) Treatment With Buprenorphine in the Times of COVID-19 Pandemic: A Retrospective Chart Review
Jagdeep Kaur*¹, Irakli Mania², Raghavendra Tirupathi², Lakshmi Polavarapu³
¹University of California, Davis, ²Keystone Health Rural Center, ³Saddler Health Center

T91. Naloxone Provision and Overdose Prevention Education for Patients with Opioid Use Disorder in Four Urban Emergency Departments
Kathryn Hawk*¹, Marek Chawarski¹, Patrick O’Connor¹, E. Jennifer Edelman¹, Shara Martel¹, Patricia Owens¹, Edward Coutet¹, Lauren Whiteside⁴, Ethan Cowan³, Lynne Richardson³, Michael Lyons⁴, Caroline Freiermuth⁴, Richard Rothman⁵, David Fiellin¹, Gail D’Onofrio¹
¹Yale University School of Medicine, ²University of Washington, ³Icahn School of Medicine at Mount Sinai, ⁴University of Cincinnati, ⁵Johns Hopkins University School of Medicine
T92. OPENing Hearts and Minds: Lessons Learned in the Implementation and Facilitation of a Weekly Online Opioid Use Disorder Educational Series
John Lauckner¹, Michelle Lofwall², Laura Fanucchi³, Christopher Cook*¹, Sharon Walsh², Devin Oller³
¹University of Kentucky, Substance Use Priority Research Area, ²University of Kentucky, Center on Drug and Alcohol Research, ³University of Kentucky, College of Medicine

T93. Opioid Knowledge Test: Identifying Knowledge Gaps Regarding Opioids Among College Students, Researchers, and Treatment Providers
Frank Schwebel*¹, Margo Villarosa-Hurlocker², Matthew Pearson¹, Susan Baumgardner³, Jon Houck⁴, Addictions Research Team³
¹Center on Alcohol, Substance Use and Addictions (CASAA), ²University of New Mexico, ³Colorado State University, ⁴Mind Research Network

T94. Open Board

T95. Effects of Dimethylfumarate on Morphine Withdrawal Symptoms and In Vivo Neurochemistry in Morphine-Dependent Mice: A Behavioral and Proton Magnetic Resonance Spectroscopy Study
Marc Kaufman*¹, Tao Song¹, Xiaopeng Song¹, Joseph Anderson¹, Edward Meloni², Fei Du¹, Carol Paronis²
¹McLean Hospital, Brain Imaging Center, ²McLean Hospital, Harvard Medical School

T96. Analysis of Stimulant Prescriptions, Drug-Related Poisonings, and Treatment Retention Among Patients Receiving Buprenorphine for Opioid Use Disorder.
Carrie Mintz*¹, Kevin Xu¹, Ned Presnall², Sarah Hartz¹, Frances Levin², Jeffrey Scherrer³, Laura Bierut¹, Richard Grucza⁴
¹Washington University School of Medicine, ²Washington University in St Louis, ³Columbia University Irving Medical Center/ New York State Psychiatric Institute, ⁴St. Louis University School of Medicine

T97. Transcriptomic Hallmarks of Genetic Knockdown of the 5-HT2A Receptor in Rat Medial Prefrontal Cortex: Implications for Understanding Psychedelic Actions
Juliana Giacomini*¹, Christina Merritt², Jacqueline Silva², Dennis Sholler³, George Golovko², Jonathan Hommel², Noelle Anastasio², Kathryn Cunningham²
¹UTMB Center for Addiction Research, ²University of Texas Medical Branch, ³Johns Hopkins University School of Medicine

WEDNESDAY, JUNE 15, 2022

POSTER SESSION 4

W1. Alterations in Diurnal Cortisol Related to Cannabis Use Disorder and Recent Marijuana Use: A Pilot in-Field, Within-Person Intensive Monitoring Study
Stephanie Wemm*¹, Lucas Harrison¹, Marshall Tate¹, Rajita Sinha¹
¹Yale School of Medicine

W2. Assessing the Utility of the Cannabis Use Disorder Identification Test – Revised (CUDIT-R) in a Sample of Medical and Non-Medical Cannabis Using Veterans
Matthew Myers*¹, Dara Ganoczy², Kipling Bohnert³
¹Michigan State University College of Human Medicine, ²VA Government, ³University of Michigan and Department of Veterans Affairs
W3. Associations Between Maternal Prenatal Cannabis Exposure and Adolescent Cognitive Outcomes From the ABCD Study
Maria Poblete*1, Stephanie Lake2, Ziva Cooper3
1Semel Institute for Neuroscience and Human Behavior at UCLA, 2University of California, Los Angeles, 3UCLA Cannabis Research Initiative

W4. Effect of COVID-19 on Cannabis Use and Motivation to Quit Among a Community Sample of Cannabis Users: A Time Series Analysis
Catherine Psaras*1, Sarah Cousins1, Joshua Hakimian1, Maria Hanano1, Yih-Ing Hser1, Larissa Mooney1
1University of California, Los Angeles, David Geffen School of Medicine

W5. Exploring the Role of Female Gender Discrimination on Problematic Cannabis Use With Race as Moderator
Devin Whitt*1, Tamika Zapolski1
1Indiana University- Purdue University Indianapolis

W6. Gender Differences in Cannabis Use Disorder Symptoms: A Network Analysis
Emese Kroon*1, Alessandra Mansueto1, Lauren Kuhns1, Francesca Filbey2, Reinout Wiers1, Janna Cousijn3
1University of Amsterdam, 2University of Texas at Dallas, 3Erasmus University Rotterdam

W7. Open Board

W8. Patterns of Tobacco and Cannabis Use in Australia: A Latent Class Analysis and Health-Related Correlates
Carmen Lim*1, Janni Leung2, Shannon Gravely2, Coral Gartner3, Vivian Chiu1, Tianze Sun1, Jack Chung1, Daniel Stjepanovic1, Jason Connor1, Roman Scheurer4, Wayne Hall1, Gary Chan1
1National Centre for Youth Substance Use Research, The University of Queensland, 2University of Waterloo, 3NHMRC Centre of Research Excellence on Achieving the Tobacco Endgame, The University of Queensland, 4Queensland Centre for Mental Health Research, The Park Centre for Mental Health Research

W9. Social Network Analysis of Young Adults’ Cannabis Use Before and During the COVID-19 Pandemic
Graham DiGuiseppi*1, Ekaterina Fedorova2, Stephen Lankenau2, Jordan Davis1, Bridgid Conn3, Carolyn Wong4
1University of Southern California, 2Drexel University, Dornsife School of Public Health, 3Children’s Hospital Los Angeles, 4Children’s Hospital Los Angeles and University of Southern California

W10. The Association Between Workplace Drug Use Policies and Current Drug Use Among Low-Income Workers: Findings From the National Survey on Drug Use and Health
Rachel Hoopsick*1, Jaqueline Carrillo1, Michael Knipp1, Gregory Homish2
1University of Illinois Urbana-Champaign, 2State University of New York at Buffalo

W11. The Association Between Cannabis Use Disorder and Co-Occurring Anxiety and Depression
Sarah Cousins*1, Yuhui Zhu2, Huiying Guo2, Joshua Hakimian2, Tram Nguyen2, Maria Hanano2, Yih-Ing Hser2, Larissa Mooney2
1Semel Institute for Neuroscience and Human Behavior at UCLA, 2David Geffen School of Medicine, University of California, Los Angeles

W12. The Lateral Habenula: A Critical Crossroad for the Brain’s Negative and Positive Valence Systems
Kristen Platt*1, Francesca Filbey1
1The University of Texas at Dallas
W13. Age Differences in Patterns of Cannabis and Other Drug Use Within a Cohort of Medical Cannabis Patients in Pennsylvania
Ekaterina Fedorova¹, Janna Ataiants¹, Allison Mitchell¹, Stephen Lankenau*¹
¹Drexel University Dornsife School of Public Health

W14. An Exploration of Multivariate Symptom Clusters of Cannabis Use Disorder in Young Adults
Lindy Howe*¹, Allen Bailey¹, Polly Ingram¹, Peter Finn¹
¹Indiana University

W15. Cannabis Practices of Gender Minority and Cisgender Young Adults Recruited Through Social Media
Cara Struble*¹, Jacob Borodovsky¹, Mohammad Habib², Deborah Hasin³, Ofir Livne⁴, Claire Walsh⁵, Efrat Aharonovich⁶, Dvora Shmulewitz⁷, Alan Budney¹
¹Geisel School of Medicine at Dartmouth, ²Dartmouth College, ³Columbia University, ⁴Columbia University Mailman School of Public Health, ⁵Columbia University and New York State Psychiatric Institute

W16. Chronic Relief: Exploring the Use and Impact of Cannabis in the Setting of Chronic Pain Among Black American Pain Patients in Los Angeles
Dilara Üsküp¹, Jazzylyne Hudson²
¹Semel Institute for Neuroscience and Human Behavior at UCLA, ²University of California, Los Angeles

W17. Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) and Substance Use in Reducing Family Members’ Distress: Preliminary Assessment of Efficacy
Mary Grace Shinners¹, Eleanor Sultana¹, Andrea Wood¹, Roger Weiss², Dost Öngür², Kim Mueser³, James Hudson², Julie McCarthy*⁴²
¹McLean Hospital, ²McLean Hospital, Harvard Medical School, ³Boston University

W18. Empirically Derived Patterns of Motivation, Readiness, and Confidence to Stop or Reduce Cannabis Use Among Treatment-Interested Adolescents and Emerging Adults
Kathryn Gex*¹, Kyle Walters¹, Rachel Tomko¹, Kevin Gray¹
¹Medical University of South Carolina

W19. Exploring Trajectories of Days of Cannabis Use Among Young Adults: A Novel Mixed Methods Study
Stephen Lankenau*¹, Ekaterina Fedorova¹, Janna Ataiants¹, Bridgid Conn², Carolyn Wong³
¹Drexel University Dornsife School of Public Health, ²Children’s Hospital Los Angeles, ³Children’s Hospital Los Angeles and University of Southern California

W20. Longitudinal Examination of Obsessive Passion for Cannabis Use Among College Undergraduate Students
Yitong Xin*¹, Brooke Arterberry², Corrine M. Schwarting², Stacey B. Armstrong³, Erin Bonar³, Alan K. Davis¹
¹The Ohio State University, ²Iowa State University, ³University of Michigan

Tory Spindle*¹, Hayleigh Tilton¹, Spencer Lin¹, Edward Cone¹, Ruth Winecker², Eric Welsh³, Lynn Wagner³, Ron Flegel⁴, Ryan Vandrey¹
¹Johns Hopkins University School of Medicine, ²RTI International, ³Department of Defense, ⁴Substance Abuse and Mental Health Services Administration
W22. The Effects of Stress and Cues on Craving for Cannabis
Leslie Lundahl*, Mark Greenwald
Wayne State University School of Medicine

W23. Use of Pain Medication and Cannabis by Age Groups Before and After Legalization of Cannabis: An Investigation of Trends From 2017 to 2019 in a Representative Sample of Canada
Karina Thiessen*, Karling R. Luciani, Thomas Wen-Chi Chao, Christian Schütz
University of British Columbia

W24. Anxiety in a Placebo-Controlled Pharmacotherapy Trial for Adolescent Cannabis Use Disorder
Daniel Hashemi*, Nathaniel Baker, Rachel Tomko, Kevin Gray
Medical University of South Carolina

W25. Assessing Cannabis Use Disorder in Primary Care: Psychometric Performance of a Substance Use Symptom Checklist
Theresa Matson*, Kevin Hallgren, Malia Oliver, Gwen Lapham, Emily Williams, Katharine Bradley
Kaiser Permanente Washington Health Research Institute, University of Washington, Veterans Affairs Puget Sound Health Services Research and Development

W26. Delta-8 THC Use in US Adults: Sociodemographic Characteristics and Correlates
Ofir Livne*, Alan Budney, Jacob Borodovsky, Claire Walsh, Dvora Shmulewitz, David Fink, Cara Struble, Mohammad Habib, Efrat Aharonovich, Deborah Hasin
Columbia University Mailman School of Public Health, Geisel School of Medicine at Dartmouth, New York State Psychiatric Institute, Columbia University, Dartmouth Medical School, Dartmouth College, Columbia University and New York State Psychiatric Institute

W27. Marijuana Craving as a Predictor of Subjective Marijuana Effects
Ciara Cannoy*, Mark Greenwald, Leslie Lundahl
Wayne State University, Wayne State University School of Medicine

W28. Mental Health and Life Events in Adolescents With Substance Use Disorders in the United States
Ryan Sultan*, Frances Levin, Alex Zhang
Columbia University, College of Physicians and Surgeons, Columbia University Irving Medical Center/ New York State Psychiatric Institute, Columbia University

W29. Natural Reward Processing in Adults With Cannabis Use Disorder
Brian Sherman*, Zoe Brasher, Aimee McRae-Clark, Brett Froeliger
Medical University of South Carolina, University of California, Los Angeles, University of Missouri

W30. Patterns of Substance Use and Mental Health Profiles Among Pregnant Women
Mary Mitchell*, Mishka Terplan, Jennifer Brooks, George Akinwolere, Katrina Mark
Friends Research Institute, University of Maryland School of Medicine

W31. Population Patterns Linking Adolescent Risk-Taking and Substance Use
Brenden Tervo-Clemmens*, Zuena Karim, Sehyr Khan, Randi Schuster, Jodi Gilman, Anne Eden Evins
Harvard Medical School, Massachusetts General Hospital, University of Texas at Austin, Wellesley College
W32. The Reddit Cannabis Subjective Highness Scale: Applying Natural Language Processing to Inform Cannabis Use Measurement
Meredith Meacham*, Michael Gilbert, Alicia Nobles, Johannes Thrul
1University of California San Francisco, 2Independent, 3University of California San Diego, 4Johns Hopkins Bloomberg School of Public Health

W33. Validity of DSM-5 Cannabis Use Disorder Severity Levels in Adults With Problematic Substance Use
David Fink*, Dvora Shmulewitz, Malki Stohl, Zachery Mannes, Melanie Wall, Deborah Hasin
1New York State Psychiatric Institute, 2Columbia University, 3Columbia University and NYSPI

W34. Cannabinoids in Plasma by LC-MS/MS: Application to Specimens From Youths With HIV
Cynthia Coulter, Christine 9-Delta Analytical LLC, Bernard Fischer, Guglielmo Venturi, Maureen Goodenow, John Sleasman
19-Delta Analytical LLC, 2Duke University, 3maureen.goodenow@nih.gov

W35. Cannabis Predictors of Neurocognitive Outcomes in Adolescents and Young Adults After 3-Week Abstinence Period
Elizabeth Stinson*, Julia Harris, Krista Lisdahl
1University of Wisconsin-Milwaukee

W36. Chronic Oral Dosing of Cannabidiol (CBD) With And Without Low Doses Of Delta-9-Tetrahydrocannabinol (THC)
David Wolinsky, Austin Zamarripa, Tory Spindle, Edward Cone, Ruth Winecker, Ron Flegel, David Kuntz, Ryan Vandrey
1Johns Hopkins University School of Medicine, 2RTI International, 3Substance Abuse and Mental Health Services Administration, 4Clinical Reference Laboratory

W37. Health Conditions as Predictors of Longitudinal Groups of Medicinal Cannabis Use During the Legalization of Recreational Cannabis in Los Angeles
Janna Ataiants*, Carolyn Wong, Bridgid Conn, Ekaterina Fedorova, Omolola Odejimi, Stephen Lankenau
1Drexel University Dornsife School of Public Health, 2Children's Hospital Los Angeles and University of Southern California

W38. Impaired Behavioral Insight During a Probabilistic Drug Vs. Non-Drug Reinforcer Choice Task in Severe Cannabis Use Disorder: Associations With Cannabis-Related Problem Awareness and Motivation to Change
Brandon Schermitzler*, Scott Moeller, Stephanie Wemm, Richard Macatee
1Auburn University, 2Stony Brook University School of Medicine, 3Yale School of Medicine

W39. Medical Cannabis Use During Peri- And Postmenopause: A Survey Study
Mary Dahlgren*, Celine El-Abboud, Kelly Sagar, Rosemary Smith, Ashley Lambros, Staci Gruber
1McLean Hospital, Harvard Medical School, 2McLean Hospital

W40. Perceptions About Prenatal Cannabis Use in Postpartum Women With and Without a Personal History of Cannabis Use
Anna Wiese*, Nancy Jallo, Lisa Brown, Judy Chang, Nicole Karjane, Carl Wolf, Robert Balster, Divya Sharma, Enkelejda Ngjelina, Dace Svikis
1Virginia Commonwealth University, 2University of Pittsburgh
W41. Open Board

W42. The Estimated Effect of Prenatal Cannabis Exposure on Neonatal Birth Outcomes
Alyssa Vanderziel¹, James Anthony¹, Omayma Alshaarawy²
¹Michigan State University, ²Michigan State University College of Human Medicine

W43. Open Board

W44. Optimism Bias for Drug and Nondrug-Related Life Events in People With Opioid Use Disorder
Emmanuel Alvarez¹, Julia Kong², Sahar Hafezi², Darla Bonagara², Anna Konova²
¹Rutgers Robert Wood Johnson Medical School, ²UBHC, and Brain Health Institute, Rutgers University – New Brunswick

W45. Open Board

W46. Patient Perspectives on the Intersection of Social Relationships, Medication for Opioid Use Disorder, and the Criminal Justice System
Lynn Madden¹, Ruthanne Marcus², Kim Hoffman³, Marina Gaeta², Mark Beitel², Anthony Eller², Lindsay Oberleitner⁴, David Oberleitner⁵, Declan Barry⁶
¹APT Foundation, ²Yale Medical School, ³Oregon Health Sciences University, ⁴Oakland University William Beaumont School of Medicine, ⁵University of Bridgeport, ⁶Yale Medical School; APT Foundation

W47. Post-Traumatic Stress Symptoms After Childbirth Among Women in Outpatient Treatment for Opioid Use Disorder
Michelle Eglovitch¹, Anna Beth Parlier-Ahmad¹, Allison Williams¹, Dace Svikis¹, Caitlin Martin¹
¹Virginia Commonwealth University

Erin Annunziato¹, Silvia Martins¹, Pia Mauro¹
¹Columbia University

W49. Racial Differences in the Impact of Trauma on Opioid Misuse Among Justice-Involved Adolescents
Ohemaa Peprah-Asante¹, Gina Micciche¹, Micah Johnson¹
¹University of South Florida

W50. Remifentanil Dose Ranging in Individuals With Physical Opioid Dependence and Opioid Use Disorder
Joshua Lile¹, Joseph Alcorn¹, Shanna Babaloni¹, Kevin Hatton¹, Hays Lon¹, Abner Rayapati¹, Craig Rush¹, William Stoops¹, Michael Wesley¹
¹University of Kentucky, College of Medicine

W51. Responding to a Surge in Overdose Deaths: Perspectives From U.S. Syringe Services Programs
Madeline Frost¹, Elizabeth Austin¹, Maria Corcorran², Elsa Briggs¹, Czarina Behrends³, Alexa Juarez², Noah Frank², Elise Healy², Stephanie Prohaska⁴, Paul LaKosky⁴, Shashi Kapadia³, David Perlman⁵, Bruce Schackman³, Don Des Jarlais⁴, Emily Williams¹, Sara Glick²
¹University of Washington School of Public Health, ²University of Washington, ³Weill Cornell Medical College, ⁴Dave Purchase Project, North American Syringe Exchange Network, ⁵Mount Sinai Beth Israel, Icahn School of Medicine at Mount Sinai, ⁶New York University, School of Global Public Health
W52. Resumption of Methadone Following Release From Incarceration Delays Reincarceration for Any Cause in Men Eligible to Continue Methadone Treatment in Connecticut Jails
Phil Marotta*, Adam Viera#, Alissa Haas¹, Lauretta Grau¹, Robert Heimer²
¹Washington University in St. Louis, ²Yale University, ³University of Indiana Bloomington

W53. Retention on Treatment and Mortality of Opioid Use Disorder Patients After Methadone Take-Home Dosing Policy Change During COVID-19 Pandemic in Ukraine
Roman Ivasiy*, Samy Galvez¹, Lynn Madden³, Scott Farnum², Daniel J. Bromberg³, Iryna Pykalo⁴, Anna Meteliuk⁵, Zahedul Islam⁵, Frederick Altice¹
¹Yale University School of Medicine, ²APT Foundation, Inc., ³Yale School of Public Health, ⁴European Institute for Public Health Policy, ⁵Alliance for Public Health of Ukraine

W54. Risky Alcohol Use Among Patients Dispensed Opioid Medications: A Clinical Community Pharmacy Study
Gerald Cochran*, Elizabeth Charron¹, Jennifer Brown⁴, Alina Cernasev³, Kenneth Hohmeier³, T. Winhusen²
¹University of Utah, ²University of Cincinnati, ³University of Tennessee

W55. Substance Use Patterns and Self-Ascribed Masculinity/Femininity Among Incarcerated Women With a Recent History of Opioid Misuse
Martha Tillson*, Matt Webster¹, Carrie Oser¹, Michele Staton²
¹University of Kentucky, ²University of Kentucky, College of Medicine

W56. The Association Between Exercise and Opioid Misuse: A Systematic Review
Whitney Cordoba-Grueso*, Paola Mattey-Mora¹, Maria Parker¹
¹Indiana University

John Magel*, Mark Bishop², Gerald Cochran², Julie Fritz¹, Elaine Lonnemann³, Adam Gordon⁴
¹University of Utah, ²University of Florida, ³University of St. Augustine, ⁴University of Utah SoM and VASLCHCS

W58. Training, Development, and Implementation of Novel Peer Support Led Programs for Persons With Opioid Use Disorder (OUD)
Molly Gallivan*, Anna Ross², Amanda Fallin-Bennett³, Devin Oller⁴, Laura Fanucchi⁴, Christopher Cook¹, John Lauckner¹, Phoebe Wheeler-Crum², Shelley Elswick², Sharon Walsh⁵, Michelle Lofwall⁵
¹University of Kentucky, Substance Use Priority Research Area, ²Voices of Hope, ³University of Kentucky, College of Nursing; Voices of Hope, ⁴University of Kentucky, ⁵University of Kentucky, Center on Drug and Alcohol Research

W59. Open Board

W60. When Everyone's a Critic: How Social Factors Impact Individuals With Opioid Use Disorder and Influence Treatment Engagement
Emma Schweitzer*, Adelya Urmanche², Joshua Zhao³, Julia Kong⁴, Sahar Hafezi⁴, Anna Konova⁴
¹Rutgers University, ²Derner School of Psychology, Adelphi University, ³UBHC, Robert Wood Johnson Medical School, ⁴UBHC, and Brain Health Institute, Rutgers University – New Brunswick
W61. Open Board

W62. “I'm Clean And Sober, But Not Necessarily Free:” Motivations To Discontinue Treatment Among Patients On Long-Term Buprenorphine
Jessica Wyse*1, Travis Lovejoy2, Adam Gordon3, Katherine Mackey2, Ben Morasco2
1Oregon Health and Science University, 2VA Portland Health Care System, 3University of Utah SoM and VASLCHCS

W63. A Comparison of Treatment Outcomes Between Women Receiving and Not Receiving Medication for Opioid Use Disorder From a RCT of CBT4CBT for Women in Residential Treatment
Anna Parlier-Ahmad*1, Sydney Kelpin2, Caitlin Martin1, Dace Svikis1
1Virginia Commonwealth University, 2Mayo Clinic

W64. A Novel Telehealth Model for Improved Retention in Opioid Use Disorder Treatment
Arthur Robin Williams*1, Shosana Aronowitz2, Ryan Gallagher3, Emily Behar3, Zack Gray3, Adam Bisaga1
1Columbia University, 2University of Pennsylvania School of Nursing, 3Ophelia Health

W65. Addressing Barriers to Buprenorphine Treatment Among People Experiencing Homelessness: The Provider Perspective
Emily A. Levine*1, Kelly R. Knight2, Leslie W. Suen3, Joseph A. Spillane4, Maggie M. Chen1, Ya Chi Angelina Liang1, Carmen L. Masson1
1University of California, San Francisco, 2University of California, San Francisco and Center for Vulnerable Populations, 3University of California, San Francisco and San Francisco Veterans Affairs Medical Center

W66. COVID-Related Distress, Coping Motives, and Substance Use Among Women With a History of Sexual Assault During the COVID-19 Pandemic
Tosca Braun*1, Wendee Wechsberg2, Ana Abrantes1
1Butler Hospital, Alpert Medical School of Brown University, 2RTI International

W67. Characteristics Associated With Opioid Misuse Among At-Risk Adolescents
Oluchi Nwankwo*1, Ethan Kusiak1, Micah Johnson1
1University of South Florida

W68. Circumstances and Correlates of Providing Assistance With Someone's First Injection in the AIDS Linked to the Intravenous Experience Cohort, Baltimore, MD
Rachel Gicquelais*1, Jacquie Astemborski2, Dan Werb3, Elizabeth Collins1, Gregory Kirk2, Shruti H Mehta2, Becky Genberg2
1University of Wisconsin-Madison, 2Johns Hopkins Bloomberg School of Public Health, 3University of California, San Diego

W69. Contraceptive Use and Substance Use Disorder Treatment Utilization by Reproductive-Age Women Who Use Drugs in Rural Communities in the United States: A Cross-Sectional Survey
Ximena Levander*1, Canyon Foot1, Sara Magnusson2, Ryan Cook1, Jerel Ezell3, Judith Feinberg4, Vivian F. Go5, Kathryn Lancaster4, Elizabeth Salisbury-Afshar7, Gordon Smith6, Ryan Westergaard7, April Young8, Judith Tsui9, P. Todd Korthuis1
1Oregon Health and Science University, 2Comagine Health, Research and Evaluation, 3Cornell University, 4West Virginia University, 5Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, 6Ohio State University, 7University of Wisconsin - Madison, 8University of Kentucky, College of Public Health, 9University of Washington
W70. Creation of a Simple Microsimulation Model for Assessing the Impact of Treatment on Opioid Misuse in North Carolina
Kasey Jones*1, Georgiy Bobashev1
1RTI International

W71. Developing a Core Outcomes Set (COS-OUD) for Opioid Use Disorder (OUD)-Related Research
Dikla Blumberg1, Niranjan Karnik*2, Kathryn Hefner3, John Marsden4
1The Emmes Company, 2Rush Medical College of Rush University, 3Emmes Data and Statistics Center, NIDA CTN, 4Institute of Psychiatry, Psychology and Neuroscience, King’s College London

W72. Developing an Integrated Behavioral Treatment for Women With Opioid Use Disorder and Posttraumatic Stress Disorder: Patient and Provider Perspectives
Tanya Saraiya*1, Kathleen Brady1, Sudie Back1
1Medical University of South Carolina

W73. Effects of Adjunct Gabapentin on Treatment Outcomes During an Outpatient Buprenorphine Taper
Azizi Ray*1, Jeff Thostenson1, Joseph Guise1, Edward Nunes2, Michael Mancino1, Alison Oliveto1
1University of Arkansas for Medical Sciences, 2Columbia University and New York State Psychiatric Institute

W74. Examination of Sociodemographic Trends in Opioid Overdose Emergency Department Visits in Diverse Counties in New York State, 2010-2019
Navin Sanichar*1, Sharifa Z. Williams2, Helen-Maria Lekas2, Shannon M. Monnat3, Dessa K. Bergen-Cico4, Natalie Crawford5, Crystal Fuller Lewis2
1Nathan S. Kline Institute, 2Center for Research on Cultural and Structural Equity in Behavioral Health, Nathan S. Kline Institute for Psychiatric Research, 3Lerner Center for Public Health Promotion, Syracuse University, 4Syracuse University, 5Rollins School of Public Health, Emory University

W75. Examining Gender Differences in the Relationship Between Social Bonds and Opioid Misuse Treatment Completion Among Justice-Involved Adolescents
Enya Vroom*1, Zahra Akbari2, Skye Bristol2, Elzbieta Wiedbusch2, James-Angelo Suarez2, Micah Johnson2
1University of Florida, 2University of South Florida

W76. Feasibility and Acceptability of Harm Reduction Vending Machines in Philadelphia
Emily Loscalzo*4, Linden Lalley-Chareczko1, Rachel French2, Nicholas Cardamone2, Ali Tarhini3, Winna Mowenn4, Rebecca Stewart2
1Philadelphia FIGHT Community Health Centers, 2University of Pennsylvania, 3Thomas Jefferson University, 4La Salle University

W77. HEALing Transitions: Training and Development of Opioid Use Disorder (OUD) Linkage and Retention Nurse/Social Work Care Navigator Programs
Christopher Cook*1, Michelle Lofwall2, Sharon Walsh2, Katrina Nickels3, Jamie Cody4, Laura Fanucchi2
1University of Kentucky, Substance Use Priority Research Area, 2University of Kentucky, Center on Drug and Alcohol Research, 3University of Kentucky, 4Bluegrass Care Navigators
W78. Houselessness and Treatment Outcomes Among Black Adults With Opioid Use Disorder: A Secondary Analysis of X:BOT
Marissa Justen*1, Jennifer Scodes2, Martina Pavlicova3, Tse-Hwei Choo4, Manesh Gopaldas5, Angela Haeny4, Onumara Opara5, Taeho Greg Rhee6, John Rotrosen7, Edward Nunes2, Kathryn Hawk8, E. Jennifer Edelman1
1Yale University School of Medicine, 2Columbia University and NYSPI, 3Columbia University, 4Columbia University Mailman School of Public Health, 5New York State Psychiatric Institute, 6University of Connecticut School of Medicine, 7New York University School of Medicine, 8Yale University

W79. Incubation of Conditioned Opioid Withdrawal Avoidance in Methadone-Dependent Male and Female Rats
Jonathan Chow*1, Jules M. Chabot1, Rutsuko Ito2, Yavin Shaham3
1IRP/NIDA/NIH, 2University of Toronto

W80. Monovalent and Bivalent Vaccination Strategies to Protect Against Deliberate and Accidental Exposure to Carfentanil and Mixtures of Carfentanil and Fentanyl in Rats
Bethany Crouse1, Mariah Wu2, Valeria Gradinati3, Andrew Kassick3, Daihyun Song2, Saadyah Averick4, Scott Runyon5, Sandra Comer6, Marco Pravetoni1
1University of Minnesota Medical School, 2University of Minnesota, 3Allegheny-Singer Research Institute Center for Neurosciences Research, 4AHN, 5RTI International, 6Columbia University and NYSPI

W81. Open Label Trial of Lofexidine-Assisted Non-Opioid Induction Onto Naltrexone Extended-Release Injection for Opioid Use Disorder
John Mariani*1, Cale Basaraba2, Martina Pavlicova3, Daniel Alschuler2, Daniel Brooks2, Amy L. Mahony2, Christina Brezing1, Nasir Naqvi3, Frances Levin4
1Columbia University and New York Psychiatric Institute, 2NYSPI, 3Columbia University, 4Columbia University Irving Medical Center/ New York State Psychiatric Institute

W82. Opioid Use Disorder (OUD) and Treatment for Opioid Problems Among OUD Symptom Subtypes
Emily Miller*1, Angela DeVeaugh-Geiss2, Howard Chilcoat2
1Virginia Commonwealth University, 2Indivior, Inc.

W83. Overdose Fatalities in Maryland Jurisdictions and Implementation of Overdose Prevention Strategies
Catherine Tomko*1, Saba Rouhani1, Ryoko Susukida1, Himani Byregowda1, Taylor Parnham1, Masoumeh Amin-Esmaili1, Kristin Schneider1, Lyra Cooper1, Marianne Gibson2, Ju Nyeong Park2, Teresa Heath2, Robin Rickard2, Christine Boyd4, Renee Johnson1
1Johns Hopkins Bloomberg School of Public Health, 2Opioid Operational Command Center, Maryland Department of Health, 3Alpert Medical School, Brown University, 4Maryland Department of Health

W84. Pain in Recovery From Opioid Use Disorder: The Importance of Acute and Chronic Pain
William Craft*1, Allison Tegge1, Anne Le Moigne2, Angela DeVeaugh-Geiss2, Howard Chilcoat2, Warren Bickel1
1Fralin Biomedical Research Institute at Virginia Tech Carilion, 2Indivior, Inc.

W85. Preclinical Profiling of the Ampakine HJC0122 as a Novel Therapeutic for Opioid Use Disorder
Ashley Smith*1, Jimin Xu1, Kathryn Cunningham1, Jia Zhou1, Noelle Anastasio1
1University of Texas Medical Branch
W86. Retail Pharmacy Naloxone Distribution and Overdose Mortality in Rhode Island, Massachusetts, and New York City, 2016-2018
Jake Morgan*1, Christina Freibott2, Ali Jalali3, Philip Jeng3, Alexander Walley1, Avik Chatterjee1, Traci Green4, Michelle Nolan5, Benjamin Linas1, Brandon Marshall6, Sean Murphy3
1Boston University School of Medicine, 2Boston University School of Public Health, 3Weill Cornell Medical College, 4Heller School for Social Policy and Management, Brandeis University, 5Columbia University Mailman School of Public Health, 6Brown University School of Public Health

W87. Self-Management Strategies and Utilization of Medications for Opioid Use Disorder: A Qualitative Systematic Review
Scott Farnum*1, Declan Barry2, Erica Cannata3, Lynn Madden1
1APT Foundation, Inc., 2Yale University School of Medicine

W88. Sleep Architecture of OUD Patients: A Comparison of Watchpat 300 and NPSG
Vartika Parashar*1, Mohammad Sibai2, Gail Koshorek2, Josh Smith2, Mark Greenwald3, Timothy Roehrs2
1Henry Ford Hospital, 2Henry Ford Health System, 3Wayne State University

W89. Telehealth Visits Support Buprenorphine Induction During the Covid-19 Pandemic
Lindsey Hammerslag*1, Svetla Slavova1, Philip Westgate1, Michelle Lofwall2, Patricia Freeman1, Jeffery Talbert3
1University of Kentucky, 2University of Kentucky, College of Medicine, 3University of Kentucky College of Pharmacy

W90. The Heroin Hug: Opioids Acutely Produce Feelings of Being Secure and Loved
Nina Christie*1, John Monterosso1
1University of Southern California

W91. The Path Home Trial: A Comparative Effectiveness Study of Optimal Intervention Strategies for Perinatal Opioid Use Disorder in Rural Kentucky
Hilary Surratt*1, Karen Fawcett3, Jason Joy1, Sara Kuhl1, Hayley Powell1, Brandon Schanbacher1, John Bauer3, Arnold Stromberg3, Wendy Hansen1
1University of Kentucky

W92. The Relationship Between Resilience Phenotypes and Psychological Functioning in Individuals With Opioid Use Disorder
Suky Martinez*1, Albert Garcia-Romeu2, Freymon Perez1, Jermaine Jones3
1Columbia University Vagelos College of Physicians and Surgeons, 2Johns Hopkins University School of Medicine, 3Columbia University Irving Medical Center

W93. Trends in Opioid and Stimulant Treatment Admissions and Overdose Mortality in American Rural and Urban Areas
Huyen Pham*1, Yuhui Zhu1, Larissa Mooney2, Yih-Ing Hser2
1Semel Institute - UCLA, 2David Geffen School of Medicine, University of California, Los Angeles

W94. Two Novel Classes of Opioid Analogs: Discriminative Stimulus and Antinociceptive Effects
Michael Gatch*1
1University of North Texas Health Science Center
W95. What is Success in Treatment for Opioid Use Disorder? Perspectives of Physicians and Patients in Primary Care Settings
Robert Levy*, Tanner Nissly, Mary Lonergan-Cullum, Stephanie Hooker
1University of Minnesota, Medical School at Minneapolis, 2Health Partners

W96. “I Feel Like I’m Floating in Limbo”: Understanding the Impacts of the COVID-19 Pandemic on Persons Who Use Illicit Opioids in Arizona
Kaylin Sweeney*, Seol Ki, Natasha Mendoza, Raminta Daniulaityte
1Arizona State University

W97. Kratom Use Among Pregnant and Postpartum Individuals With Substance Use Disorders
Justin Bowman, Miao Lai, Jasmin Charles, Adam Gordon, Marcela Smid*
1University of Utah School of Medicine, 2University of Utah Health

W98. Umbilical Cord Homogenate Assay to Estimate Prenatal Kratom Exposure
Marcela Smid, Joseph Worden, Gerald Cochran, Melissa Hughes, Aidin O’Brien, Gwendolyn McMillin
1University of Utah Health, 2University of Utah School of Medicine, 3University of Utah, 4ARUP Lab

W99. The Controlled Substances Act Regulations on Schedule I Researcher Registrations and the Need to Investigate New Substances of Abuse
Theresa Carbonaro*, Srihari Tella, Terry Boos
1Drug Enforcement Administration, 2The United States Department of Justice

W100. Drug Overdose Deaths in the United States and Brazil Between 2000 and 2018: A Comparison Analysis of Sociodemographics and Intentionality
Marina Bianco, Vitor Tardelli, Emily Brooks, Kelsy Areco, Adalberto Tardelli, Paulo Bandiera-Paiva, Luis Segura, João Castaldelli-Maia, Silvia Martins, Thiago Fidalgo
1Universidade Federal de São Paulo, 2Universidade Federal de São Paulo/Centre for Addiction and Mental Health - University of Toronto, 3Columbia University Mailman School of Public Health, 4Medical School, University of São Paulo, 5Columbia University

DIGITAL POSTER PRESENTATIONS

Evaluating Loneliness and Binge Drinking Through a COVID-19 Follow-Up Survey Among Women in a Community Engagement Program in North Central Florida
Alyssa Berger*, Linda Cottler
1University of Florida

Reproductive History and Outcomes in the Young Women Arrested for Methamphetamine Use in Taiwan
Chuan-Yu Chen*, I-An Wang, Rosetta Siew, An-Jou Chen
1National Yang Ming Chiao Tung University, 2Center of Neuropsychiatric Research, National Health Research Institutes

A Spatial Science Approach to Inform Delivery of a Smartphone-Based Smoking Cessation Intervention
Amanda Luken*, Michael Desjardins, Johannes Thrul
1Johns Hopkins Bloomberg School of Public Health
Building Organizational Capacity and Expertise to Treat Tobacco Dependence Within Behavioral Health Treatment Centers: A Qualitative Study of “Champion” Trainees’ Perspectives of a Train-The-Trainer Program
Isabel Martinez Leal1, Jayda Martinez1, Virmarie Correa-Fernandez1, Maggie Britton1, Tzuan Chen1, Vijay Nitturi1, Kelli Drenner1, Bryce Kyburz2, Teresa Williams2, Kathleen Casey2, Marcel de Dios1, Ezemenari Obasi1, Lorraine Reitzel1
1University of Houston, 2Integral Care

Development and Process Evaluation of an Educational Intervention to Support Primary Care Based Sparing of Opioid Analgesics for Pain From New or Ongoing Non-Cancer Causes Among Opioid Naïve Patients
Shawna Narayan1, Stefania Rizzardo2, Ian Cooper3, Michee Ana Hamilton1, Malcolm Maclure1, Rita McCracken1, Jan Klimas*1
1University of British Columbia, 2Ryerson University, 3University of Alberta

Leveraging SARS-CoV-2 Vaccination Efforts Through Latino MSM Drug Use and Sexual Networks
Mariano Kanamori*1, Alfonso Yepes1, Edda Rodriguez1, Ariana Johnson1, Cho-Hee Shrader2, Kyle Self3, Lacey Cracker1, Nonie Kalra1, Stephen Fallon1, Steven Safren1, John Skvoretz5
1Miller School of Medicine, University of Miami, 2ICAP at Columbia University, 3Latinos Salud, 4University of Miami, 5University of Central Florida
<table>
<thead>
<tr>
<th>Author</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acheson, Liam</td>
<td>52</td>
</tr>
<tr>
<td>Acri, Jane</td>
<td>27</td>
</tr>
<tr>
<td>Adan, Fatumastar</td>
<td>71</td>
</tr>
<tr>
<td>Addicott, Merideth</td>
<td>61</td>
</tr>
<tr>
<td>Akbari, Zahra</td>
<td>63</td>
</tr>
<tr>
<td>Al'Absi, Mustafa</td>
<td>34</td>
</tr>
<tr>
<td>Alexander, Karen</td>
<td>68</td>
</tr>
<tr>
<td>Alexandre, Jean-Marc</td>
<td>74</td>
</tr>
<tr>
<td>Allen, Alicia</td>
<td>65</td>
</tr>
<tr>
<td>Allen, Diamond</td>
<td>65</td>
</tr>
<tr>
<td>Alshaarawy, Omayma</td>
<td>24</td>
</tr>
<tr>
<td>Alvarez, Emmanuel</td>
<td>87</td>
</tr>
<tr>
<td>Ana, Elizabeth Santa</td>
<td>24</td>
</tr>
<tr>
<td>Angelone, Leonardo</td>
<td>26, 31</td>
</tr>
<tr>
<td>Annunziato, Erin</td>
<td>87</td>
</tr>
<tr>
<td>Ansell, Emily</td>
<td>43</td>
</tr>
<tr>
<td>Antoine, Denis</td>
<td>29</td>
</tr>
<tr>
<td>Aponte-Melendez, Yesenia</td>
<td>76</td>
</tr>
<tr>
<td>Appel, Nathan</td>
<td>27</td>
</tr>
<tr>
<td>Apsley, Hannah</td>
<td>72</td>
</tr>
<tr>
<td>Aquino, Joao De</td>
<td>60</td>
</tr>
<tr>
<td>Arnold, Rachel</td>
<td>75</td>
</tr>
<tr>
<td>Aronson, Ian</td>
<td>71</td>
</tr>
<tr>
<td>Ashrafioun, Lisham</td>
<td>68</td>
</tr>
<tr>
<td>Ataiants, Janna</td>
<td>86</td>
</tr>
<tr>
<td>Athamneh, Liqa</td>
<td>73</td>
</tr>
<tr>
<td>Austin, Elizabeth</td>
<td>80</td>
</tr>
<tr>
<td>Bahji, Anees</td>
<td>56</td>
</tr>
<tr>
<td>Bailey, Amelia</td>
<td>75</td>
</tr>
<tr>
<td>Baillet, Emmanuelle</td>
<td>62</td>
</tr>
<tr>
<td>Baldwin, Aileen</td>
<td>70</td>
</tr>
<tr>
<td>Barrington-Trimis, Jessica</td>
<td>23</td>
</tr>
<tr>
<td>Bart, Gavin</td>
<td>36</td>
</tr>
<tr>
<td>Bazan, Carolyn</td>
<td>76</td>
</tr>
<tr>
<td>Bazzi, Angela</td>
<td>66, 76</td>
</tr>
<tr>
<td>Beams, Ryan</td>
<td>27</td>
</tr>
<tr>
<td>Bedillion, Margaret</td>
<td>43</td>
</tr>
<tr>
<td>Beeler-Stinn, Sara</td>
<td>74</td>
</tr>
<tr>
<td>Behrends, Czarina</td>
<td>66</td>
</tr>
<tr>
<td>Belfer, Inna</td>
<td>15</td>
</tr>
<tr>
<td>Bello, Mariel</td>
<td>59</td>
</tr>
<tr>
<td>Bennett, Allyson</td>
<td>36</td>
</tr>
<tr>
<td>Berger, Alyssa</td>
<td>93</td>
</tr>
<tr>
<td>Bergeria, Cecilia</td>
<td>80</td>
</tr>
<tr>
<td>Bernal, Kristen</td>
<td>63</td>
</tr>
<tr>
<td>Berro, Lais</td>
<td>25, 26</td>
</tr>
<tr>
<td>Bhatia, Devika</td>
<td>64</td>
</tr>
<tr>
<td>Bhatraju, Elenore</td>
<td>67</td>
</tr>
<tr>
<td>Bidwell, L. Cinnamon</td>
<td>24</td>
</tr>
<tr>
<td>Bierut, Laura</td>
<td>14, 46</td>
</tr>
<tr>
<td>Black, Joshua</td>
<td>63</td>
</tr>
<tr>
<td>Bluthenthal, Ricky</td>
<td>80</td>
</tr>
<tr>
<td>Boggis, Jesse</td>
<td>60</td>
</tr>
<tr>
<td>Bonner, Courtney</td>
<td>22, 50</td>
</tr>
<tr>
<td>Brandt, Laura</td>
<td>17, 78</td>
</tr>
<tr>
<td>Braun, Tosca</td>
<td>89</td>
</tr>
<tr>
<td>Bristol, Skye</td>
<td>49</td>
</tr>
<tr>
<td>Brown, Kanila</td>
<td>63</td>
</tr>
<tr>
<td>Brown, Randall</td>
<td>66</td>
</tr>
<tr>
<td>Browne, Felicia</td>
<td>21, 22</td>
</tr>
<tr>
<td>Browne, Thom</td>
<td>39</td>
</tr>
<tr>
<td>Burduli, Ekaterina</td>
<td>45, 46</td>
</tr>
<tr>
<td>Burlew, A. Kathleen</td>
<td>20</td>
</tr>
<tr>
<td>Burwell, Scott</td>
<td>31, 70</td>
</tr>
<tr>
<td>Bushnell, Greta</td>
<td>47</td>
</tr>
<tr>
<td>Butler, Devin</td>
<td>38</td>
</tr>
<tr>
<td>Buttram, Mance</td>
<td>25</td>
</tr>
<tr>
<td>Byrne, Kaileigh</td>
<td>31, 32</td>
</tr>
<tr>
<td>Cadet, Techna</td>
<td>66</td>
</tr>
<tr>
<td>Cain, Gloria</td>
<td>20</td>
</tr>
<tr>
<td>Cannoy, Ciara</td>
<td>85</td>
</tr>
<tr>
<td>Carbonaro, Theresa</td>
<td>93</td>
</tr>
<tr>
<td>Carney, Tara</td>
<td>22</td>
</tr>
<tr>
<td>Caro, Yohanka</td>
<td>51</td>
</tr>
<tr>
<td>Carpenter, Kenneth</td>
<td>39</td>
</tr>
<tr>
<td>Carreiro, Stephanie</td>
<td>31, 70</td>
</tr>
<tr>
<td>Carroll, Marilyn</td>
<td>53</td>
</tr>
<tr>
<td>Carson, Ian</td>
<td>63</td>
</tr>
<tr>
<td>Chatterjee, Biswadip</td>
<td>48</td>
</tr>
<tr>
<td>Chen, An-Jou</td>
<td>66</td>
</tr>
<tr>
<td>Chen, Chuan-Yu</td>
<td>93</td>
</tr>
<tr>
<td>Chen, Lian-Yu</td>
<td>52</td>
</tr>
<tr>
<td>Chen, Ling</td>
<td>58</td>
</tr>
<tr>
<td>Chen, Ren-Hao</td>
<td>49</td>
</tr>
<tr>
<td>Cheng, Hui</td>
<td>61</td>
</tr>
<tr>
<td>Chilcoat, Howard</td>
<td>19</td>
</tr>
<tr>
<td>Choi, Jenny</td>
<td>27</td>
</tr>
<tr>
<td>Chou, Jessica</td>
<td>39</td>
</tr>
<tr>
<td>Chow, Jonathan</td>
<td>91</td>
</tr>
<tr>
<td>Christie, Nina</td>
<td>92</td>
</tr>
<tr>
<td>Ciceron, Chantae</td>
<td>77</td>
</tr>
<tr>
<td>Claypool, Sarah</td>
<td>68</td>
</tr>
<tr>
<td>Clingan, Sarah</td>
<td>79</td>
</tr>
<tr>
<td>Cochran, Gerald</td>
<td>88</td>
</tr>
<tr>
<td>Colledge, Samantha</td>
<td>66</td>
</tr>
<tr>
<td>Comer, Sandra</td>
<td>36</td>
</tr>
<tr>
<td>Conrad, Christopher</td>
<td>70</td>
</tr>
<tr>
<td>Cook, Christopher</td>
<td>82, 90</td>
</tr>
<tr>
<td>Cook, Ryan</td>
<td>73</td>
</tr>
<tr>
<td>Cooper, Hannah</td>
<td>30</td>
</tr>
<tr>
<td>Author Name</td>
<td>Page(s)</td>
</tr>
<tr>
<td>------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Cooper, Ziva</td>
<td>23</td>
</tr>
<tr>
<td>Cordoba-Grueso, Whitney</td>
<td>88</td>
</tr>
<tr>
<td>Cottler, Linda</td>
<td>27</td>
</tr>
<tr>
<td>Coulter, Cynthia</td>
<td>86</td>
</tr>
<tr>
<td>Cousins, Sarah</td>
<td>83</td>
</tr>
<tr>
<td>Craft, William</td>
<td>91</td>
</tr>
<tr>
<td>Crouch, Taylor</td>
<td>72</td>
</tr>
<tr>
<td>Crouse, Bethany</td>
<td>91</td>
</tr>
<tr>
<td>Crump, Alisha</td>
<td>61</td>
</tr>
<tr>
<td>Cuttler, Carrie</td>
<td>24</td>
</tr>
<tr>
<td>Dahlgren, Mary</td>
<td>86</td>
</tr>
<tr>
<td>Dakwar, Elias</td>
<td>42</td>
</tr>
<tr>
<td>Davis, Alan</td>
<td>65</td>
</tr>
<tr>
<td>Davis, Danielle</td>
<td>62</td>
</tr>
<tr>
<td>de Dios, Constanza</td>
<td>78</td>
</tr>
<tr>
<td>de Martell, Sierra Castedo</td>
<td>70</td>
</tr>
<tr>
<td>Denis, Cecile</td>
<td>69</td>
</tr>
<tr>
<td>Dennis, Michael</td>
<td>40, 41</td>
</tr>
<tr>
<td>Des Jarlais, Don</td>
<td>78</td>
</tr>
<tr>
<td>DeWitt, Haley</td>
<td>49</td>
</tr>
<tr>
<td>Dickerson, Daniel</td>
<td>40</td>
</tr>
<tr>
<td>Dickson, Megan</td>
<td>73</td>
</tr>
<tr>
<td>DiGuiseppi, Graham</td>
<td>83</td>
</tr>
<tr>
<td>Dobbins, Robert</td>
<td>68</td>
</tr>
<tr>
<td>D’Onofrio, Gail</td>
<td>33</td>
</tr>
<tr>
<td>Dugosh, Karen</td>
<td>72</td>
</tr>
<tr>
<td>Dunbar, Joi</td>
<td>51</td>
</tr>
<tr>
<td>Duncan, Alexandra</td>
<td>29</td>
</tr>
<tr>
<td>Dunn, Kelly</td>
<td>23</td>
</tr>
<tr>
<td>Dwyer, Candice</td>
<td>62</td>
</tr>
<tr>
<td>Ebrahimi, Chantel</td>
<td>77</td>
</tr>
<tr>
<td>Edmiston, Jeffery</td>
<td>60</td>
</tr>
<tr>
<td>Eglovitch, Michelle</td>
<td>87</td>
</tr>
<tr>
<td>Eisman, Andria</td>
<td>59</td>
</tr>
<tr>
<td>Ekhtiari, Hamed</td>
<td>16, 17</td>
</tr>
<tr>
<td>Eller, Anthony</td>
<td>57</td>
</tr>
<tr>
<td>Elliott, Amy</td>
<td>69</td>
</tr>
<tr>
<td>Ellis, Jennifer</td>
<td>75</td>
</tr>
<tr>
<td>Ellis, Matthew</td>
<td>25</td>
</tr>
<tr>
<td>Engel, Shaydel</td>
<td>59</td>
</tr>
<tr>
<td>Ertl, Melissa</td>
<td>76, 77</td>
</tr>
<tr>
<td>España, Rodrigo</td>
<td>26</td>
</tr>
<tr>
<td>Evans-Polce, Rebecca</td>
<td>61</td>
</tr>
<tr>
<td>Fahey, Margaret</td>
<td>44</td>
</tr>
<tr>
<td>Falise, Alyssa</td>
<td>77</td>
</tr>
<tr>
<td>Farnum, Scott</td>
<td>92</td>
</tr>
<tr>
<td>Feelemeyer, Jonathan</td>
<td>54</td>
</tr>
<tr>
<td>Feinstein, Marc Jerome</td>
<td>61</td>
</tr>
<tr>
<td>Fidalgo, Thiago</td>
<td>93</td>
</tr>
<tr>
<td>Filbey, Francesca</td>
<td>35, 38</td>
</tr>
<tr>
<td>Fink, David</td>
<td>86</td>
</tr>
<tr>
<td>Fitzgerald, Nicole</td>
<td>28, 76</td>
</tr>
<tr>
<td>Fitzpatrick, Ben</td>
<td>70</td>
</tr>
<tr>
<td>Flannagan, Kerry</td>
<td>60</td>
</tr>
<tr>
<td>Fleming, Taylor</td>
<td>51</td>
</tr>
<tr>
<td>Foot, Canyon</td>
<td>79</td>
</tr>
<tr>
<td>Foster, Katrina</td>
<td>21</td>
</tr>
<tr>
<td>Franken, Ingmar</td>
<td>37, 38</td>
</tr>
<tr>
<td>Franklin, Teresa</td>
<td>37</td>
</tr>
<tr>
<td>Freeman, Patricia</td>
<td>34</td>
</tr>
<tr>
<td>Freitas-Lemos, Roberta</td>
<td>61, 81</td>
</tr>
<tr>
<td>French, Rachel</td>
<td>57</td>
</tr>
<tr>
<td>Frost, Madeline</td>
<td>87</td>
</tr>
<tr>
<td>Funada, Masahiko</td>
<td>50</td>
</tr>
<tr>
<td>Funmaker, George</td>
<td>40</td>
</tr>
<tr>
<td>Fuoco, Morgan Justice</td>
<td>18</td>
</tr>
<tr>
<td>Fuster, Daniel</td>
<td>48</td>
</tr>
<tr>
<td>Gaalema, Diann</td>
<td>29</td>
</tr>
<tr>
<td>Gallivan, Molly</td>
<td>88</td>
</tr>
<tr>
<td>Galloway, Gantt</td>
<td>50</td>
</tr>
<tr>
<td>Gannon, Meghan</td>
<td>46</td>
</tr>
<tr>
<td>Garcia-Romeu, Albert</td>
<td>42</td>
</tr>
<tr>
<td>Gatch, Michael</td>
<td>92</td>
</tr>
<tr>
<td>Gelberg, Lillian</td>
<td>64</td>
</tr>
<tr>
<td>Gentry, Brooks</td>
<td>21</td>
</tr>
<tr>
<td>Gex, Kathryn</td>
<td>84</td>
</tr>
<tr>
<td>Giacomini, Juliana</td>
<td>82</td>
</tr>
<tr>
<td>Gicquelais, Rachel</td>
<td>89</td>
</tr>
<tr>
<td>Gilmore-Thomas, Adrienne</td>
<td>72</td>
</tr>
<tr>
<td>Glass, Joseph</td>
<td>18</td>
</tr>
<tr>
<td>Go, Vivian</td>
<td>30</td>
</tr>
<tr>
<td>Gonzalez, Angela</td>
<td>54</td>
</tr>
<tr>
<td>Gorfinkel, Lauren</td>
<td>79</td>
</tr>
<tr>
<td>Gould, Robert</td>
<td>25, 26</td>
</tr>
<tr>
<td>Gray, Frank</td>
<td>67</td>
</tr>
<tr>
<td>Gray, Joy</td>
<td>74</td>
</tr>
<tr>
<td>Greenwald, Mark</td>
<td>41</td>
</tr>
<tr>
<td>Griffith, Kevin</td>
<td>65</td>
</tr>
<tr>
<td>Griffiths, Paul</td>
<td>39</td>
</tr>
<tr>
<td>Gruber, Staci</td>
<td>16</td>
</tr>
<tr>
<td>Grundmann, Oliver</td>
<td>22, 23</td>
</tr>
<tr>
<td>Gryczynski, Jan</td>
<td>56</td>
</tr>
<tr>
<td>Gueguen, Maëlle</td>
<td>57</td>
</tr>
<tr>
<td>Guerin, Alexandre</td>
<td>52</td>
</tr>
<tr>
<td>Gupta, Abhishek</td>
<td>48</td>
</tr>
<tr>
<td>Gust, Steve</td>
<td>39</td>
</tr>
<tr>
<td>Gutkind, Sarah</td>
<td>58</td>
</tr>
<tr>
<td>Haeny, Angela</td>
<td>20</td>
</tr>
<tr>
<td>Hales, Tim</td>
<td>34</td>
</tr>
<tr>
<td>Author Name</td>
<td>Page</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Hamilton, Leah</td>
<td>75</td>
</tr>
<tr>
<td>Hammerslag, Lindsey</td>
<td>92</td>
</tr>
<tr>
<td>Hammond, David</td>
<td>35</td>
</tr>
<tr>
<td>Han, Benjamin</td>
<td>44</td>
</tr>
<tr>
<td>Han, Dae Hee</td>
<td>62</td>
</tr>
<tr>
<td>Hand, Dennis</td>
<td>45</td>
</tr>
<tr>
<td>Haney, Margaret</td>
<td>43</td>
</tr>
<tr>
<td>Hanlon, Colleen</td>
<td>17</td>
</tr>
<tr>
<td>Haque, Lamia</td>
<td>48</td>
</tr>
<tr>
<td>Hard, Gregory</td>
<td>74</td>
</tr>
<tr>
<td>Harlow, Alyssa</td>
<td>61</td>
</tr>
<tr>
<td>Harris, Julia</td>
<td>49</td>
</tr>
<tr>
<td>Harris, Miriam</td>
<td>74</td>
</tr>
<tr>
<td>Harrison, Katherine</td>
<td>75</td>
</tr>
<tr>
<td>Harton, Moriah</td>
<td>69</td>
</tr>
<tr>
<td>Hashemi, Daniel</td>
<td>85</td>
</tr>
<tr>
<td>Hasin, Deborah</td>
<td>59</td>
</tr>
<tr>
<td>Hatoum, Alexander</td>
<td>18</td>
</tr>
<tr>
<td>Hawk, Kathryn</td>
<td>81</td>
</tr>
<tr>
<td>Heidari, Omeid</td>
<td>80</td>
</tr>
<tr>
<td>Heil, Sarah</td>
<td>54</td>
</tr>
<tr>
<td>Heimer, Robert</td>
<td>57</td>
</tr>
<tr>
<td>Hennessy, Emily</td>
<td>41</td>
</tr>
<tr>
<td>Henningfield, Jack</td>
<td>23, 78</td>
</tr>
<tr>
<td>Hermes, Gretchen</td>
<td>51</td>
</tr>
<tr>
<td>Higgins,Stephen</td>
<td>13</td>
</tr>
<tr>
<td>Hill, Mandy</td>
<td>63</td>
</tr>
<tr>
<td>Hoadley, Ariel</td>
<td>57</td>
</tr>
<tr>
<td>Hoeftlich, Carolin</td>
<td>77</td>
</tr>
<tr>
<td>Hoffman, Kim</td>
<td>75</td>
</tr>
<tr>
<td>Hoffman, Paula</td>
<td>27</td>
</tr>
<tr>
<td>Hong, Judy</td>
<td>78</td>
</tr>
<tr>
<td>Hooker, Stephanie</td>
<td>80</td>
</tr>
<tr>
<td>Hoopsick, Rachel</td>
<td>83</td>
</tr>
<tr>
<td>Hooten, W. Michael</td>
<td>21</td>
</tr>
<tr>
<td>Hoots, Jennifer</td>
<td>53</td>
</tr>
<tr>
<td>Horta, Marilyn</td>
<td>44</td>
</tr>
<tr>
<td>Horton, Gabriella</td>
<td>53</td>
</tr>
<tr>
<td>Howe, Lindy</td>
<td>84</td>
</tr>
<tr>
<td>Huhn, Andrew</td>
<td>42</td>
</tr>
<tr>
<td>Hunter, John</td>
<td>27</td>
</tr>
<tr>
<td>Hurd, Yasmin</td>
<td>16</td>
</tr>
<tr>
<td>Hyves, Kelly</td>
<td>73</td>
</tr>
<tr>
<td>Ingersoll, Karen</td>
<td>47</td>
</tr>
<tr>
<td>Ivasiy, Roman</td>
<td>88</td>
</tr>
<tr>
<td>Iwanicki, Janetta</td>
<td>25</td>
</tr>
<tr>
<td>Jain, Raka</td>
<td>48, 49</td>
</tr>
<tr>
<td>James, Morgan</td>
<td>42</td>
</tr>
<tr>
<td>Janes, Amy</td>
<td>16</td>
</tr>
<tr>
<td>Javanbakht, Marjan</td>
<td>58</td>
</tr>
<tr>
<td>Jenkins, Richard</td>
<td>30</td>
</tr>
<tr>
<td>Jentsch, J. David</td>
<td>13</td>
</tr>
<tr>
<td>Johnson, Carrie</td>
<td>40</td>
</tr>
<tr>
<td>Jones, Abenaa</td>
<td>76</td>
</tr>
<tr>
<td>Jones, Jermaine</td>
<td>56</td>
</tr>
<tr>
<td>Jones, Kasey</td>
<td>90</td>
</tr>
<tr>
<td>Jordan, Ayana</td>
<td>20</td>
</tr>
<tr>
<td>Jordan, Dephanie</td>
<td>20</td>
</tr>
<tr>
<td>Joseph, Elizabeth</td>
<td>73</td>
</tr>
<tr>
<td>Joseph, Verlin</td>
<td>77</td>
</tr>
<tr>
<td>Joudrey, Paul</td>
<td>69</td>
</tr>
<tr>
<td>Julien, Lovelyne</td>
<td>78</td>
</tr>
<tr>
<td>Justen, Marissa</td>
<td>91</td>
</tr>
<tr>
<td>Kalmin, Mariah</td>
<td>71</td>
</tr>
<tr>
<td>Kaminsky, Stephen</td>
<td>21</td>
</tr>
<tr>
<td>Kampman, Kyle</td>
<td>54</td>
</tr>
<tr>
<td>Kanamori, Mariano</td>
<td>94</td>
</tr>
<tr>
<td>Karelitz, Joshua</td>
<td>61</td>
</tr>
<tr>
<td>Karnik, Niranjan</td>
<td>90</td>
</tr>
<tr>
<td>Karns-Wright, Tara</td>
<td>69</td>
</tr>
<tr>
<td>Katz, Brian</td>
<td>60</td>
</tr>
<tr>
<td>Kaufman, Marc</td>
<td>82</td>
</tr>
<tr>
<td>Kaur, Jagdeep</td>
<td>81</td>
</tr>
<tr>
<td>Kelly, John</td>
<td>41</td>
</tr>
<tr>
<td>Kelpin, Sydney</td>
<td>57</td>
</tr>
<tr>
<td>Keyser-Marcus, Lori</td>
<td>42</td>
</tr>
<tr>
<td>Khan, Maria</td>
<td>34</td>
</tr>
<tr>
<td>Khoury, Dalia</td>
<td>52</td>
</tr>
<tr>
<td>Kiluk, Brian</td>
<td>75</td>
</tr>
<tr>
<td>Klemperer, Elias</td>
<td>67</td>
</tr>
<tr>
<td>Kleykamp, Bethea</td>
<td>44, 45</td>
</tr>
<tr>
<td>Klimas, Jan</td>
<td>94</td>
</tr>
<tr>
<td>Knudsen, Hannah</td>
<td>81</td>
</tr>
<tr>
<td>Konsin, John</td>
<td>31</td>
</tr>
<tr>
<td>Koob, George</td>
<td>12</td>
</tr>
<tr>
<td>Korthuis, Todd</td>
<td>36, 37</td>
</tr>
<tr>
<td>Kral, Alex</td>
<td>64</td>
</tr>
<tr>
<td>Krause, Alexis</td>
<td>51</td>
</tr>
<tr>
<td>Kroon, Emese</td>
<td>83</td>
</tr>
<tr>
<td>Kuhns, Lauren</td>
<td>35</td>
</tr>
<tr>
<td>Kulak, Jessica</td>
<td>64</td>
</tr>
<tr>
<td>Kundu, Soumya</td>
<td>18</td>
</tr>
<tr>
<td>Lacy, Ryan</td>
<td>29</td>
</tr>
<tr>
<td>Laffont, Celine</td>
<td>56</td>
</tr>
<tr>
<td>LaForge, Kate</td>
<td>55</td>
</tr>
<tr>
<td>Lambert, Laura</td>
<td>62</td>
</tr>
<tr>
<td>Lane, Scott</td>
<td>41</td>
</tr>
<tr>
<td>Lankenau, Stephen</td>
<td>84</td>
</tr>
<tr>
<td>Lapham, Gwen</td>
<td>18</td>
</tr>
<tr>
<td>LaValley, Christina</td>
<td>53</td>
</tr>
<tr>
<td>Malaspina,25</td>
<td>Mall, Daniel</td>
</tr>
<tr>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>Mancini, Michael</td>
<td>81</td>
</tr>
<tr>
<td>Mannes, Andrew</td>
<td>27</td>
</tr>
<tr>
<td>Mariani, John</td>
<td>91</td>
</tr>
<tr>
<td>Marra, Ashton</td>
<td>45</td>
</tr>
<tr>
<td>Martinez, Suky</td>
<td>92</td>
</tr>
<tr>
<td>Martin, Theresa</td>
<td>85</td>
</tr>
<tr>
<td>Maust, Donovan</td>
<td>47</td>
</tr>
<tr>
<td>Mayer, Samara</td>
<td>80</td>
</tr>
<tr>
<td>McCabe, Sean Esteban</td>
<td>52</td>
</tr>
<tr>
<td>McCarty, Dennis</td>
<td>36</td>
</tr>
<tr>
<td>McCue, Christopher</td>
<td>40</td>
</tr>
<tr>
<td>McDowell, Tyre</td>
<td>80</td>
</tr>
<tr>
<td>Meacham, Meredith</td>
<td>86</td>
</tr>
<tr>
<td>Mericle, Amy</td>
<td>65</td>
</tr>
<tr>
<td>Miloslavich, Krista</td>
<td>49</td>
</tr>
<tr>
<td>Mitchell, Mary</td>
<td>85</td>
</tr>
<tr>
<td>Monico, Laura</td>
<td>74</td>
</tr>
<tr>
<td>Moran, Lauren</td>
<td>53</td>
</tr>
<tr>
<td>Morochnik, Michelle</td>
<td>53</td>
</tr>
<tr>
<td>Moses, Tabitha</td>
<td>68</td>
</tr>
<tr>
<td>Myers, Matthew</td>
<td>82</td>
</tr>
<tr>
<td>Nawrockik-Madrid, Acacia</td>
<td>50</td>
</tr>
<tr>
<td>Nelson, Douglas</td>
<td>70</td>
</tr>
<tr>
<td>Nguyen, Trang</td>
<td>54</td>
</tr>
<tr>
<td>Nisbett, Kenisha</td>
<td>65</td>
</tr>
<tr>
<td>Novak, Matthew</td>
<td>63</td>
</tr>
<tr>
<td>Nwankwo, Oluchi</td>
<td>89</td>
</tr>
<tr>
<td>Odom, Gabriel</td>
<td>17</td>
</tr>
<tr>
<td>Olayinka, Olaniyi</td>
<td>79</td>
</tr>
<tr>
<td>Ompad, Danielle</td>
<td>65</td>
</tr>
<tr>
<td>Onigbogi, Olanrewaju</td>
<td>72</td>
</tr>
<tr>
<td>Palamar, Joseph</td>
<td>50</td>
</tr>
<tr>
<td>Panicker, Sangeeta</td>
<td>36</td>
</tr>
<tr>
<td>Parashar, Vartika</td>
<td>92</td>
</tr>
<tr>
<td>Parker, Maria</td>
<td></td>
</tr>
<tr>
<td>Parashar, Vartika</td>
<td>92</td>
</tr>
</tbody>
</table>
AUTHOR INDEX

Parlier-Ahmad, Anna 89
Parvaz, Muhammad 38
Patton, Thomas 67
Peckham, Andrew 64
Peng, Kah-Whye 21
Peoples, JaNiene 64
Peprah-Asante, Ohemaa 87
Pericot-Valverde, Irene 31, 32, 81
Peters, Erica 29
Pfister, Brian 66
Pham, Huyen 92
Philbin, Morgan 58
Pho, Mai 30
Platt, Kristen 83
Poblete, Maria 83
Polak, Kathryn 47
Preiss, Alexander 71
Psaras, Catherine 83
Rabinowitz, Jill 49
Rains, Alex 72
Rai, Tekendra 76
Raleigh, Michael 55
Ramirez, Miranda 53
Randall-Thompson, Jovita 29
Ray, Azizi 90
Reich, Jeffrey 27, 69
Reji, Angitha 49
Reynolds, Maureen 24
Ridenour, Ty 71
Rosen, Marc 80
Roth, Prerana 32
Rowlett, James 35
Roy, Payel 56
Sacco, Paul 39
Salisbury-Afshar, Elizabeth 15
Sanichar, Navin 90
Santo, Thomas 69
Saraiya, Tanya 90
Satterfield, Jason 70
Saunders, David 63
Saunders, Elizabeth 81
Schermitzer, Brandon 86
Schmeichel, Brooke 42
Schmid, Laura 74
Schwab, Nathan 55
Schwarting, Corrine M. 48
Schwebel, Frank 82
Schweitzer, Emma 88
Seow, Tricia 42
Serafine, Katherine 13

Serre, Fuschia 71
Setnik, Beatrice 51
Severtson, Stevan 81
Shah, Samay 76
Shearer, Riley 54
Sherman, Brian 85
Shoptaw, Steve 37
Shover, Chelsea 19, 20
Shrestha, Roman 53
Shulman, Matisyahu 65
Sibai, Mohammad 57
Siew, Rosetta 50
Sigmon, Stacey 33, 34
Silwal, Anita 56
Simpson, Kelsey 55
Sitar, Siara 64
Skinstad, Anne 77
Smid, Marcela 93
Smith, Ashley 91
Smith, Crystal 46
Smith, Danielle 76
Smith, Doug 40, 41
Smith, Keisha 74
Smith, Kirsten 22, 23, 79
Smith, Lia 28
Song, Daihyun 70
Sorg, Barbara 32, 33
Soto, Claradina 40
Spindle, Tory 84
Stack, Erin 73
Stark, Haidyn 62
Steele, Vaughn 37, 38
Stewart, Jennifer 58
Stinson, Elizabeth 86
Stoltman, Jonathan 45
Stoops, William 12, 13, 41
Stopka, Thomas 30
Stoudt, Matthew 26
Streck, Joanna 60
Strickland, Justin 19
Struble, Cara 84
Suarez, James-Angelo 63
Sugarman, Dawn 63
Sullivan, Ryan 48
Sultan, Ryan 85
Sung, Young-Hoon 54
Sunshine, Jacob 31
Surratt, Hilary 92
Svikis, Dace 38, 47
Sweeney, Kaylin 93
Takano, Ayumi 52
Tang, Victor 48
Tardelli, Vitor 70
Taxman, Faye 15
Taylor, Linh 67
Teale, Tanisse 72
Tegge, Allison 19, 69
Terplan, Mishka 50
Tervo-Clemmens, Brenden 85
Thabaleh, Ammar 73
Thakrar, Ashish 79
Thiessen, Karina 85
Thrailkill, Eric 61
Tien, Celine 26
Tillson, Martha 73, 88
Toegel, Forrest 29
Tomko, Catherine 91
Tomlinson, Devin 58
Tompkins, D. Andrew 68
Tripathi, Richa 49
Tsui, Judith 18
Üsküp, Dilara 84
Vanderziel, Alyssa 87
Veliz, Philip 52
Vergunst, Francis 64
Vest, Bonnie 77
Vest, Noel 20
Vidot, Denise 28
Vincent, Robert 41
Vogel, Erin 59
Volkow, Nora 12
Vroom, Enya 90
Wade, Natasha 58
Wahab, Suzaily 51
Wallace, Alexander 62
Walsh, Claire 51
Walsh, Sharon 33, 34
Wang, Anna 28, 75
Ward, Sara Jane 16
Wartko, Paige 18
Washio, Yukiko 22
Weaver, Victoria 69
Webster, Matt 64
Wechsberg, Wendee 21, 22
Wemm, Stephanie 43, 82
White, David 21
Whitt, Devin 83
Wiedbusch, Elzbieta 49
Wiese, Anna 86
Wiley, Jenny 15, 16
Wiley, Rhiannon 59
Wilkerson, J. Michael 74
Williams, Arthur Robin 36, 37, 89
Wilson, Deja 77
Wilson-Poe, Adrianne 23, 24
Winstanley, Erin 34
Wirtz, Hailey 60
Wisor, Jonathan 33
Witkiewitz, Katie 17
Wolinsky, David 86
Won, Nae 28, 78
Worden, Joseph 93
Wright, Susan 17
Wyse, Jessica 89
Xin, Yitong 84
Xu, Kevin 46, 53
Yang, Allen 55
Yang, Yang 65
Yeager, Samantha 55
Yeh, Yu-Hua 60
Yi, Richard 19
Young, April 30
Zamora, Joshua 51
Zhu, Yuhui 79
Zilverstand, Anna 17
Zule, William 30, 57
2021-2022 DONORS

Judy Ashworth
Sudie Back
Jack Bergman
Qiana Brown
Kathleen Bucholz
Alan Budney
F. Ivy Carroll
Sandra Comer
Andrew Coop
Ziva Cooper
Richard De La Garza
Kelly Dunn
Linda Dwoskin
Linda Dykstra
Loretta Finnegan
Albert Garcia-Romeu
Ellen Geller
Charles Gorodetzky
Margaret Haney
Deborah Hasin
Angela Heads
Sarah Heil
Frederic Hopf
Jesse Howard

Amy Janes
Jermaine Jones
Scott Lane
Frances Levin
Scott Lukas
Wendy Lynch
Bertha Madras
Deborah Mash
Rick Mees
Tasha Perdue
Marco Pravetoni
James Rowlett
Sidney Schnoll
Staceey Sigmon
Maxine Stitzer
William Stoops
Eric Strain
Yung-Fong Sung-Holtzman
Dace Svikis
Michael Taffe
Judith Tsui
Wendee Wechsberg
Erin Winstanley
George Woody